[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_byId_c9dcdf0d-1f44-46cc-93b6-4b34cd3868a8":3,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:c9dcdf0d-1f44-46cc-93b6-4b34cd3868a8,\"}":136},{"code":4,"data":5,"meta":22},"SUCCESS",{"id":6,"createTime":7,"updateTime":8,"relativeEntities":9,"slug":10,"properties":11,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":24,"manageAffiliations":57,"indexDatabases":80,"url":122,"thumbnailPath":22,"statistic":123,"gsStatistic":22,"type":22,"analyzePriority":22},"c9dcdf0d-1f44-46cc-93b6-4b34cd3868a8","2023-05-29T10:55:48.592+00:00","2025-11-21T09:54:15.321+00:00",[],"JHEP-Reports",{"country":12,"issn":14,"introduce":16,"title":18},{"VOID":13},"NL",{"VOID":15},"25895559",{"EN":17},"JHEP Reports is an open access companion title to the highly-respected Journal of Hepatology. It publishes original papers, reviews, and letters to the Editor concerned with basic, translation and clinical research in the field of hepatology. JHEP Reports is an innovative Journal publishing articles on global issues in hepatology, with specific focus on clinical trials, novel diagnostics, precision medicine and therapeutics, cellular and molecular research, metabolism, cancer, microbiome, systems biology, epidemiology, and biotechnology advances and devices.",{"EN":19},"JHEP Reports","PUBLISHER","PENDING",null,2,[25,33,41,49],{"id":26,"createTime":27,"updateTime":28,"relativeEntities":29,"label":30,"description":32,"parentId":22,"standard":22,"scholarHubFieldId":22},"a520f91c-9c10-4000-96b1-c80ea7776e25","2023-05-29T10:24:12.053+00:00","2023-11-21T07:53:13.948+00:00",[],{"EN":31},"Gastroenterology",{},{"id":34,"createTime":35,"updateTime":36,"relativeEntities":37,"label":38,"description":40,"parentId":22,"standard":22,"scholarHubFieldId":22},"01203b2d-e9ba-432d-a4b0-d0f3ced5dfa6","2023-05-29T10:24:07.274+00:00","2023-11-21T07:04:43.214+00:00",[],{"EN":39},"Hepatology",{},{"id":42,"createTime":43,"updateTime":44,"relativeEntities":45,"label":46,"description":48,"parentId":22,"standard":22,"scholarHubFieldId":22},"6dc081f7-79a9-45f6-8ed3-54ef5518db41","2023-05-29T10:24:14.547+00:00","2023-11-21T07:19:21.114+00:00",[],{"EN":47},"Immunology and Allergy",{},{"id":50,"createTime":51,"updateTime":52,"relativeEntities":53,"label":54,"description":56,"parentId":22,"standard":22,"scholarHubFieldId":22},"77761c13-d9ff-4113-b615-60dad0c16000","2023-05-29T10:24:33.231+00:00","2023-11-21T06:06:57.205+00:00",[],{"EN":55},"Internal Medicine",{},[58,70],{"id":59,"createTime":60,"updateTime":61,"relativeEntities":62,"slug":63,"properties":64,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":68,"url":22,"parentIds":69,"statistic":22},"c204a4fd-ec04-47ff-9c5b-5d693c99cecf","2023-05-29T10:24:07.053+00:00","2024-02-19T16:29:56.082+00:00",[],"Elsevier-BV",{"title":65},{"EN":66},"Elsevier BV","AFFILIATION",9,[],{"id":71,"createTime":72,"updateTime":73,"relativeEntities":74,"slug":75,"properties":76,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":78,"url":22,"parentIds":79,"statistic":22},"c749757b-dddf-4e6f-9697-b9c441adc06c","2023-05-29T10:24:07.401+00:00","2025-11-21T10:06:14.206+00:00",[],"Elsevier",{"title":77},{"EN":75},11,[],[81,100],{"id":82,"indexDatabase":83,"url":97,"indexYears":22,"academicFieldIds":98,"indexDatabaseRanking":22},"21daddc5-e029-427b-8e9d-2d0c7d1e9c43",{"id":84,"createTime":85,"updateTime":86,"relativeEntities":87,"label":88,"description":90,"key":93,"publicationTags":94,"standard":22},"a4921856-b128-4d9f-8f1f-e80813d3bbd4","2023-05-22T09:59:31.026+00:00","2025-11-21T10:07:52.153+00:00",[],{"EN":89,"VI":89},"ISI\u002FSCIE - Science Citation Index Expanded",{"VI":91,"EN":92},"Cơ sở dữ liệu SCIE","SCIE database","scie",[95,96],"SCIE","ISI","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002Fnull",[99],"4b2c1694-c69d-4b20-b2eb-9687848dfb30",{"id":101,"indexDatabase":102,"url":114,"indexYears":115,"academicFieldIds":116,"indexDatabaseRanking":121},"06399bf7-4dc2-49a2-9071-967c7609630f",{"id":103,"createTime":104,"updateTime":105,"relativeEntities":106,"label":107,"description":109,"key":111,"publicationTags":112,"standard":22},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9","2023-05-22T09:57:18.509+00:00","2025-11-21T10:07:52.274+00:00",[],{"EN":108,"VI":108},"Scopus - Elsevier",{"EN":108,"VI":110},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[113],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F21101037196","2019-2025",[117,118,119,120],"34ca0c58-3b99-4064-9bf3-a754a6e2e9a7","d39aa686-8d5d-45f0-81c4-13c21a0f2f39","7e7a8be0-3213-4ad0-b9db-1ab0e7d051c8","e872d6d8-194c-4b83-9ea3-8b78dd28210d","NONE","https:\u002F\u002Fwww.jhep-reports.eu\u002F",{"impactFactor":124,"impactFactorByYear":125,"i10Index":124,"i10IndexLast5Year":124,"totalPublication":126,"totalPublicationByYear":127,"totalCitation":124,"totalCitationByYear":134,"totalCitationPerPublication":124,"totalCitationPerPublicationByYear":135,"hindexLast5Year":124,"hindex":124},0,{},78,{"2019":128,"2020":129,"2021":130,"2022":131,"2023":132,"2024":133},7,4,17,14,33,3,{},{},{"meta":137,"data":139},{"total":138},"277",[140,416,709,923,1071,1177,1403,1505,1624,1931],{"id":141,"createTime":142,"updateTime":142,"relativeEntities":143,"slug":22,"properties":144,"entityType":151,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":152,"primaryUrl":153,"fullTextUrl":22,"authors":154,"publicationType":377,"publisherRelationship":378,"citationCount":22,"citationInfo":22,"publishDate":413,"publishYear":414,"citationAnalyzeStatus":21,"lastCitationAnalyze":22,"indexDatabases":22,"openAccess":22,"references":22,"isForceReanalyzing":415},"35f14714-6c46-4aa0-b9b1-72afb6c28905","2024-01-04T23:58:41.757+00:00",[],{"references":145,"title":147,"doi":149},{"VOID":146},"Finn, 2020, Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma, N Engl J Med, 382, 1894, 10.1056\u002FNEJMoa1915745\nCheng, 2022, Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma, J Hepatol, 76, 862, 10.1016\u002Fj.jhep.2021.11.030\nLee, 2020, Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity, Exp Mol Med, 52, 1475, 10.1038\u002Fs12276-020-00500-y\nCheon, 2022, Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma, Liver Int, 42, 674, 10.1111\u002Fliv.15102\nMaesaka, 2022, Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy, Hepatol Res, 52, 298, 10.1111\u002Fhepr.13741\nYumita, 2022, Analysis of hyperprogressive disease due to atezolizumab combined with bevacizumab treatment in patients with advanced hepatocellular carcinoma, Res Square\nKim, 2022, Association of high levels of antidrug antibodies against atezolizumab with clinical outcomes and T-cell responses in patients with hepatocellular carcinoma, JAMA Oncol, 8, 10.1001\u002Fjamaoncol.2022.4733\nAn, 2021, Peripheral blood-based biomarkers for immune checkpoint inhibitors, Int J Mol Sci, 22, 9414, 10.3390\u002Fijms22179414\nBruix, 2011, Management of hepatocellular carcinoma: an update, Hepatology, 53, 1020, 10.1002\u002Fhep.24199\nDi Tommaso, 2019, Role of liver biopsy in hepatocellular carcinoma, World J Gastroenterol, 25, 6041, 10.3748\u002Fwjg.v25.i40.6041\nStenken, 2015, Bioanalytical chemistry of cytokines – a review, Anal Chim Acta, 853, 95, 10.1016\u002Fj.aca.2014.10.009\nHirano, 2000, Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors, Oncogene, 19, 2548, 10.1038\u002Fsj.onc.1203551\nKumari, 2016, Role of interleukin-6 in cancer progression and therapeutic resistance, Tumor Biol, 37, 11553, 10.1007\u002Fs13277-016-5098-7\nFisher, 2014, The two faces of IL-6 in the tumor microenvironment, Semin Immunol, 26, 38, 10.1016\u002Fj.smim.2014.01.008\nHoejberg, 2012, Interleukin-6 and melanoma, Melanoma Res, 22, 327, 10.1097\u002FCMR.0b013e3283543d72\nMa, 2017, IL-6, IL-8 and TNF-α levels correlate with disease stage in breast cancer patients, Adv Clin Exp Med, 26, 421, 10.17219\u002Facem\u002F62120\nFeng, 2018, Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer, J Int Med Res, 46, 5228\nShakiba, 2018, Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis, Clin Exp Hepatol, 4, 182, 10.5114\u002Fceh.2018.78122\nKalbasi, 2020, Tumour-intrinsic resistance to immune checkpoint blockade, Nat Rev Immunol, 20, 25, 10.1038\u002Fs41577-019-0218-4\nFlint, 2016, Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity, Cell Metab, 24, 672, 10.1016\u002Fj.cmet.2016.10.010\nHailemichael, 2022, Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity, Cancer Cell, 40, 509, 10.1016\u002Fj.ccell.2022.04.004\nSang, 2022, High serum levels of IL-6 predict poor responses in patients treated with pembrolizumab plus axitinib for advanced renal cell carcinoma, Cancers (Basel), 14, 5985, 10.3390\u002Fcancers14235985\nTsukamoto, 2015, IL-6-mediated environmental conditioning of defective Th1 differentiation dampens antitumour immune responses in old age, Nat Commun, 6, 1, 10.1038\u002Fncomms7702\nNakanishi, 2009, CD8+ T lymphocyte mobilization to virus-infected tissue requires CD4+ T-cell help, Nature, 462, 510, 10.1038\u002Fnature08511\nTsukamoto, 2018, Immune-suppressive effects of interleukin-6 on T-cell-mediated anti-tumor immunity, Cancer Sci, 109, 523, 10.1111\u002Fcas.13433\nHeimbach, 2018, AASLD guidelines for the treatment of hepatocellular carcinoma, Hepatology, 67, 358, 10.1002\u002Fhep.29086\nJiang, 2018, Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response, Nat Med, 24, 1550, 10.1038\u002Fs41591-018-0136-1\nPark, 2021, High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer, J Immunother Cancer, 9\nYang, 2019, STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade, J Clin Invest, 129, 4350, 10.1172\u002FJCI125413\nLausen, 1992, Maximally selected rank statistics, Biometrics, 48, 73, 10.2307\u002F2532740\nScheiner, 2022, Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score, J Hepatol, 76, 353, 10.1016\u002Fj.jhep.2021.09.035\nYavuz, 2021, Current landscape and future directions of biomarkers for immunotherapy in hepatocellular carcinoma, J Hepatocell Carcinoma, 8, 1195, 10.2147\u002FJHC.S322289\nHyung, 2022, Histopathologic and molecular biomarkers of PD-1\u002FPD-L1 inhibitor treatment response among patients with microsatellite instability-high colon cancer, Cancer Res Treat, 54, 1175, 10.4143\u002Fcrt.2021.1133\nKim, 2021, Combination immunotherapies to overcome intrinsic resistance to checkpoint blockade in microsatellite stable colorectal cancer, Cancers (Basel), 13, 4906, 10.3390\u002Fcancers13194906\nVillaruz, 2013, The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement, Clin Cancer Res, 19, 2629, 10.1158\u002F1078-0432.CCR-12-2935\nMyojin, 2022, Interleukin-6 is a circulating prognostic biomarker for hepatocellular carcinoma patients Treated with Combined Immunotherapy, Cancers, 14, 883, 10.3390\u002Fcancers14040883\nKitamura, 2017, Interleukin-6\u002FSTAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy, Cancer Sci, 108, 1947, 10.1111\u002Fcas.13332\nWeber, 2021, IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy, Cell Immunol, 359, 10.1016\u002Fj.cellimm.2020.104254\nHardy-Werbin, 2019, Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer, Oncoimmunology, 8, 10.1080\u002F2162402X.2019.1593810\nLaino, 2020, Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition, J Immunother Cancer, 8",{"EN":148},"High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma",{"VOID":150},"10.1016\u002Fj.jhepr.2023.100672","PUBLICATION",1,"https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2589555923000034",[155,172,187,205,220,232,244,257,273,290,305,327,340,355],{"id":156,"sortIndex":157,"researcher":22,"roles":158,"affiliations":160,"properties":169},"9f94774d-f7f0-447c-a6a0-900abafeb48c",6,[159],"AUTHOR",[161],{"id":22,"sortIndex":124,"affiliation":162,"properties":22},{"id":163,"createTime":164,"updateTime":164,"relativeEntities":165,"slug":22,"properties":166,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"ef809a8d-b1e4-4d70-9925-076f57fb1945","2024-01-04T23:58:41.890+00:00",[],{"title":167},{"VI":168},"Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea",{"title":170},{"VI":171},"Won Suk Lee",{"id":173,"sortIndex":133,"researcher":22,"roles":174,"affiliations":175,"properties":184},"411a616d-e32f-4a8f-9837-89bdd150afe5",[159],[176],{"id":22,"sortIndex":124,"affiliation":177,"properties":22},{"id":178,"createTime":179,"updateTime":179,"relativeEntities":180,"slug":22,"properties":181,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"b83291ee-d37d-46c0-881a-78988e3cb094","2024-01-04T23:58:41.839+00:00",[],{"title":182},{"VI":183},"Department of Surgery, CHA Bundang Medical Center, Seongnam, Republic of Korea",{"title":185},{"VI":186},"Sung Hwan Lee",{"id":188,"sortIndex":189,"researcher":22,"roles":190,"affiliations":191,"properties":202},"1c8daf10-bb20-4d94-ac2d-3171a550b646",10,[159],[192],{"id":22,"sortIndex":124,"affiliation":193,"properties":22},{"id":194,"createTime":195,"updateTime":196,"relativeEntities":197,"slug":198,"properties":199,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"4b873a93-4d9e-46f6-b80c-073068d51830","2024-01-16T07:11:46.151+00:00","2024-12-02T08:29:53.412+00:00",[],"F-Hoffmann-La-Roche-Ltd-Basel-Switzerland",{"title":200},{"VI":201},"F. Hoffmann-La Roche Ltd, Basel, Switzerland",{"title":203},{"VI":204},"Vincent E. Gaillard",{"id":206,"sortIndex":128,"researcher":22,"roles":207,"affiliations":208,"properties":217},"f648e864-f1e1-4485-9616-1acc7cc19daa",[159],[209],{"id":22,"sortIndex":124,"affiliation":210,"properties":22},{"id":211,"createTime":212,"updateTime":212,"relativeEntities":213,"slug":22,"properties":214,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"c90ff676-1b3d-4983-aef0-454cc7757b55","2024-01-04T23:58:41.915+00:00",[],{"title":215},{"VI":216},"Department of Pathology, CHA Bundang Medical Center, Seongnam, Republic of Korea",{"title":218},{"VI":219},"Gwangil Kim",{"id":221,"sortIndex":78,"researcher":22,"roles":222,"affiliations":223,"properties":229},"86af753f-c0f2-4e62-a053-434a8f253130",[159],[224],{"id":22,"sortIndex":124,"affiliation":225,"properties":22},{"id":163,"createTime":164,"updateTime":164,"relativeEntities":226,"slug":22,"properties":227,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":228},{"VI":168},{"title":230},{"VI":231},"Jaekyung Cheon",{"id":233,"sortIndex":124,"researcher":22,"roles":234,"affiliations":235,"properties":241},"1efc0588-aed3-4596-a9b7-c901e5423164",[159],[236],{"id":22,"sortIndex":124,"affiliation":237,"properties":22},{"id":163,"createTime":164,"updateTime":164,"relativeEntities":238,"slug":22,"properties":239,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":240},{"VI":168},{"title":242},{"VI":243},"Hannah Yang",{"id":245,"sortIndex":246,"researcher":22,"roles":247,"affiliations":248,"properties":254},"ad6a1980-ce34-4bc2-b40e-245bf26428c6",13,[159],[249],{"id":22,"sortIndex":124,"affiliation":250,"properties":22},{"id":163,"createTime":164,"updateTime":164,"relativeEntities":251,"slug":22,"properties":252,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":253},{"VI":168},{"title":255},{"VI":256},"Hong Jae Chon",{"id":258,"sortIndex":259,"researcher":22,"roles":260,"affiliations":261,"properties":270},"608f9c6d-7c1b-49eb-a512-acbc1d6e2a25",8,[159],[262],{"id":22,"sortIndex":124,"affiliation":263,"properties":22},{"id":264,"createTime":265,"updateTime":265,"relativeEntities":266,"slug":22,"properties":267,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"cc9d7b53-8cae-435b-966f-3fb5031a3287","2024-01-04T23:58:41.927+00:00",[],{"title":268},{"VI":269},"Department of Radiology, CHA Bundang Medical Center, Seongnam, Republic of Korea",{"title":271},{"VI":272},"Sanghoon Jung",{"id":274,"sortIndex":275,"researcher":22,"roles":276,"affiliations":277,"properties":287},"21df343c-953d-4c38-9c2e-5f6aa4faa20e",5,[159],[278],{"id":22,"sortIndex":124,"affiliation":279,"properties":22},{"id":280,"createTime":281,"updateTime":281,"relativeEntities":282,"slug":283,"properties":284,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"2b38c330-90cd-4db6-a181-e8bdf34061de","2024-04-13T21:31:01.793+00:00",[],"Department-of-Internal-Medicine-Ulsan-University-Hospital-University-of-Ulsan-College-of-Medicine-Ulsan-Republic-of-Korea",{"title":285},{"EN":286},"Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea",{"title":288},{"VI":289},"Hyeyeong Kim",{"id":291,"sortIndex":23,"researcher":22,"roles":292,"affiliations":293,"properties":302},"d5fdd537-80da-4c52-aa4e-541afd7334a7",[159],[294],{"id":22,"sortIndex":124,"affiliation":295,"properties":22},{"id":296,"createTime":297,"updateTime":297,"relativeEntities":298,"slug":22,"properties":299,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"40793c3d-cad2-479d-8508-8d6a7b5adbbc","2024-01-04T23:58:41.814+00:00",[],{"title":300},{"VI":301},"Department of Gastroenterology, CHA Bundang Medical Center, Seongnam, Republic of Korea",{"title":303},{"VI":304},"Yeonjung Ha",{"id":306,"sortIndex":152,"researcher":22,"roles":307,"affiliations":308,"properties":324},"d763c8ea-121f-482c-9813-df27ebb6c5f6",[159],[309,314],{"id":22,"sortIndex":124,"affiliation":310,"properties":22},{"id":163,"createTime":164,"updateTime":164,"relativeEntities":311,"slug":22,"properties":312,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":313},{"VI":168},{"id":315,"sortIndex":152,"affiliation":316,"properties":323},"772d613c-78fe-431a-b45f-927787000ad6",{"id":317,"createTime":318,"updateTime":318,"relativeEntities":319,"slug":22,"properties":320,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"b13e6b3c-7f68-4153-a8b6-b70b37766042","2024-01-04T23:58:41.785+00:00",[],{"title":321},{"VI":322},"Yonsei Graduate School, Yonsei University College of Medicine, Seoul, Republic of Korea",{},{"title":325},{"VI":326},"Beodeul Kang",{"id":328,"sortIndex":329,"researcher":22,"roles":330,"affiliations":331,"properties":337},"5aefc63f-d7fc-4d95-a3ad-afb5843d2632",12,[159],[332],{"id":22,"sortIndex":124,"affiliation":333,"properties":22},{"id":163,"createTime":164,"updateTime":164,"relativeEntities":334,"slug":22,"properties":335,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":336},{"VI":168},{"title":338},{"VI":339},"Chan Kim",{"id":341,"sortIndex":129,"researcher":22,"roles":342,"affiliations":343,"properties":352},"b861313e-d7b5-4265-b084-b1f7d569798b",[159],[344],{"id":22,"sortIndex":124,"affiliation":345,"properties":22},{"id":346,"createTime":347,"updateTime":347,"relativeEntities":348,"slug":22,"properties":349,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"ba0038a7-59f1-4257-be48-5ae4256fcd99","2024-01-04T23:58:41.852+00:00",[],{"title":350},{"VI":351},"Division of Oncology, Department of Internal Medicine, Inje University College of Medicine, Haeundae Paik Hospital, Busan, Republic of Korea",{"title":353},{"VI":354},"Ilhwan Kim",{"id":356,"sortIndex":68,"researcher":22,"roles":357,"affiliations":358,"properties":374},"61d4a274-f747-4b4f-967c-bef3e3036af9",[159],[359,364],{"id":22,"sortIndex":124,"affiliation":360,"properties":22},{"id":317,"createTime":318,"updateTime":318,"relativeEntities":361,"slug":22,"properties":362,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":363},{"VI":322},{"id":365,"sortIndex":152,"affiliation":366,"properties":373},"f5eb7753-9bba-4aac-b961-1217e9105cda",{"id":367,"createTime":368,"updateTime":368,"relativeEntities":369,"slug":22,"properties":370,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"60d75bee-06cc-4fde-8cb0-0404364736d7","2023-12-31T05:24:37.106+00:00",[],{"title":371},{"VI":372},"Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea",{},{"title":375},{"VI":376},"Sun Young Rha","ARTICLE",{"url":153,"publisher":379,"properties":408},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":380,"slug":10,"properties":381,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":386,"manageAffiliations":387,"indexDatabases":388,"url":122,"thumbnailPath":22,"statistic":403,"gsStatistic":22,"type":22,"analyzePriority":22},[],{"country":382,"issn":383,"introduce":384,"title":385},{"VOID":13},{"VOID":15},{"EN":17},{"EN":19},[],[],[389,396],{"id":101,"indexDatabase":390,"url":114,"indexYears":115,"academicFieldIds":395,"indexDatabaseRanking":121},{"id":103,"createTime":104,"updateTime":105,"relativeEntities":391,"label":392,"description":393,"key":111,"publicationTags":394,"standard":22},[],{"EN":108,"VI":108},{"EN":108,"VI":110},[113],[117,118,119,120],{"id":82,"indexDatabase":397,"url":97,"indexYears":22,"academicFieldIds":402,"indexDatabaseRanking":22},{"id":84,"createTime":85,"updateTime":86,"relativeEntities":398,"label":399,"description":400,"key":93,"publicationTags":401,"standard":22},[],{"EN":89,"VI":89},{"VI":91,"EN":92},[95,96],[99],{"impactFactor":124,"impactFactorByYear":404,"i10Index":124,"i10IndexLast5Year":124,"totalPublication":126,"totalPublicationByYear":405,"totalCitation":124,"totalCitationByYear":406,"totalCitationPerPublication":124,"totalCitationPerPublicationByYear":407,"hindexLast5Year":124,"hindex":124},{},{"2019":128,"2020":129,"2021":130,"2022":131,"2023":132,"2024":133},{},{},{"volume":409,"pages":411},{"VOID":410},"5",{"VOID":412},"100672","2023-04-01",2023,false,{"id":417,"createTime":418,"updateTime":419,"relativeEntities":420,"slug":421,"properties":422,"entityType":151,"verifyStatus":429,"verifyTime":419,"verifyNote":430,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124,"primaryUrl":431,"fullTextUrl":22,"authors":432,"publicationType":377,"publisherRelationship":672,"citationCount":22,"citationInfo":22,"publishDate":707,"publishYear":708,"citationAnalyzeStatus":21,"lastCitationAnalyze":22,"indexDatabases":22,"openAccess":22,"references":22,"isForceReanalyzing":415},"141bbfd0-6917-479e-b383-90a1d682ce73","2024-01-08T12:26:15.688+00:00","2025-02-23T23:56:28.427+00:00",[],"Abnormal-brain-oxygen-homeostasis-in-an-animal-model-of-liver-disease",{"references":423,"title":425,"doi":427},{"VOID":424},"Wijdicks, 2016, Hepatic encephalopathy, N Engl J Med, 375, 1660, 10.1056\u002FNEJMra1600561\nHadjihambi, 2018, Hepatic encephalopathy: a critical current review, Hepatol Int, 12, 135, 10.1007\u002Fs12072-017-9812-3\nFichet, 2009, Prognosis and 1-year mortality of intensive care unit patients with severe hepatic encephalopathy, J Crit Care, 24, 364, 10.1016\u002Fj.jcrc.2009.01.008\nKornerup, 2019, Cognitive impairment after liver transplantation: residual hepatic encephalopathy or posttransplant encephalopathy?, Hepat Med, 11, 41, 10.2147\u002FHMER.S144667\nShawcross, 2010, Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis, Hepatology, 51, 1062, 10.1002\u002Fhep.23367\nHadjihambi, 2014, Pharmacotherapy for hyperammonemia, Expert Opin Pharmacother, 15, 1685, 10.1517\u002F14656566.2014.931372\nBajaj, 2011, Review article: the design of clinical trials in hepatic encephalopathy – an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement, Aliment Pharmacol Ther, 33, 739, 10.1111\u002Fj.1365-2036.2011.04590.x\nCauli, 2009, Glutamatergic and gabaergic neurotransmission and neuronal circuits in hepatic encephalopathy, Metab Brain Dis, 24, 69, 10.1007\u002Fs11011-008-9115-4\nHyder, 2006, Neuronal–glial glucose oxidation and glutamatergic-GABAergic function, J Cereb Blood Flow Metab, 26, 865, 10.1038\u002Fsj.jcbfm.9600263\nBraissant, 2019, Longitudinal neurometabolic changes in the hippocampus of a rat model of chronic hepatic encephalopathy, J Hepatol, 71, 505, 10.1016\u002Fj.jhep.2019.05.022\nHadjihambi, 2017, Ammonia mediates cortical hemichannel dysfunction in rodent models of chronic liver disease, Hepatology, 65, 1306, 10.1002\u002Fhep.29031\nRao, 2001, Cerebral energy metabolism in hepatic encephalopathy and hyperammonemia, Metab Brain Dis, 16, 67, 10.1023\u002FA:1011666612822\nAttwell, 2001, An energy budget for signaling in the grey matter of the brain, J Cereb Blood Flow Metab, 21, 1133, 10.1097\u002F00004647-200110000-00001\nIversen, 2014, Oxidative metabolism of astrocytes is not reduced in hepatic encephalopathy: a PET study with [(11)C]acetate in humans, Front Neurosci, 8, 353, 10.3389\u002Ffnins.2014.00353\nDhanda, 2018, Mitochondrial dysfunctions contribute to energy deficits in rodent model of hepatic encephalopathy, Metab Brain Dis, 33, 209, 10.1007\u002Fs11011-017-0136-8\nHeidari, 2019, Brain mitochondria as potential therapeutic targets for managing hepatic encephalopathy, Life Sci, 218, 65, 10.1016\u002Fj.lfs.2018.12.030\nWillie, 2014, Integrative regulation of human brain blood flow, J Physiol, 592, 841, 10.1113\u002Fjphysiol.2013.268953\nHosford, 2019, What is the key mediator of the neurovascular coupling response?, Neurosci Biobehav Rev, 96, 174, 10.1016\u002Fj.neubiorev.2018.11.011\nLourenço, 2015, Neurovascular and neurometabolic derailment in aging and Alzheimer's disease, Front Aging Neurosci, 7, 103\nIadecola, 2017, The neurovascular unit coming of age: a journey through neurovascular coupling in health and disease, Neuron, 96, 17, 10.1016\u002Fj.neuron.2017.07.030\nKhot, 2006, Long-term neurological complications after hypoxic-ischemic encephalopathy, Semin Neurol, 26, 422, 10.1055\u002Fs-2006-948323\nDam, 2013, Hepatic encephalopathy is associated with decreased cerebral oxygen metabolism and blood flow, not increased ammonia uptake, Hepatology, 57, 258, 10.1002\u002Fhep.25995\nIversen, 2009, Low cerebral oxygen consumption and blood flow in patients with cirrhosis and an acute episode of hepatic encephalopathy, Gastroenterology, 136, 863, 10.1053\u002Fj.gastro.2008.10.057\nWeiss, 2018, Ammonia: this is not the end but rather the end of the beginning, J Hepatol, 68, 1110, 10.1016\u002Fj.jhep.2018.03.027\nJalan, 2007, L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy, Med Hypotheses, 69, 1064, 10.1016\u002Fj.mehy.2006.12.061\nPercie du Sert, 2020, The ARRIVE guidelines 2.0: updated guidelines for reporting animal research, PLoS Biol, 18\nHarry, 1999, Increased sensitivity to endotoxemia in the bile duct-ligated cirrhotic rat, Hepatology, 30, 1198, 10.1002\u002Fhep.510300515\nRackayova, 2016, 1H and 31P magnetic resonance spectroscopy in a rat model of chronic hepatic encephalopathy: in vivo longitudinal measurements of brain energy metabolism, Metab Brain Dis, 31, 1303, 10.1007\u002Fs11011-015-9715-8\nHadjihambi, 2019, Impaired brain glymphatic flow in experimental hepatic encephalopathy, J Hepatol, 70, 40, 10.1016\u002Fj.jhep.2018.08.021\nDavies, 2009, L-Ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats, Hepatology, 50, 155, 10.1002\u002Fhep.22897\nHosford, 2018, A critical role for the ATP-sensitive potassium channel subunit KIR 6.1 in the control of cerebral blood flow, J Cereb Blood Flow Metab, 39, 2089, 10.1177\u002F0271678X18780602\nNizari, 2021, Glucagon-like peptide-1 (GLP-1) receptor activation dilates cerebral arterioles, increases cerebral blood flow, and mediates remote (pre)conditioning neuroprotection against ischaemic stroke, Basic Res Cardiol, 116, 32, 10.1007\u002Fs00395-021-00873-9\nHaase, 2005, Influences of caffeine, acetazolamide and cognitive stimulation on cerebral blood flow velocities, Prog Neuropsychopharmacol Biol Psychiatry, 29, 549, 10.1016\u002Fj.pnpbp.2005.01.006\nVorstrup, 1984, Effect of acetazolamide on cerebral blood flow and cerebral metabolic rate for oxygen, J Clin Invest, 74, 1634, 10.1172\u002FJCI111579\nTheparambil, 2020, Astrocytes regulate brain extracellular pH via a neuronal activity-dependent bicarbonate shuttle, Nat Commun, 11, 5073, 10.1038\u002Fs41467-020-18756-3\nEstrela, 2016, Differential sympathetic vasomotor activation induced by liver cirrhosis in rats, PLoS One, 11, 10.1371\u002Fjournal.pone.0152512\nLeithner, 2014, The oxygen paradox of neurovascular coupling, J Cereb Blood Flow Metab, 34, 19, 10.1038\u002Fjcbfm.2013.181\nBalasubramaniyan, 2012, Ammonia reduction with ornithine phenylacetate restores brain eNOS activity via the DDAH-ADMA pathway in bile duct-ligated cirrhotic rats, Am J Physiol Gastrointest Liver Physiol, 302, G145, 10.1152\u002Fajpgi.00097.2011\nHoiland, 2019, Regulation of the cerebral circulation by arterial carbon dioxide, Compr Physiol, 9, 1101, 10.1002\u002Fcphy.c180021\nHein, 2006, Dilation of retinal arterioles in response to lactate: role of nitric oxide, guanylyl cyclase, and ATP-sensitive potassium channels, Invest Ophthalmol Vis Sci, 47, 693, 10.1167\u002Fiovs.05-1224\nGordon, 2008, Brain metabolism dictates the polarity of astrocyte control over arterioles, Nature, 456, 745, 10.1038\u002Fnature07525\nSimicic, 2019, 33 in vivo longitudinal 1H MRS study of hippocampal, cerebral and striatal metabolic changes in the adult brain using an animal model of chronic hepatic encephalopathy, Am J Gastroenterol, 114, 10.14309\u002F01.ajg.0000582108.29364.13\nMosso, 2022, PET CMRglc mapping and 1H MRS show altered glucose uptake and neurometabolic profiles in BDL rats, Anal Biochem, 647, 10.1016\u002Fj.ab.2022.114606\nWatts, 2018, Brain energy and oxygen metabolism: emerging role in normal function and disease, Front Mol Neurosci, 11, 216, 10.3389\u002Ffnmol.2018.00216\nSilverman, 2001, Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome, JAMA, 286, 2120, 10.1001\u002Fjama.286.17.2120\nZhou, 2008, Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance, Ann N Y Acad Sci, 1147, 93, 10.1196\u002Fannals.1427.023\nHadengue, 1998, Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome, J Hepatol, 29, 565, 10.1016\u002FS0168-8278(98)80151-7\nGinès, 2009, Renal failure in cirrhosis, N Engl J Med, 361, 1279, 10.1056\u002FNEJMra0809139\nHosford, 2019, Electrochemical carbon fiber-based technique for simultaneous recordings of brain tissue PO2, pH, and extracellular field potentials, Biosens Bioelectron X, 3\nClément, 2021, Bile-duct ligation renders the brain susceptible to hypotension-induced neuronal degeneration: implications of ammonia, J Neurochem, 157, 561, 10.1111\u002Fjnc.15290\nGibson, 1981, Brain dysfunction in mild to moderate hypoxia, Am J Med, 70, 1247, 10.1016\u002F0002-9343(81)90834-2\nAngelova, 2015, Functional oxygen sensitivity of astrocytes, J Neurosci, 35, 10460, 10.1523\u002FJNEUROSCI.0045-15.2015\nBanasiak, 1998, Hypoxia-induced apoptosis: effect of hypoxic severity and role of p53 in neuronal cell death, Brain Res, 797, 295, 10.1016\u002FS0006-8993(98)00286-8",{"EN":426},"Abnormal brain oxygen homeostasis in an animal model of liver disease",{"VOID":428},"10.1016\u002Fj.jhepr.2022.100509","VERIFIED","Auto Verify","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2589555922000817",[433,448,475,511,538,557,569,596,615,627,660],{"id":434,"sortIndex":129,"researcher":22,"roles":435,"affiliations":436,"properties":445},"9243abab-58d1-40cf-b697-0e2ed6681d32",[159],[437],{"id":22,"sortIndex":124,"affiliation":438,"properties":22},{"id":439,"createTime":440,"updateTime":440,"relativeEntities":441,"slug":22,"properties":442,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"e8066f52-bce5-45b8-a7aa-2d4681280a85","2024-01-08T12:26:15.786+00:00",[],{"title":443},{"VI":444},"Institute of Sports Science and Department of Physiology, University of Lausanne, Lausanne, Switzerland",{"title":446},{"VI":447},"Chris Donnelly",{"id":449,"sortIndex":68,"researcher":22,"roles":450,"affiliations":451,"properties":472},"f3688dc6-3beb-4f8d-bb46-b42a725ca055",[159],[452,464],{"id":453,"sortIndex":152,"affiliation":454,"properties":463},"02ede318-1197-452c-96b4-e4e24406561b",{"id":455,"createTime":456,"updateTime":457,"relativeEntities":458,"slug":459,"properties":460,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"2fcf721c-c498-4612-92d7-4373e4f25c5e","2024-01-08T12:26:15.859+00:00","2024-10-14T12:45:52.947+00:00",[],"European-Foundation-for-the-Study-of-Chronic-Liver-Failure",{"title":461},{"VI":462},"European Foundation for the Study of Chronic Liver Failure",{},{"id":22,"sortIndex":124,"affiliation":465,"properties":22},{"id":466,"createTime":467,"updateTime":467,"relativeEntities":468,"slug":22,"properties":469,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"d798ef26-d626-4ffa-ac52-6c654b39773e","2024-01-08T12:26:15.855+00:00",[],{"title":470},{"VI":471},"UCL Institute for Liver and Digestive Health, Division of Medicine, UCL Medical School, Royal Free Hospital, Rowland Hill Street, London, UK",{"title":473},{"VI":474},"Rajiv Jalan",{"id":476,"sortIndex":23,"researcher":22,"roles":477,"affiliations":478,"properties":508},"52c1f9a6-ea70-4fcf-8f4f-2702f92f9d42",[159],[479,489,499],{"id":480,"sortIndex":152,"affiliation":481,"properties":488},"137549aa-071c-47df-835f-fecfca4628db",{"id":482,"createTime":483,"updateTime":483,"relativeEntities":484,"slug":22,"properties":485,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"81f48d3c-825f-47a4-bb5b-7a102ca48b99","2024-01-08T12:26:15.773+00:00",[],{"title":486},{"VI":487},"Animal Imaging and Technology, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland",{},{"id":490,"sortIndex":23,"affiliation":491,"properties":498},"813656c6-7108-429e-b404-657440829b32",{"id":492,"createTime":493,"updateTime":493,"relativeEntities":494,"slug":22,"properties":495,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"5f06e4bc-a6db-4b79-88d7-77b577efed01","2024-01-21T14:22:08.976+00:00",[],{"title":496},{"VI":497},"Laboratory of Functional and Metabolic Imaging, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland",{},{"id":22,"sortIndex":124,"affiliation":500,"properties":22},{"id":501,"createTime":502,"updateTime":502,"relativeEntities":503,"slug":504,"properties":505,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"2920f6f1-d71d-4a7e-8e6c-99e22f8df2e9","2023-11-24T18:28:17.956+00:00",[],"CIBM-Center-for-Biomedical-Imaging-Lausanne-Switzerland",{"title":506},{"VI":507},"CIBM Center for Biomedical Imaging, Lausanne, Switzerland",{"title":509},{"VI":510},"Katarzyna Pierzchala",{"id":512,"sortIndex":189,"researcher":22,"roles":513,"affiliations":514,"properties":535},"c9a08090-e639-452e-809c-45d1bae9b326",[159],[515,525],{"id":516,"sortIndex":152,"affiliation":517,"properties":524},"7fec4a5e-e312-4f1f-816e-a75518b6df7e",{"id":518,"createTime":519,"updateTime":519,"relativeEntities":520,"slug":22,"properties":521,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"f6b9ad6a-7901-4b70-92ed-62ed62a3bafb","2024-01-30T06:47:22.687+00:00",[],{"title":522},{"VI":523},"William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, London, UK",{},{"id":22,"sortIndex":124,"affiliation":526,"properties":22},{"id":527,"createTime":528,"updateTime":529,"relativeEntities":530,"slug":531,"properties":532,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"0bbf31a4-b620-4bf9-82c8-5f0c234687e7","2024-01-08T12:26:15.872+00:00","2025-06-12T00:36:19.064+00:00",[],"Centre-for-Cardiovascular-and-Metabolic-Neuroscience-Neuroscience-Physiology-and-Pharmacology-University-College-London-London-UK",{"title":533},{"VI":534},"Centre for Cardiovascular and Metabolic Neuroscience, Neuroscience, Physiology and Pharmacology, University College London, London, UK",{"title":536},{"VI":537},"Patrick S. Hosford",{"id":539,"sortIndex":152,"researcher":22,"roles":540,"affiliations":541,"properties":554},"186010d1-9786-45b2-9ccb-7bfcb6225c32",[159],[542,549],{"id":543,"sortIndex":152,"affiliation":544,"properties":548},"45a3b262-5a9b-4783-9501-d5a6653033a0",{"id":482,"createTime":483,"updateTime":483,"relativeEntities":545,"slug":22,"properties":546,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":547},{"VI":487},{},{"id":22,"sortIndex":124,"affiliation":550,"properties":22},{"id":501,"createTime":502,"updateTime":502,"relativeEntities":551,"slug":504,"properties":552,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":553},{"VI":507},{"title":555},{"VI":556},"Cristina Cudalbu",{"id":558,"sortIndex":259,"researcher":22,"roles":559,"affiliations":560,"properties":566},"af675d54-d533-4cf3-96d5-7cf5ddbcc488",[159],[561],{"id":22,"sortIndex":124,"affiliation":562,"properties":22},{"id":527,"createTime":528,"updateTime":529,"relativeEntities":563,"slug":531,"properties":564,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":565},{"VI":534},{"title":567},{"VI":568},"Alexander V. Gourine",{"id":570,"sortIndex":275,"researcher":22,"roles":571,"affiliations":572,"properties":593},"c752cd09-a1fa-46ea-9dc8-07a185cf7a0e",[159],[573,581],{"id":22,"sortIndex":124,"affiliation":574,"properties":22},{"id":575,"createTime":576,"updateTime":576,"relativeEntities":577,"slug":22,"properties":578,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"da9da89a-2dd3-4ca5-99b0-81620259fcf1","2024-01-18T01:30:46.802+00:00",[],{"title":579},{"VI":580},"The Roger Williams Institute of Hepatology London, Foundation for Liver Research, London, UK",{"id":582,"sortIndex":152,"affiliation":583,"properties":592},"17e596ee-b8d0-4b2a-b942-e5c514e96b39",{"id":584,"createTime":585,"updateTime":586,"relativeEntities":587,"slug":588,"properties":589,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"b7e894ef-6cac-445a-9f55-0c374a9a7078","2024-01-08T12:26:15.712+00:00","2025-01-30T16:42:21.070+00:00",[],"Faculty-of-Life-Sciences-and-Medicine-King-s-College-London-London-UK",{"title":590},{"VI":591},"Faculty of Life Sciences and Medicine, King’s College London, London, UK",{},{"title":594},{"VI":595},"Christos Konstantinou",{"id":597,"sortIndex":133,"researcher":22,"roles":598,"affiliations":599,"properties":612},"fe63084e-b277-4e84-8602-d780e9780054",[159],[600,605],{"id":22,"sortIndex":124,"affiliation":601,"properties":22},{"id":501,"createTime":502,"updateTime":502,"relativeEntities":602,"slug":504,"properties":603,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":604},{"VI":507},{"id":606,"sortIndex":152,"affiliation":607,"properties":611},"035c1761-626c-480c-99b5-d7d5f1acffd0",{"id":482,"createTime":483,"updateTime":483,"relativeEntities":608,"slug":22,"properties":609,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":610},{"VI":487},{},{"title":613},{"VI":614},"Dunja Simicic",{"id":616,"sortIndex":128,"researcher":22,"roles":617,"affiliations":618,"properties":624},"4a56522e-96a6-4b11-8c9e-8d083b01b904",[159],[619],{"id":22,"sortIndex":124,"affiliation":620,"properties":22},{"id":466,"createTime":467,"updateTime":467,"relativeEntities":621,"slug":22,"properties":622,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":623},{"VI":471},{"title":625},{"VI":626},"Abeba Habtesion",{"id":628,"sortIndex":124,"researcher":22,"roles":629,"affiliations":630,"properties":657},"a16c9e2b-1808-45cb-a055-abbf5694cc83",[159],[631,638,643,650],{"id":632,"sortIndex":23,"affiliation":633,"properties":637},"8fac9d87-62a5-4535-a60c-68bf7f72dc84",{"id":575,"createTime":576,"updateTime":576,"relativeEntities":634,"slug":22,"properties":635,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":636},{"VI":580},{},{"id":22,"sortIndex":124,"affiliation":639,"properties":22},{"id":466,"createTime":467,"updateTime":467,"relativeEntities":640,"slug":22,"properties":641,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":642},{"VI":471},{"id":644,"sortIndex":152,"affiliation":645,"properties":649},"145b9f91-a848-46d1-8791-6a0da9f97605",{"id":527,"createTime":528,"updateTime":529,"relativeEntities":646,"slug":531,"properties":647,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":648},{"VI":534},{},{"id":651,"sortIndex":133,"affiliation":652,"properties":656},"13e13167-85fe-45e7-9d38-f0fc1544233a",{"id":584,"createTime":585,"updateTime":586,"relativeEntities":653,"slug":588,"properties":654,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":655},{"VI":591},{},{"title":658},{"VI":659},"Anna Hadjihambi",{"id":661,"sortIndex":157,"researcher":22,"roles":662,"affiliations":663,"properties":669},"2f7da273-4409-4511-a9b9-c00d96157004",[159],[664],{"id":22,"sortIndex":124,"affiliation":665,"properties":22},{"id":466,"createTime":467,"updateTime":467,"relativeEntities":666,"slug":22,"properties":667,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":668},{"VI":471},{"title":670},{"VI":671},"Nathan Davies",{"url":431,"publisher":673,"properties":702},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":674,"slug":10,"properties":675,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":680,"manageAffiliations":681,"indexDatabases":682,"url":122,"thumbnailPath":22,"statistic":697,"gsStatistic":22,"type":22,"analyzePriority":22},[],{"country":676,"issn":677,"introduce":678,"title":679},{"VOID":13},{"VOID":15},{"EN":17},{"EN":19},[],[],[683,690],{"id":101,"indexDatabase":684,"url":114,"indexYears":115,"academicFieldIds":689,"indexDatabaseRanking":121},{"id":103,"createTime":104,"updateTime":105,"relativeEntities":685,"label":686,"description":687,"key":111,"publicationTags":688,"standard":22},[],{"EN":108,"VI":108},{"EN":108,"VI":110},[113],[117,118,119,120],{"id":82,"indexDatabase":691,"url":97,"indexYears":22,"academicFieldIds":696,"indexDatabaseRanking":22},{"id":84,"createTime":85,"updateTime":86,"relativeEntities":692,"label":693,"description":694,"key":93,"publicationTags":695,"standard":22},[],{"EN":89,"VI":89},{"VI":91,"EN":92},[95,96],[99],{"impactFactor":124,"impactFactorByYear":698,"i10Index":124,"i10IndexLast5Year":124,"totalPublication":126,"totalPublicationByYear":699,"totalCitation":124,"totalCitationByYear":700,"totalCitationPerPublication":124,"totalCitationPerPublicationByYear":701,"hindexLast5Year":124,"hindex":124},{},{"2019":128,"2020":129,"2021":130,"2022":131,"2023":132,"2024":133},{},{},{"volume":703,"pages":705},{"VOID":704},"4",{"VOID":706},"100509","2022-08-01",2022,{"id":710,"createTime":711,"updateTime":712,"relativeEntities":713,"slug":714,"properties":715,"entityType":151,"verifyStatus":429,"verifyTime":712,"verifyNote":430,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124,"primaryUrl":722,"fullTextUrl":22,"authors":723,"publicationType":377,"publisherRelationship":888,"citationCount":22,"citationInfo":22,"publishDate":922,"publishYear":414,"citationAnalyzeStatus":21,"lastCitationAnalyze":22,"indexDatabases":22,"openAccess":22,"references":22,"isForceReanalyzing":415},"6a82010f-8fa8-4ade-90c2-120061b08983","2024-01-09T06:48:26.670+00:00","2024-12-27T23:56:07.219+00:00",[],"Immuno-genomic-radiomics-to-predict-response-of-biliary-tract-cancer-to-camrelizumab-plus-GEMOX-in-a-single-arm-phase-II-trial",{"references":716,"title":718,"doi":720},{"VOID":717},"Adeva, 2019, Medical treatment for cholangiocarcinoma, Liver Int, 39, 123, 10.1111\u002Fliv.14100\nScott, 2022, Precision medicine in biliary tract cancer, J Clin Oncol, 40, 2716, 10.1200\u002FJCO.21.02576\nValle, 2021, Biliary tract cancer, Lancet, 397, 428, 10.1016\u002FS0140-6736(21)00153-7\nOh, 2022, A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1, J Clin Oncol, 40, 378, 10.1200\u002FJCO.2022.40.4_suppl.378\nRoth, 2023, Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine?, Eur J Cancer, 179, 1, 10.1016\u002Fj.ejca.2022.11.006\nLoeuillard, 2019, Immunobiology of cholangiocarcinoma, JHEP Rep, 1, 297, 10.1016\u002Fj.jhepr.2019.06.003\nBang, 2019, Pembrolizumab (pembro) for advanced biliary adenocarcinoma: results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies, J Clin Oncol, 37, 4079, 10.1200\u002FJCO.2019.37.15_suppl.4079\nCarapeto, 2022, The immunogenomic landscape of resected intrahepatic cholangiocarcinoma, Hepatology, 75, 297, 10.1002\u002Fhep.32150\nSanmamed, 2018, A paradigm shift in cancer immunotherapy: from enhancement to normalization, Cell, 175, 313, 10.1016\u002Fj.cell.2018.09.035\nChen, 2019, Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging, Eur Radiol, 29, 4177, 10.1007\u002Fs00330-018-5986-x\nGillies, 2016, Radiomics: images are more than pictures, they are data, Radiology, 278, 563, 10.1148\u002Fradiol.2015151169\nKing, 2020, Outcomes assessment in intrahepatic cholangiocarcinoma using qualitative and quantitative imaging features, Cancer Imaging, 20, 43, 10.1186\u002Fs40644-020-00323-0\nYang, 2020, Radiomics model of magnetic resonance imaging for predicting pathological grading and lymph node metastases of extrahepatic cholangiocarcinoma, Cancer Lett, 470, 1, 10.1016\u002Fj.canlet.2019.11.036\nChen, 2020, Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial, J Immunother Cancer, 8\nChen, 2021, Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes, J Immunother Cancer, 9\nSchwartz, 2016, RECIST 1.1-Update and clarification: from the RECIST committee, Eur J Cancer, 62, 132, 10.1016\u002Fj.ejca.2016.03.081\nTibshirani, 1997, The lasso method for variable selection in the Cox model, Stat Med, 16, 385, 10.1002\u002F(SICI)1097-0258(19970228)16:4\u003C385::AID-SIM380>3.0.CO;2-3\nLiao, 2019, Preoperative radiomic approach to evaluate tumor-infiltrating CD8(+) T cells in hepatocellular carcinoma patients using contrast-enhanced computed tomography, Ann Surg Oncol, 26, 4537, 10.1245\u002Fs10434-019-07815-9\nZhang, 2020, Machine learning: an approach to preoperatively predict PD-1\u002FPD-L1 expression and outcome in intrahepatic cholangiocarcinoma using MRI biomarkers, ESMO Open, 5, 10.1136\u002Fesmoopen-2020-000910\nLin, 2022, Biomarkers for response to immunotherapy in hepatobiliary malignancies, Hepatobiliary Pancreat Dis Int, 21, 413, 10.1016\u002Fj.hbpd.2022.08.002\nJi, 2019, Biliary tract cancer at CT: a radiomics-based model to predict lymph node metastasis and survival outcomes, Radiology, 290, 90, 10.1148\u002Fradiol.2018181408\nLi, 2021, Role of noninvasive imaging in the evaluation of intrahepatic cholangiocarcinoma: from diagnosis and prognosis to treatment response, Expert Rev Gastroenterol Hepatol, 15, 1267, 10.1080\u002F17474124.2021.1974294\nRiley, 2020, Calculating the sample size required for developing a clinical prediction model, BMJ, 368, m441, 10.1136\u002Fbmj.m441\nRiley, 2022, Minimum sample size calculations for external validation of a clinical prediction model with a time-to-event outcome, Stat Med, 41, 1280, 10.1002\u002Fsim.9275",{"EN":719},"Immuno-genomic-radiomics to predict response of biliary tract cancer to camrelizumab plus GEMOX in a single-arm phase II trial",{"VOID":721},"10.1016\u002Fj.jhepr.2023.100763","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2589555923000940",[724,739,764,779,813,828,840,852,864,876],{"id":725,"sortIndex":128,"researcher":22,"roles":726,"affiliations":727,"properties":736},"dd7a00ce-2c8e-4284-aee5-443c9332131e",[159],[728],{"id":22,"sortIndex":124,"affiliation":729,"properties":22},{"id":730,"createTime":731,"updateTime":731,"relativeEntities":732,"slug":22,"properties":733,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"383f2890-530a-455f-9b98-ea5d4e24688a","2024-01-11T01:52:40.107+00:00",[],{"title":734},{"VI":735},"Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China",{"title":737},{"VI":738},"Xiao-Feng Wu",{"id":740,"sortIndex":133,"researcher":22,"roles":741,"affiliations":742,"properties":761},"0c852f44-86d9-4bb1-b187-34daf667fd77",[159],[743,753],{"id":744,"sortIndex":152,"affiliation":745,"properties":752},"4129aa3d-1b8f-4eff-9071-040d9c6f1736",{"id":746,"createTime":747,"updateTime":747,"relativeEntities":748,"slug":22,"properties":749,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"95b74fac-ebc3-40df-a881-c61df102d714","2023-12-19T20:51:51.859+00:00",[],{"title":750},{"VI":751},"Gusu School, Nanjing Medical University, Suzhou, China",{},{"id":22,"sortIndex":124,"affiliation":754,"properties":22},{"id":755,"createTime":756,"updateTime":756,"relativeEntities":757,"slug":22,"properties":758,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"8318096c-d678-4a90-a9bc-3ba673d9f845","2024-01-09T06:48:26.951+00:00",[],{"title":759},{"VI":760},"Department of Oncology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China",{"title":762},{"VI":763},"Fen Guo",{"id":765,"sortIndex":259,"researcher":22,"roles":766,"affiliations":767,"properties":776},"0e3d4708-db11-4f8d-bb3a-9f8d13322b7a",[159],[768],{"id":22,"sortIndex":124,"affiliation":769,"properties":22},{"id":770,"createTime":771,"updateTime":771,"relativeEntities":772,"slug":22,"properties":773,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"532a7671-2a8a-4dd2-9c7e-f802495e419c","2024-01-20T00:09:29.349+00:00",[],{"title":774},{"VI":775},"Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029, China",{"title":777},{"VI":778},"Yu-Dong Zhang",{"id":780,"sortIndex":68,"researcher":22,"roles":781,"affiliations":782,"properties":810},"24d9c75d-fd49-4dba-b128-a29af055c793",[159],[783,793,800],{"id":22,"sortIndex":124,"affiliation":784,"properties":22},{"id":785,"createTime":786,"updateTime":787,"relativeEntities":788,"slug":789,"properties":790,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"85e448df-0b46-4e6d-8a44-6a36ced7182b","2024-01-09T06:48:27.068+00:00","2024-07-18T16:44:39.614+00:00",[],"Department-of-Oncology-The-First-Affiliated-Hospital-of-Nanjing-Medical-University-Nanjing-Jiangsu-China",{"title":791},{"VI":792},"Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China",{"id":794,"sortIndex":152,"affiliation":795,"properties":799},"8455020c-f621-4a80-8393-7d6bff9bf7f2",{"id":746,"createTime":747,"updateTime":747,"relativeEntities":796,"slug":22,"properties":797,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":798},{"VI":751},{},{"id":801,"sortIndex":23,"affiliation":802,"properties":809},"8f1d563f-0e2c-4657-a492-174cfa14a27d",{"id":803,"createTime":804,"updateTime":804,"relativeEntities":805,"slug":22,"properties":806,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"5e1c763a-898f-4a68-a162-601cb2ff2b62","2024-01-09T06:48:27.116+00:00",[],{"title":807},{"VI":808},"Department of Oncology, Pukou Branch Hospital of Jiangsu Province Hospital, Nanjing, China",{},{"title":811},{"VI":812},"Xiao-Feng Chen",{"id":814,"sortIndex":152,"researcher":22,"roles":815,"affiliations":816,"properties":825},"6ac71d13-bf73-4b02-80f3-9dd2771108fc",[159],[817],{"id":22,"sortIndex":124,"affiliation":818,"properties":22},{"id":819,"createTime":820,"updateTime":820,"relativeEntities":821,"slug":22,"properties":822,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"6009e527-6c39-414b-9e9c-56a1451f1fdb","2024-01-09T06:48:26.791+00:00",[],{"title":823},{"VI":824},"Department of Oncology, Liyang People’s Hospital, Liyang, China",{"title":826},{"VI":827},"Jie Tang",{"id":829,"sortIndex":275,"researcher":22,"roles":830,"affiliations":831,"properties":837},"be07c202-cfb1-4768-9b25-7edb286414f1",[159],[832],{"id":22,"sortIndex":124,"affiliation":833,"properties":22},{"id":785,"createTime":786,"updateTime":787,"relativeEntities":834,"slug":789,"properties":835,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":836},{"VI":792},{"title":838},{"VI":839},"Lan-Lan Pan",{"id":841,"sortIndex":129,"researcher":22,"roles":842,"affiliations":843,"properties":849},"c128142e-9570-4130-9d78-d687a818fa71",[159],[844],{"id":22,"sortIndex":124,"affiliation":845,"properties":22},{"id":785,"createTime":786,"updateTime":787,"relativeEntities":846,"slug":789,"properties":847,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":848},{"VI":792},{"title":850},{"VI":851},"Ling Ma",{"id":853,"sortIndex":157,"researcher":22,"roles":854,"affiliations":855,"properties":861},"23c8b7cc-0c2a-4868-a5eb-796abccf1079",[159],[856],{"id":22,"sortIndex":124,"affiliation":857,"properties":22},{"id":785,"createTime":786,"updateTime":787,"relativeEntities":858,"slug":789,"properties":859,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":860},{"VI":792},{"title":862},{"VI":863},"Yi-Tong Tian",{"id":865,"sortIndex":124,"researcher":22,"roles":866,"affiliations":867,"properties":873},"d3538b27-f805-4d2a-a2e5-5757f98e9a37",[159],[868],{"id":22,"sortIndex":124,"affiliation":869,"properties":22},{"id":770,"createTime":771,"updateTime":771,"relativeEntities":870,"slug":22,"properties":871,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":872},{"VI":775},{"title":874},{"VI":875},"Qiu-Ping Liu",{"id":877,"sortIndex":23,"researcher":22,"roles":878,"affiliations":879,"properties":885},"2ae74cfa-0a63-40a8-b38a-1b3388a9877c",[159],[880],{"id":22,"sortIndex":124,"affiliation":881,"properties":22},{"id":785,"createTime":786,"updateTime":787,"relativeEntities":882,"slug":789,"properties":883,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":884},{"VI":792},{"title":886},{"VI":887},"Yi-Zhang Chen",{"url":722,"publisher":889,"properties":918},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":890,"slug":10,"properties":891,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":896,"manageAffiliations":897,"indexDatabases":898,"url":122,"thumbnailPath":22,"statistic":913,"gsStatistic":22,"type":22,"analyzePriority":22},[],{"country":892,"issn":893,"introduce":894,"title":895},{"VOID":13},{"VOID":15},{"EN":17},{"EN":19},[],[],[899,906],{"id":101,"indexDatabase":900,"url":114,"indexYears":115,"academicFieldIds":905,"indexDatabaseRanking":121},{"id":103,"createTime":104,"updateTime":105,"relativeEntities":901,"label":902,"description":903,"key":111,"publicationTags":904,"standard":22},[],{"EN":108,"VI":108},{"EN":108,"VI":110},[113],[117,118,119,120],{"id":82,"indexDatabase":907,"url":97,"indexYears":22,"academicFieldIds":912,"indexDatabaseRanking":22},{"id":84,"createTime":85,"updateTime":86,"relativeEntities":908,"label":909,"description":910,"key":93,"publicationTags":911,"standard":22},[],{"EN":89,"VI":89},{"VI":91,"EN":92},[95,96],[99],{"impactFactor":124,"impactFactorByYear":914,"i10Index":124,"i10IndexLast5Year":124,"totalPublication":126,"totalPublicationByYear":915,"totalCitation":124,"totalCitationByYear":916,"totalCitationPerPublication":124,"totalCitationPerPublicationByYear":917,"hindexLast5Year":124,"hindex":124},{},{"2019":128,"2020":129,"2021":130,"2022":131,"2023":132,"2024":133},{},{},{"volume":919,"pages":920},{"VOID":410},{"VOID":921},"100763","2023-07-01",{"id":924,"createTime":925,"updateTime":926,"relativeEntities":927,"slug":928,"properties":929,"entityType":151,"verifyStatus":429,"verifyTime":926,"verifyNote":430,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124,"primaryUrl":936,"fullTextUrl":22,"authors":937,"publicationType":377,"publisherRelationship":1034,"citationCount":22,"citationInfo":22,"publishDate":1069,"publishYear":1070,"citationAnalyzeStatus":21,"lastCitationAnalyze":22,"indexDatabases":22,"openAccess":22,"references":22,"isForceReanalyzing":415},"b45f06c4-81e2-41c6-9af7-e1befcd95838","2024-01-30T12:18:58.519+00:00","2025-01-13T23:55:25.591+00:00",[],"Acute-on-chronic-liver-failure-Definitions-pathophysiology-and-principles-of-treatment",{"references":930,"title":932,"doi":934},{"VOID":931},"Arroyo, 2020, Acute-on-chronic liver failure, N Engl J Med, 382, 2137, 10.1056\u002FNEJMra1914900\nMoreau, 2013, Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis, Gastroenterology, 144, 1426, 10.1053\u002Fj.gastro.2013.02.042\nBajaj, 2014, Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures, Hepatology, 60, 250, 10.1002\u002Fhep.27077\nWu, 2018, Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure, Gut, 67, 2181, 10.1136\u002Fgutjnl-2017-314641\nSarin, 2019, Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL): an update, Hepatol Int, 13, 353, 10.1007\u002Fs12072-019-09946-3\nSarin, 2009, Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL), Hepatol Int, 3, 269, 10.1007\u002Fs12072-008-9106-x\nSarin, 2014, Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014, Hepatol Int, 8, 453, 10.1007\u002Fs12072-014-9580-2\nJalan, 2014, Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure, J Hepatol, 61, 1038, 10.1016\u002Fj.jhep.2014.06.012\nO'Leary, 2018, NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis, Hepatology, 67, 2367, 10.1002\u002Fhep.29773\nFernández, 2018, Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis, Gut, 67, 1870, 10.1136\u002Fgutjnl-2017-314240\nMahmud, 2019, Incidence and mortality of acute-on-chronic liver failure using two definitions in patients with compensated cirrhosis, Hepatology, 69, 2150, 10.1002\u002Fhep.30494\nPiano, 2017, Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis, J Hepatol, 67, 1177, 10.1016\u002Fj.jhep.2017.07.008\nSundaram, 2018, Class III obesity is a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis, J Hepatol, 69, 617, 10.1016\u002Fj.jhep.2018.04.016\nGustot, 2015, Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis, Hepatology, 62, 243, 10.1002\u002Fhep.27849\nLi, 2016, Characteristics, diagnosis and prognosis of acute-on-chronic liver failure in cirrhosis associated to hepatitis B, Sci Rep, 6, 25487, 10.1038\u002Fsrep25487\nKim, 2016, Characteristics and discrepancies in acute-on-chronic liver failure: need for a unified definition, PLoS One, 11, e0146745, 10.1371\u002Fjournal.pone.0146745\nHernaez, 2019, Prevalence and short-term mortality of acute-on-chronic liver failure: a national cohort study from the USA, J Hepatol, 70, 639, 10.1016\u002Fj.jhep.2018.12.018\nAmarapurkar, 2015, Acute-on-chronic liver failure: a prospective study to determine the clinical profile, outcome, and factors predicting mortality, Indian J Gastroenterol, 34, 216, 10.1007\u002Fs12664-015-0574-3\nShi, 2015, Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults, Hepatology, 62, 232, 10.1002\u002Fhep.27795\nAbbas, 2015, Pattern and profile of chronic liver disease in acute on chronic liver failure, Hepatol Int, 9, 366, 10.1007\u002Fs12072-015-9627-z\nChen, 2019, Complications constitute a major risk factor for mortality in hepatitis B virus-related acute-on-chronic liver failure patients: a multi-national study from the Asia-Pacific region, Hepatol Int, 13, 695, 10.1007\u002Fs12072-019-09992-x\nKarvellas, 2018, Dynamic prognostication in critically ill cirrhotic patients with multiorgan failure in ICUs in Europe and North America: a multicenter analysis, Crit Care Med, 46, 1783, 10.1097\u002FCCM.0000000000003369\nClària, 2016, Systemic inflammation in decompensated cirrhosis. Characterization and role in acute-on-chronic liver failure, Hepatology, 64, 1249, 10.1002\u002Fhep.28740\nIwasaki, 2015, Control of adaptive immunity by the innate immune system, Nat Immunol, 16, 343, 10.1038\u002Fni.3123\nBianchi, 2007, DAMPs, PAMPs and alarmins: all we need to know about danger, J Leukoc Biol, 81, 1, 10.1189\u002Fjlb.0306164\nBernardi, 2015, Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis, J Hepatol, 63, 1272, 10.1016\u002Fj.jhep.2015.07.004\nMoreau, 2018, Effects of long-term norfloxacin therapy in patients with advanced cirrhosis, Gastroenterology, 155, 1816, 10.1053\u002Fj.gastro.2018.08.026\nWiest, 2014, Pathological bacterial translocation in liver cirrhosis, J Hepatol, 60, 197, 10.1016\u002Fj.jhep.2013.07.044\nMedzhitov, 2008, Origin and physiological roles of inflammation, Nature, 454, 428, 10.1038\u002Fnature07201\nPetrasek, 2013, STING-IRF3 pathway links endoplasmic reticulum stress with hepatocyte apoptosis in early alcoholic liver disease, Proc Natl Acad Sci USA, 110, 16544, 10.1073\u002Fpnas.1308331110\nEvankovich, 2010, High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity, J Biol Chem, 285, 39888, 10.1074\u002Fjbc.M110.128348\nLi, 2015, Submassive hepatic necrosis distinguishes HBV-associated acute on chronic liver failure from cirrhotic patients with acute decompensation, J Hepatol, 63, 50, 10.1016\u002Fj.jhep.2015.01.029\nBortoluzzi, 2013, Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms, Hepatology, 57, 266, 10.1002\u002Fhep.26021\nRodríguez-Roisin, 2008, Hepatopulmonary syndrome - a liver-induced lung vascular disorder, N Engl J Med, 358, 2378, 10.1056\u002FNEJMra0707185\nGustot, 2009, Severe sepsis in cirrhosis, Hepatology, 50, 2022, 10.1002\u002Fhep.23264\nAlobaidi, 2015, Sepsis-associated acute kidney injury, Semin Nephrol, 35, 2, 10.1016\u002Fj.semnephrol.2015.01.002\nMoreau, 2020, Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF, J Hepatol, 72, 688, 10.1016\u002Fj.jhep.2019.11.009\nBajaj, 2018, Prediction of fungal infection development and their impact on survival using the NACSELD cohort, Am J Gastroenterol, 113, 556, 10.1038\u002Fajg.2017.471\nLi, 2020, Clinical characteristics and 28-d outcomes of bacterial infections in patients with hepatitis B virus-related acute-on-chronic liver failure, World J Clin Cases, 8, 1042, 10.12998\u002Fwjcc.v8.i6.1042\nSu, 2020, Characteristics and outcome of nosocomial bloodstream infection in patients with acute-on-chronic liver failure, Eur J Gastroenterol Hepatol, 10.1097\u002FMEG.0000000000001699\nCai, 2017, Characteristics of infection and its impact on short-term outcome in patients with acute-on-chronic liver failure, Medicine (Baltimore), 96, e8057, 10.1097\u002FMD.0000000000008057\nClària, 2019, Orchestration of tryptophan-kynurenine pathway, acute decompensation, and acute-on-chronic liver failure in cirrhosis, Hepatology, 69, 1686, 10.1002\u002Fhep.30363\nBernsmeier, 2015, Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK, Gastroenterology, 148, 603, 10.1053\u002Fj.gastro.2014.11.045\nBernsmeier, 2018, CD14+ CD15- HLA-DR- myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure, Gut, 67, 1155, 10.1136\u002Fgutjnl-2017-314184\nWeichselbaum, 2020, Epigenetic basis for monocyte dysfunction in patients with severe alcoholic hepatitis, J Hepatol, 73, 303, 10.1016\u002Fj.jhep.2020.02.017\nRolas, 2018, NADPH oxidase depletion in neutrophils from patients with cirrhosis and restoration via toll-like receptor 7\u002F8 activation, Gut, 67, 1505, 10.1136\u002Fgutjnl-2016-313443\nMcPhail, 2018, Incidence and outcomes for patients with cirrhosis admitted to the United Kingdom critical care units, Crit Care Med, 46, 705, 10.1097\u002FCCM.0000000000002961\nGalbois, 2014, Improved prognosis of septic shock in patients with cirrhosis: a multicenter study, Crit Care Med, 42, 1666, 10.1097\u002FCCM.0000000000000321\nKarvellas, 2014, Advances in management and prognostication in critically ill cirrhotic patients, Curr Opin Crit Care, 20, 210, 10.1097\u002FMCC.0000000000000067\nWeil, 2017, Prognosis of cirrhotic patients admitted to intensive care unit: a meta-analysis, Ann Intensive Care, 7, 33, 10.1186\u002Fs13613-017-0249-6\nPiano, 2019, Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide, Gastroenterology, 156, 1368, 10.1053\u002Fj.gastro.2018.12.005\n2018, EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis, J Hepatol, 69, 406, 10.1016\u002Fj.jhep.2018.03.024\nGustot, 2019, Acute-on-chronic liver failure in patients with alcohol-related liver disease, J Hepatol, 70, 319, 10.1016\u002Fj.jhep.2018.12.008\nSersté, 2018, The prognostic value of acute-on-chronic liver failure during the course of severe alcoholic hepatitis, J Hepatol, 69, 318, 10.1016\u002Fj.jhep.2018.02.022\nForrest, 2018, Prevalent acute-on-chronic liver failure and response to corticosteroids in alcoholic hepatitis, J Hepatol, 69, 1200, 10.1016\u002Fj.jhep.2018.06.019\nTrebicka, 2020, Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS, J Hepatol, 73, 1082, 10.1016\u002Fj.jhep.2020.04.024\nBernardi, 2020, Albumin in decompensated cirrhosis: new concepts and perspectives, Gut, 69, 1127, 10.1136\u002Fgutjnl-2019-318843\nFernández, 2019, Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis, Gastroenterology, 157, 149, 10.1053\u002Fj.gastro.2019.03.021\nArroyo, 2014, Human serum albumin, systemic inflammation, and cirrhosis, J Hepatol, 61, 396, 10.1016\u002Fj.jhep.2014.04.012\nO'Brien, 2014, Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2, Nat Med, 20, 518, 10.1038\u002Fnm.3516\nPaugam-Burtz, 2020, Management of liver failure in general intensive care unit, Anaesth Crit Care Pain Med, 39, 143, 10.1016\u002Fj.accpm.2019.06.014\nFernández, 2020, Efficacy of albumin treatment for patients with cirrhosis and infections unrelated to spontaneous bacterial peritonitis, Clin Gastroenterol Hepatol, 18, 963, 10.1016\u002Fj.cgh.2019.07.055\nGaudry, 2020, Delayed vs. early initiation of renal replacement therapy for severe acute kidney injury: a systematic review and individual patient data meta-analysis of randomised clinical trials, Lancet, 395, 1506, 10.1016\u002FS0140-6736(20)30531-6\nZhang, 2015, Role of renal replacement therapy in patients with type 1 hepatorenal syndrome receiving combination treatment of vasoconstrictor plus albumin, J Crit Care, 30, 969, 10.1016\u002Fj.jcrc.2015.05.006\nKarvellas, 2019, Intraoperative continuous renal replacement therapy during liver transplantation: a pilot randomized-controlled trial (INCEPTION), Can J Anaesth, 66, 1151, 10.1007\u002Fs12630-019-01454-0\nBañares, 2013, Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial, Hepatology, 57, 1153, 10.1002\u002Fhep.26185\nKribben, 2012, Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure, Gastroenterology, 142, 782, 10.1053\u002Fj.gastro.2011.12.056\nGerth, 2017, Molecular adsorbent recirculating system can reduce short-term mortality among patients with acute-on-chronic liver failure - a retrospective analysis, Crit Care Med, 45, 1616, 10.1097\u002FCCM.0000000000002562\nShen, 2016, Survival benefits with artificial liver support system for acute-on-chronic liver failure: a time series-based meta-analysis, Medicine (Baltimore), 95, e2506, 10.1097\u002FMD.0000000000002506\nSmets, 2019, Transplantation, 103, 1903, 10.1097\u002FTP.0000000000002605\nSundaram, 2019, Factors associated with survival of patients with severe acute-on-chronic liver failure before and after liver transplantation, Gastroenterology, 156, 1381, 10.1053\u002Fj.gastro.2018.12.007\nLevesque, 2017, Impact of acute-on-chronic liver failure on 90-day mortality following a first liver transplantation, Liver Int, 37, 684, 10.1111\u002Fliv.13355\nArtru, 2017, Liver transplantation in the most severely ill cirrhotic patients: a multicenter study in acute-on-chronic liver failure grade 3, J Hepatol, 67, 708, 10.1016\u002Fj.jhep.2017.06.009\nArroyo, 2019, Acute-on-chronic liver failure in cirrhosis requires expedited decisions for liver transplantation, Gastroenterology, 156, 1248, 10.1053\u002Fj.gastro.2019.03.004\nHernaez, 2020, Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure, J Hepatol\nSundaram, 2019, Patients with acute on chronic liver failure grade 3 have greater 14-day waitlist mortality than status-1a patients, Hepatology, 70, 334, 10.1002\u002Fhep.30624\nWeiss, 2020, When is a critically ill cirrhotic patient too sick to transplant? Development of consensus criteria by a multidisciplinary panel of 35 international experts, Transplantation, 10.1097\u002FTP.0000000000003364\nArtzner, 2020, Liver transplantation for critically ill cirrhotic patients: stratifying utility based on pretransplant factors, Am J Transplant, 20, 2437, 10.1111\u002Fajt.15852",{"EN":933},"Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment",{"VOID":935},"10.1016\u002Fj.jhepr.2020.100176","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2589555920301105",[938,977,1002],{"id":939,"sortIndex":23,"researcher":22,"roles":940,"affiliations":941,"properties":974},"6dab6539-3c57-40e2-8460-5769a19de55b",[159],[942,952,964],{"id":943,"sortIndex":152,"affiliation":944,"properties":951},"e80987ba-df4d-4d31-aae7-8337bbee6690",{"id":945,"createTime":946,"updateTime":946,"relativeEntities":947,"slug":22,"properties":948,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"f705a5dc-32f6-4113-a1a3-186025d830b4","2024-01-30T12:18:58.561+00:00",[],{"title":949},{"VI":950},"Inserm et Université de Paris, Centre de Recherche sur l'Inflammation (CRI), Paris, France",{},{"id":953,"sortIndex":124,"affiliation":954,"properties":961},"41d911f3-e4ea-423d-8fdc-a8d360a68fdb",{"id":955,"createTime":956,"updateTime":956,"relativeEntities":957,"slug":22,"properties":958,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"5bba9648-9196-4519-b405-d13b2dbfb16e","2024-02-07T12:05:55.403+00:00",[],{"title":959},{"VI":960},"European Foundation for the Study of Chronic Liver Failure - EF Clif, Barcelona, Spain",{"title":962},{"VI":963},"European Foundation for the Study of Chronic Liver Failure (EF-CLIF), Barcelona, Spain",{"id":965,"sortIndex":23,"affiliation":966,"properties":973},"368b108e-4f68-4259-ba52-22cadfdcfade",{"id":967,"createTime":968,"updateTime":968,"relativeEntities":969,"slug":22,"properties":970,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"44e650bb-a95c-45b8-98e4-7a38952e4e26","2024-01-30T12:18:58.585+00:00",[],{"title":971},{"VI":972},"Service d'Hépatologie, Hôpital Beaujon, AP-HP, Clichy, France",{},{"title":975},{"VI":976},"Richard Moreau",{"id":978,"sortIndex":124,"researcher":22,"roles":979,"affiliations":980,"properties":999},"40a2326a-dcd8-492d-8bdd-9ed3b0d193fd",[159],[981,989],{"id":982,"sortIndex":152,"affiliation":983,"properties":987},"dc4c8554-ae41-48b2-bf20-72a295903d28",{"id":955,"createTime":956,"updateTime":956,"relativeEntities":984,"slug":22,"properties":985,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":986},{"VI":960},{"title":988},{"VI":963},{"id":22,"sortIndex":124,"affiliation":990,"properties":22},{"id":991,"createTime":992,"updateTime":993,"relativeEntities":994,"slug":995,"properties":996,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"70c8062c-5548-4707-870e-450e172730fb","2023-12-02T00:25:33.842+00:00","2025-01-30T16:42:19.706+00:00",[],"Department-of-Medical-and-Surgical-Sciences-University-of-Bologna-Bologna-Italy",{"title":997},{"VI":998},"Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy",{"title":1000},{"VI":1001},"Giacomo Zaccherini",{"id":1003,"sortIndex":152,"researcher":22,"roles":1004,"affiliations":1005,"properties":1031},"ecd98301-f902-4338-a20d-9471e5624db5",[159],[1006,1014,1024],{"id":1007,"sortIndex":124,"affiliation":1008,"properties":1012},"f6935362-accb-426f-b255-6c183f5e072d",{"id":955,"createTime":956,"updateTime":956,"relativeEntities":1009,"slug":22,"properties":1010,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1011},{"VI":960},{"title":1013},{"VI":963},{"id":1015,"sortIndex":152,"affiliation":1016,"properties":1023},"c0dc9b3d-25d3-4ecc-bc6c-b41d5c38572e",{"id":1017,"createTime":1018,"updateTime":1018,"relativeEntities":1019,"slug":22,"properties":1020,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"f07a74a7-f707-4ba9-92e5-81b186e9c0c6","2024-01-24T23:24:10.000+00:00",[],{"title":1021},{"VI":1022},"Department of Anesthesiology and Critical Care, Beaujon Hospital, DMU Parabol, AP-HP.Nord, Paris, France",{},{"id":1025,"sortIndex":23,"affiliation":1026,"properties":1030},"b6ec5ab9-e4a3-47ea-bf22-db064a521ee8",{"id":945,"createTime":946,"updateTime":946,"relativeEntities":1027,"slug":22,"properties":1028,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1029},{"VI":950},{},{"title":1032},{"VI":1033},"Emmanuel Weiss",{"url":936,"publisher":1035,"properties":1064},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1036,"slug":10,"properties":1037,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":1042,"manageAffiliations":1043,"indexDatabases":1044,"url":122,"thumbnailPath":22,"statistic":1059,"gsStatistic":22,"type":22,"analyzePriority":22},[],{"country":1038,"issn":1039,"introduce":1040,"title":1041},{"VOID":13},{"VOID":15},{"EN":17},{"EN":19},[],[],[1045,1052],{"id":101,"indexDatabase":1046,"url":114,"indexYears":115,"academicFieldIds":1051,"indexDatabaseRanking":121},{"id":103,"createTime":104,"updateTime":105,"relativeEntities":1047,"label":1048,"description":1049,"key":111,"publicationTags":1050,"standard":22},[],{"EN":108,"VI":108},{"EN":108,"VI":110},[113],[117,118,119,120],{"id":82,"indexDatabase":1053,"url":97,"indexYears":22,"academicFieldIds":1058,"indexDatabaseRanking":22},{"id":84,"createTime":85,"updateTime":86,"relativeEntities":1054,"label":1055,"description":1056,"key":93,"publicationTags":1057,"standard":22},[],{"EN":89,"VI":89},{"VI":91,"EN":92},[95,96],[99],{"impactFactor":124,"impactFactorByYear":1060,"i10Index":124,"i10IndexLast5Year":124,"totalPublication":126,"totalPublicationByYear":1061,"totalCitation":124,"totalCitationByYear":1062,"totalCitationPerPublication":124,"totalCitationPerPublicationByYear":1063,"hindexLast5Year":124,"hindex":124},{},{"2019":128,"2020":129,"2021":130,"2022":131,"2023":132,"2024":133},{},{},{"volume":1065,"pages":1067},{"VOID":1066},"3",{"VOID":1068},"100176","2021-02-01",2021,{"id":1072,"createTime":1073,"updateTime":1074,"relativeEntities":1075,"slug":1076,"properties":1077,"entityType":151,"verifyStatus":429,"verifyTime":1074,"verifyNote":430,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":152,"primaryUrl":1084,"fullTextUrl":22,"authors":1085,"publicationType":377,"publisherRelationship":1140,"citationCount":22,"citationInfo":22,"publishDate":1175,"publishYear":1176,"citationAnalyzeStatus":21,"lastCitationAnalyze":22,"indexDatabases":22,"openAccess":22,"references":22,"isForceReanalyzing":415},"141896f7-8d9d-412e-9e84-95e7871f1726","2024-01-05T21:57:48.675+00:00","2025-01-19T23:47:38.065+00:00",[],"Are-the-new-genetic-tools-for-diagnosis-of-Wilson-disease-helpful-in-clinical-practice-",{"references":1078,"title":1080,"doi":1082},{"VOID":1079},"Ferenci, 2019, Age and sex but not ATP7B genotype effectively influence the clinical phenotype of Wilson disease, Hepatology, 69, 1464, 10.1002\u002Fhep.30280\nCzłonkowska, 2018, Wilson disease, Nat Rev Dis Primers, 4, 21, 10.1038\u002Fs41572-018-0018-3\nSteindl, 1997, Wilson's disease in patients presenting with liver disease: a diagnostic challenge, Gastroenterology, 113, 212, 10.1016\u002FS0016-5085(97)70097-0\nFerenci, 2003, Diagnosis and phenotypic classification of Wilson disease. Final report of the proceedings of the working party at the 8th International Meeting on Wilson disease and Menkes disease,Leipzig\u002FGermany, April 16-18,2001, Liver Int, 23, 139, 10.1034\u002Fj.1600-0676.2003.00824.x\n2012, EASL clinical practice guidelines: Wilson disease, J Hepatol, 56, 671, 10.1016\u002Fj.jhep.2011.11.007\nSocha, 2018, Wilson's disease in children: a position paper by the Hepatology Committee of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition, J Pediatr Gastroenterol Nutr, 66, 334, 10.1097\u002FMPG.0000000000001787\nFerenci, 2006, Regional distribution of mutations of the ATP7B gene in patients with Wilson disease - impact on genetic testing, Hum Genet, 120, 151, 10.1007\u002Fs00439-006-0202-5\nGomes, 2016, Geographic distribution of ATP7B mutations in Wilson disease, Hum Biol, 43, 1, 10.3109\u002F03014460.2015.1051492\nMaier-Dobersberger, 1997, Detection of the His1069Gln mutation in Wilson disease by a rapid polymerase chain reaction, Ann Intern Med, 127, 21, 10.7326\u002F0003-4819-127-1-199707010-00004\nDastsooz, 2013, Multiplex ARMS PCR to detect 8 common mutations of ATP7B gene in patients with Wilson disease, Hepat Mon, 13, e8375, 10.5812\u002Fhepatmon.8375\nCheng, 2017, Spectrum of ATP7B mutations and genotype–phenotype correlation in large-scale Chinese patients with Wilson disease, Clin Genet, 92, 69, 10.1111\u002Fcge.12951\nHGMD Professional vs 2018.2 (Accessed December 26, 2019).\nMukherjee, 2014, Genetic defects in Indian Wilson disease patients and genotype-phenotype correlation, Parkinsonism Relat Disord, 20, 75, 10.1016\u002Fj.parkreldis.2013.09.021\nSánchez-Monteagudo, 2020, Genetics of Wilson disease and Wilson-like phenotype in a clinical series from eastern Spain, Clin Genet, 97, 758, 10.1111\u002Fcge.13719\nCoffey, 2013, A genetic study of Wilson's disease in the United Kingdom, Brain, 136, 1476, 10.1093\u002Fbrain\u002Fawt035\nCollet, 2018, High genetic carrier frequency of Wilson's disease in France: discrepancies with clinical prevalence, BMC Med Genet, 19, 143, 10.1186\u002Fs12881-018-0660-3\nKudryavtseva, 2017, The frequency of mutations in the ATP7B gene in Russia, Metagene, 13, 173\nGropman, 2007, Atypical patterns of inheritance, Semin Pediatr Neurol, 14, 34, 10.1016\u002Fj.spen.2006.11.007\nGromadzka, 2005, Frameshift and nonsense mutations in the gene for ATPase7B are associated with severe impairment of copper metabolism and with an early clinical manifestation of Wilson's disease, Clin Genet, 68, 524, 10.1111\u002Fj.1399-0004.2005.00528.x\nHakim, 2019, Clinical utility of genomic analysis in adults with idiopathic liver disease, J Hepatol, 70, 1214, 10.1016\u002Fj.jhep.2019.01.036\nWright, 2018, Paediatric genomics: diagnosing rare disease in children, Nat Rev Genet, 19, 253, 10.1038\u002Fnrg.2017.116\nStenson, 2017, The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies, Hum Genet, 136, 665, 10.1007\u002Fs00439-017-1779-6\nHuster, 2012, Diverse functional properties of Wilson disease ATP7B variants, Gastroenterology, 142, 947, 10.1053\u002Fj.gastro.2011.12.048\nSquitti, 2014, In silico investigation of the ATP7B gene: insights from functional prediction of non-synonymous substitution to protein structure, Biometals, 27, 53, 10.1007\u002Fs10534-013-9686-3\nMaier-Dobersberger, 1995, Diagnosis of Wilson's disease in an asymptomatic sibling by DNA linkage analysis, Gastroenterology, 109, 2015, 10.1016\u002F0016-5085(95)90771-8\nHofer, 2012, Identification of a novel Wilson disease gene mutation frequent in Upper Austria: a genetic and clinical study, J Hum Genet, 57, 564, 10.1038\u002Fjhg.2012.65\nDufernez, 2013, Wilson disease in offspring of affected patients: report of four French families, Clin Res Hepatol Gastroenterol, 37, 240, 10.1016\u002Fj.clinre.2013.01.001\nLoudianos, 2013, Wilson disease in two consecutive generations: the detection of three mutated alleles in the ATP7B gene in two Sardinian families, Dig Liver Dis, 45, 342, 10.1016\u002Fj.dld.2012.10.017\nFirneisz, 2001, Wilson disease in two consecutive generations: an exceptional family, Am J Gastroenterol, 96, 2069, 10.1111\u002Fj.1572-0241.2001.03983.x\nLoudianos, 2016, Wilson disease in an adult asymptomatic patient: a potential role for modifying factors of copper metabolism, Ann Gastroenterol, 29, 96\nYamaguchi, 1999, Mass screening for Wilson disease: results and recommendations, Pediatr Int, 41, 405, 10.1046\u002Fj.1442-200x.1999.01096.x\nNakayama, 2008, Early and presymptomatic detection of Wilson disease at the mandatory 3-year-old medical health care examination in Hokkaido Prefecture with the use of a novel automated urinary ceruloplasmin assay, Mol Genet Metab, 94, 363, 10.1016\u002Fj.ymgme.2008.03.002\nJang, 2017, Carrier frequency of Wilson disease in the Korean population: a DNA-based approach, J Hum Genet, 62, 815, 10.1038\u002Fjhg.2017.49\nGialluisi, 2013, The homozygosity index (HI) approach reveals high allele frequency for Wilson disease in the Sardinian population, Eur J Hum Genet, 21, 1308, 10.1038\u002Fejhg.2013.43\nSandahl, 2020, The prevalence of Wilson's disease: an update, Hepatology, 71, 722, 10.1002\u002Fhep.30911\nSquitti, 2016, Non-ceruloplasmin bound copper and ATP7B gene variants in Alzheimer's disease. (Review), Metallomics, 8, 863, 10.1039\u002FC6MT00101G\nWhiteaker, 2010, An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers, Mol Cell Proteomics, 9, 184, 10.1074\u002Fmcp.M900254-MCP200\nJung, 2017, Quantification of ATP7B protein in dried blood spots by peptide immuno-SRM as a potential screen for Wilson disease, J Proteome Res, 16, 862, 10.1021\u002Facs.jproteome.6b00828\nHahn, 2020, Proteolytic immuno-SRM-MS\u002FMS analysis of ATP7B in dried blood spots: a potential application for diagnosis of Wilson disease, J Hepatol\nDufernez, 2013, Wilson disease in offspring of affected patients: report of four French families, Clin Res Hepatol Gastroenterol, 37, 240, 10.1016\u002Fj.clinre.2013.01.001\nBrunet, 2012, Familial screening in Wilson's disease: think at the previous generation!, J Hepatol, 57, 1394, 10.1016\u002Fj.jhep.2012.07.011\nDenoyer, 2013, Neurological Wilson's disease lethal for the son, asymptomatic in the father, Mov Disord, 28, 402, 10.1002\u002Fmds.25290\nKluska, 2019, Whole-exome sequencing identifies novel pathogenic variants across the ATP7B gene and some modifiers of Wilson's disease phenotype, Liver Int, 39, 177, 10.1111\u002Fliv.13967\nMordaunt, 2019, Epigenomic signatures in liver and blood of Wilson disease patients include hypermethylation of liver-specific enhancers, Epigenetics Chromatin, 12, 10, 10.1186\u002Fs13072-019-0255-z\nFinkenstedt, 2010, Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation, J Hepatol, 53, 1101, 10.1016\u002Fj.jhep.2010.04.039\nJansen, 2016, CCDC115 deficiency causes a disorder of Golgi homeostasis with abnormal protein glycosylation, Am J Hum Genet, 98, 310, 10.1016\u002Fj.ajhg.2015.12.010\nGirard, 2018, CCDC115-CDG: a new rare and misleading inherited cause of liver disease, Mol Genet Metab, 124, 228, 10.1016\u002Fj.ymgme.2018.05.002\nVajro, 2018, Three unreported cases of TMEM199-CDG, a rare genetic liver disease with abnormal glycosylation, Orphanet J Rare Dis, 13, 4, 10.1186\u002Fs13023-017-0757-3\nRamraj, 2012, Progressive familial intrahepatic cholestasis type 3: overlapping presentation with Wilson disease, Clin Pediatr, 51, 689, 10.1177\u002F0009922812451076\nBoga, 2015, Presentation of progressive familial intrahepatic cholestasis type 3 Mimicking Wilson disease: molecular genetic diagnosis and response to treatment, Pediatr Gastroenterol Hepatol Nutr, 18, 202, 10.5223\u002Fpghn.2015.18.3.202\nMontpetit, 2008, Disruption of AP1S1, causing a novel neurocutaneous syndrome, perturbs development of the skin and spinal cord, PLoS Genet, 4, e1000296, 10.1371\u002Fjournal.pgen.1000296\nMartinelli, 2013, MEDNIK syndrome: a novel defect of copper metabolism treatable by zinc acetate therapy, Brain, 136, 872, 10.1093\u002Fbrain\u002Fawt012\nHermann, 2019, Classification and differential diagnosis of Wilson's disease, Ann Transl Med, 7, S63, 10.21037\u002Fatm.2019.02.07\nTanner, 1983, Early introduction of copper-contaminated animal milk feeds as a possible cause of Indian childhood cirrhosis, Lancet, 2, 992, 10.1016\u002FS0140-6736(83)90980-7\nMuller, 1996, Endemic Tyrolean infantile cirrhosis: an ecogenetic disorder, Lancet, 347, 877, 10.1016\u002FS0140-6736(96)91351-3\nHarada, 2020, Idiopathic copper toxicosis: is abnormal copper metabolism a primary cause of this disease?, Med Mol Morphol, 53, 50, 10.1007\u002Fs00795-019-00227-4\nLalioti, 2017, Disorders in hepatic copper secretion: Wilson's disease and pleomorphic syndromes, Semin Liver Dis, 37, 175, 10.1055\u002Fs-0037-1602764\nMedici, 2013, Wilson's disease: changes in methionine metabolism and inflammation affect global DNA methylation in early liver disease, Hepatology, 57, 555, 10.1002\u002Fhep.26047\nMedici, 2014, Maternal choline modifies fetal liver copper, gene expression, DNA methylation, and neonatal growth in the tx-j mouse model of Wilson disease, Epigenetics, 9, 286, 10.4161\u002Fepi.27110\nGeng, 2018, Association study of gut flora in Wilson's disease through high-throughput sequencing, Medicine (Baltimore), 97, e11743, 10.1097\u002FMD.0000000000011743\nChaturvedi, 2012, The siderophore yersiniabactin binds copper to protect pathogens during infection, Nat Chem Biol, 8, 731, 10.1038\u002Fnchembio.1020\nLichtmannegger, 2016, Methanobactin reverses acute liver failure in a rat model of Wilson disease, J Clin Invest, 126, 2721, 10.1172\u002FJCI85226\nEichler, 2019, Genetic variation, comparative genomics and the diagnosis of disease, N Engl J Med, 381, 64, 10.1056\u002FNEJMra1809315\nVilarinho, 2019, Exome sequencing in clinical hepatology, Hepatology, 70, 2185, 10.1002\u002Fhep.30826\nStättermayer, 2019, The dilemma to diagnose Wilson disease by genetic testing alone, Eur J Clin Invest, 49, e13147, 10.1111\u002Feci.13147\nPanzer, 2019, Wilson disease caused by synonymous ATP7B variants, Hepatology, 70, 1179A",{"EN":1081},"Are the new genetic tools for diagnosis of Wilson disease helpful in clinical practice?",{"VOID":1083},"10.1016\u002Fj.jhepr.2020.100114","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2589555920300483",[1086,1101],{"id":1087,"sortIndex":152,"researcher":22,"roles":1088,"affiliations":1089,"properties":1098},"8d76b82d-eb07-4c85-b063-6fea87c50b11",[159],[1090],{"id":22,"sortIndex":124,"affiliation":1091,"properties":22},{"id":1092,"createTime":1093,"updateTime":1093,"relativeEntities":1094,"slug":22,"properties":1095,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"1edd0b4b-38ff-4352-b988-7f6637b34ee3","2024-01-05T21:57:48.699+00:00",[],{"title":1096},{"VI":1097},"Department of Internal Medicine 3, Gastroenterology and Hepatology, Medical University of Vienna, Austria",{"title":1099},{"VI":1100},"Peter Ferenci",{"id":1102,"sortIndex":124,"researcher":22,"roles":1103,"affiliations":1104,"properties":1137},"ed73f184-29fc-4c9a-bd33-ba30d98cc339",[159],[1105,1117,1129],{"id":1106,"sortIndex":152,"affiliation":1107,"properties":1116},"429c3f3e-2e06-4b1d-82f5-0cc2cbec13c5",{"id":1108,"createTime":1109,"updateTime":1110,"relativeEntities":1111,"slug":1112,"properties":1113,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"0b728037-aa6b-4fa0-812b-2df07d322a69","2024-01-20T18:47:53.657+00:00","2025-06-12T00:19:20.990+00:00",[],"Rare-Diseases-Joint-Units-CIPF-IIS-La-Fe-INCLIVA-Valencia-Spain",{"title":1114},{"VI":1115},"Rare Diseases Joint Units, CIPF-IIS La Fe & INCLIVA, Valencia, Spain",{},{"id":1118,"sortIndex":23,"affiliation":1119,"properties":1128},"6690f15a-632d-4557-81e1-1e0c2e886afe",{"id":1120,"createTime":1121,"updateTime":1122,"relativeEntities":1123,"slug":1124,"properties":1125,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"851a1c51-1ce7-4f6b-b16b-7f4365c7f2d8","2023-12-23T16:11:23.244+00:00","2024-09-12T00:56:01.360+00:00",[],"Department-of-Genetics-Universitat-de-Val%C3%A8ncia-Valencia-Spain",{"title":1126},{"VI":1127},"Department of Genetics, Universitat de València, Valencia, Spain",{},{"id":22,"sortIndex":124,"affiliation":1130,"properties":22},{"id":1131,"createTime":1132,"updateTime":1132,"relativeEntities":1133,"slug":22,"properties":1134,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"bbae8b7c-2a09-4788-9a78-66d84496e78f","2024-01-30T02:20:01.574+00:00",[],{"title":1135},{"VI":1136},"Unit of Genetics and Genomics of Neuromuscular and Neurodegenerative Disorders, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain",{"title":1138},{"VI":1139},"Carmen Espinós",{"url":1084,"publisher":1141,"properties":1170},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1142,"slug":10,"properties":1143,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":1148,"manageAffiliations":1149,"indexDatabases":1150,"url":122,"thumbnailPath":22,"statistic":1165,"gsStatistic":22,"type":22,"analyzePriority":22},[],{"country":1144,"issn":1145,"introduce":1146,"title":1147},{"VOID":13},{"VOID":15},{"EN":17},{"EN":19},[],[],[1151,1158],{"id":101,"indexDatabase":1152,"url":114,"indexYears":115,"academicFieldIds":1157,"indexDatabaseRanking":121},{"id":103,"createTime":104,"updateTime":105,"relativeEntities":1153,"label":1154,"description":1155,"key":111,"publicationTags":1156,"standard":22},[],{"EN":108,"VI":108},{"EN":108,"VI":110},[113],[117,118,119,120],{"id":82,"indexDatabase":1159,"url":97,"indexYears":22,"academicFieldIds":1164,"indexDatabaseRanking":22},{"id":84,"createTime":85,"updateTime":86,"relativeEntities":1160,"label":1161,"description":1162,"key":93,"publicationTags":1163,"standard":22},[],{"EN":89,"VI":89},{"VI":91,"EN":92},[95,96],[99],{"impactFactor":124,"impactFactorByYear":1166,"i10Index":124,"i10IndexLast5Year":124,"totalPublication":126,"totalPublicationByYear":1167,"totalCitation":124,"totalCitationByYear":1168,"totalCitationPerPublication":124,"totalCitationPerPublicationByYear":1169,"hindexLast5Year":124,"hindex":124},{},{"2019":128,"2020":129,"2021":130,"2022":131,"2023":132,"2024":133},{},{},{"volume":1171,"pages":1173},{"VOID":1172},"2",{"VOID":1174},"100114","2020-08-01",2020,{"id":1178,"createTime":1179,"updateTime":1180,"relativeEntities":1181,"slug":1182,"properties":1183,"entityType":151,"verifyStatus":429,"verifyTime":1180,"verifyNote":430,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124,"primaryUrl":1190,"fullTextUrl":22,"authors":1191,"publicationType":377,"publisherRelationship":1368,"citationCount":22,"citationInfo":22,"publishDate":1402,"publishYear":1070,"citationAnalyzeStatus":21,"lastCitationAnalyze":22,"indexDatabases":22,"openAccess":22,"references":22,"isForceReanalyzing":415},"b828f2a0-cff5-435f-a3dd-276e7163b183","2023-12-30T05:48:35.066+00:00","2025-01-28T23:47:28.860+00:00",[],"Hepatic-microbiome-in-healthy-lean-and-obese-humans",{"references":1184,"title":1186,"doi":1188},{"VOID":1185},"Younossi, 2018, Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention, Nat Rev Gastroenterol Hepatol, 15, 11, 10.1038\u002Fnrgastro.2017.109\nWong, 2015, Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States, Gastroenterology, 148, 547, 10.1053\u002Fj.gastro.2014.11.039\nLindenmeyer, 2018, The natural history of nonalcoholic fatty liver disease—an evolving view, Clin Liver Dis, 22, 11, 10.1016\u002Fj.cld.2017.08.003\nZoller, 2016, Nonalcoholic fatty liver disease and hepatocellular carcinoma, Metabolism, 65, 1151, 10.1016\u002Fj.metabol.2016.01.010\nFriedman, 2018, Mechanisms of NAFLD development and therapeutic strategies, Nat Med, 24, 908, 10.1038\u002Fs41591-018-0104-9\nKim, 2018, Nonalcoholic fatty liver disease and metabolic syndrome, Clin Liver Dis, 22, 133, 10.1016\u002Fj.cld.2017.08.010\nAbu-Shanab, 2010, The role of the gut microbiota in nonalcoholic fatty liver disease, Nat Rev Gastroenterol Hepatol, 7, 691, 10.1038\u002Fnrgastro.2010.172\nLey, 2006, Microbial ecology: human gut microbes associated with obesity, Nature, 444, 1022, 10.1038\u002F4441022a\nTurnbaugh, 2006, An obesity-associated gut microbiome with increased capacity for energy harvest, Nature, 444, 1027, 10.1038\u002Fnature05414\nBrun, 2007, Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis, Am J Physiol Gastrointest Liver Physiol, 292, G518, 10.1152\u002Fajpgi.00024.2006\nPendyala, 2012, A high-fat diet is associated with endotoxemia that originates from the gut, Gastroenterology, 142, 10.1053\u002Fj.gastro.2012.01.034\nHenao-Mejia, 2012, Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity, Nature, 482, 179, 10.1038\u002Fnature10809\nSeki, 2007, TLR4 enhances TGF-β signaling and hepatic fibrosis, Nat Med, 13, 1324, 10.1038\u002Fnm1663\nLeung, 2016, The role of the gut microbiota in NAFLD, Nat Rev Gastroenterol Hepatol, 13, 412, 10.1038\u002Fnrgastro.2016.85\nTilg, 2016, Gut microbiome and liver diseases, Gut, 65, 2035, 10.1136\u002Fgutjnl-2016-312729\nSeki, 2012, Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut, J Physiol, 590, 447, 10.1113\u002Fjphysiol.2011.219691\nDe Minicis, 2014, Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice, Hepatology, 59, 1738, 10.1002\u002Fhep.26695\nPaïssé, 2016, Comprehensive description of blood microbiome from healthy donors assessed by 16S targeted metagenomic sequencing, Transfusion (Paris), 56, 1138, 10.1111\u002Ftrf.13477\nLelouvier, 2016, Changes in blood microbiota profiles associated with liver fibrosis in obese patients: a pilot analysis, Hepatology, 64, 2015, 10.1002\u002Fhep.28829\nBalmer, 2014, The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota, Sci Transl Med, 6, 237ra66, 10.1126\u002Fscitranslmed.3008618\nSchierwagen, 2019, Circulating microbiome in blood of different circulatory compartments, Gut, 68, 578, 10.1136\u002Fgutjnl-2018-316227\nLluch, 2015, The characterization of novel tissue microbiota using an optimized 16S metagenomic sequencing pipeline, PLoS One, 10, 10.1371\u002Fjournal.pone.0142334\nSchierwagen, 2020, Trust is good, control is better: technical considerations in blood microbiome analysis, Gut, 69, 1362, 10.1136\u002Fgutjnl-2019-319123\nAnhê, 2020, Type 2 diabetes influences bacterial tissue compartmentalisation in human obesity, Nat Metab, 2, 233, 10.1038\u002Fs42255-020-0178-9\nSuppli, 2020, Glucagon resistance at the level of amino acid turnover in obese subjects with hepatic steatosis, Diabetes, 69, 1090, 10.2337\u002Fdb19-0715\nSuppli, 2019, Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals, Am J Physiol Gastrointest Liver Physiol, 316, G462, 10.1152\u002Fajpgi.00358.2018\nEriksen, 2019, Non-alcoholic fatty liver disease alters expression of genes governing hepatic nitrogen conversion, Liver Int, 39, 2094, 10.1111\u002Fliv.14205\nEscudié, 2018, FROGS: find, rapidly, OTUs with galaxy solution, Bioinformatics, 34, 1287, 10.1093\u002Fbioinformatics\u002Fbtx791\nStewart, 2012, Growing unculturable bacteria, J Bacteriol, 194, 4151, 10.1128\u002FJB.00345-12\nSookoian, 2020, Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease, Gut, 69, 1483, 10.1136\u002Fgutjnl-2019-318811\nMarchesini, 2003, Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome, Hepatology, 37, 917, 10.1053\u002Fjhep.2003.50161\nMiele, 2009, Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease, Hepatology, 49, 1877, 10.1002\u002Fhep.22848\nVolynets, 2012, Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD), Dig Dis Sci, 57, 1932, 10.1007\u002Fs10620-012-2112-9\nTurnbaugh, 2009, A core gut microbiome in obese and lean twins, Nature, 457, 480, 10.1038\u002Fnature07540\nLe Chatelier, 2013, Richness of human gut microbiome correlates with metabolic markers, Nature, 500, 541, 10.1038\u002Fnature12506\nRivera, 2007, Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis, J Hepatol, 47, 571, 10.1016\u002Fj.jhep.2007.04.019\nBellot, 2010, Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis, Hepatology, 52, 2044, 10.1002\u002Fhep.23918\nAmar, 2013, Blood microbiota dysbiosis is associated with the onset of cardiovascular events in a large general population: the D.E.S.I.R. study, PloS One, 8, 10.1371\u002Fjournal.pone.0054461",{"EN":1187},"Hepatic microbiome in healthy lean and obese humans",{"VOID":1189},"10.1016\u002Fj.jhepr.2021.100299","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2589555921000756",[1192,1209,1221,1238,1253,1301,1313,1325,1337,1349],{"id":1193,"sortIndex":23,"researcher":22,"roles":1194,"affiliations":1195,"properties":1206},"946949a8-c948-412f-b869-78b99d63b419",[159],[1196],{"id":22,"sortIndex":124,"affiliation":1197,"properties":22},{"id":1198,"createTime":1199,"updateTime":1200,"relativeEntities":1201,"slug":1202,"properties":1203,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"2f164984-f735-41cf-900f-1010651b3a03","2023-12-30T05:48:35.184+00:00","2024-09-22T02:10:38.008+00:00",[],"Vaiomer-Lab%C3%A8ge-France",{"title":1204},{"VI":1205},"Vaiomer, Labège, France",{"title":1207},{"VI":1208},"Benjamin Lelouvier",{"id":1210,"sortIndex":133,"researcher":22,"roles":1211,"affiliations":1212,"properties":1218},"4f95d882-7b32-4531-ada6-9b2973edc7c0",[159],[1213],{"id":22,"sortIndex":124,"affiliation":1214,"properties":22},{"id":1198,"createTime":1199,"updateTime":1200,"relativeEntities":1215,"slug":1202,"properties":1216,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1217},{"VI":1205},{"title":1219},{"VI":1220},"Amandine Broha",{"id":1222,"sortIndex":129,"researcher":22,"roles":1223,"affiliations":1224,"properties":1235},"516a67b5-13df-410d-bebc-cae98a73ce40",[159],[1225],{"id":22,"sortIndex":124,"affiliation":1226,"properties":22},{"id":1227,"createTime":1228,"updateTime":1229,"relativeEntities":1230,"slug":1231,"properties":1232,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"93246ebc-e744-4218-ab54-abf056044767","2023-12-06T05:56:41.254+00:00","2024-12-17T07:11:35.539+00:00",[],"Center-for-Clinical-Metabolic-Research-Gentofte-Hospital-University-of-Copenhagen-Hellerup-Denmark",{"title":1233},{"VI":1234},"Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark",{"title":1236},{"VI":1237},"Mia Demant",{"id":1239,"sortIndex":275,"researcher":22,"roles":1240,"affiliations":1241,"properties":1250},"8c5d0d98-33fa-4d80-9760-52129761d043",[159],[1242],{"id":22,"sortIndex":124,"affiliation":1243,"properties":22},{"id":1244,"createTime":1245,"updateTime":1245,"relativeEntities":1246,"slug":22,"properties":1247,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"5ae57acc-4b60-4ee8-8da3-3e8371c0507e","2023-12-30T05:48:35.298+00:00",[],{"title":1248},{"VI":1249},"Department of Radiology, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark",{"title":1251},{"VI":1252},"Merete Juhl Kønig",{"id":1254,"sortIndex":68,"researcher":22,"roles":1255,"affiliations":1256,"properties":1298},"361d96de-f5c6-4527-91ee-ff4c232fcc52",[159],[1257,1269,1274,1286],{"id":1258,"sortIndex":23,"affiliation":1259,"properties":1268},"f3da55a2-9441-4929-aa25-8acf18191772",{"id":1260,"createTime":1261,"updateTime":1262,"relativeEntities":1263,"slug":1264,"properties":1265,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"e2d6cfd1-2c6b-4f95-b40a-9ed97d8f9449","2023-12-02T22:01:39.339+00:00","2024-12-17T07:11:43.689+00:00",[],"Steno-Diabetes-Center-Copenhagen-Gentofte-Denmark",{"title":1266},{"VI":1267},"Steno Diabetes Center Copenhagen, Gentofte, Denmark",{},{"id":22,"sortIndex":124,"affiliation":1270,"properties":22},{"id":1227,"createTime":1228,"updateTime":1229,"relativeEntities":1271,"slug":1231,"properties":1272,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1273},{"VI":1234},{"id":1275,"sortIndex":133,"affiliation":1276,"properties":1285},"76a93389-3cdf-4888-a19c-03184e90b9bd",{"id":1277,"createTime":1278,"updateTime":1279,"relativeEntities":1280,"slug":1281,"properties":1282,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"698d5ba3-7467-4bea-b6ce-c1081ff54050","2024-01-01T16:20:41.570+00:00","2024-12-17T07:11:43.675+00:00",[],"Novo-Nordisk-Foundation-Center-for-Basic-Metabolic-Research-Faculty-of-Health-and-Medical-Sciences-University-of-Copenhagen-Copenhagen-Denmark",{"title":1283},{"VI":1284},"Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark",{},{"id":1287,"sortIndex":152,"affiliation":1288,"properties":1297},"1b77b565-c9cb-4988-adbc-905061df1d0a",{"id":1289,"createTime":1290,"updateTime":1291,"relativeEntities":1292,"slug":1293,"properties":1294,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"422927d1-f843-407c-885e-ac204760ce7e","2023-12-28T06:00:17.262+00:00","2024-12-17T07:11:43.686+00:00",[],"Department-of-Clinical-Medicine-Faculty-of-Health-and-Medical-Sciences-University-of-Copenhagen-Copenhagen-Denmark",{"title":1295},{"VI":1296},"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark",{},{"title":1299},{"VI":1300},"Filip Krag Knop",{"id":1302,"sortIndex":157,"researcher":22,"roles":1303,"affiliations":1304,"properties":1310},"def6a49f-d3b1-46cd-9a1c-015355302233",[159],[1305],{"id":22,"sortIndex":124,"affiliation":1306,"properties":22},{"id":1244,"createTime":1245,"updateTime":1245,"relativeEntities":1307,"slug":22,"properties":1308,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1309},{"VI":1249},{"title":1311},{"VI":1312},"Charlotte Strandberg",{"id":1314,"sortIndex":124,"researcher":22,"roles":1315,"affiliations":1316,"properties":1322},"8b6aed10-b603-456e-9992-9e3b47da063b",[159],[1317],{"id":22,"sortIndex":124,"affiliation":1318,"properties":22},{"id":1227,"createTime":1228,"updateTime":1229,"relativeEntities":1319,"slug":1231,"properties":1320,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1321},{"VI":1234},{"title":1323},{"VI":1324},"Malte Palm Suppli",{"id":1326,"sortIndex":152,"researcher":22,"roles":1327,"affiliations":1328,"properties":1334},"bf184295-d373-43cb-abeb-c01a90643424",[159],[1329],{"id":22,"sortIndex":124,"affiliation":1330,"properties":22},{"id":1227,"createTime":1228,"updateTime":1229,"relativeEntities":1331,"slug":1231,"properties":1332,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1333},{"VI":1234},{"title":1335},{"VI":1336},"Jonatan Ising Bagger",{"id":1338,"sortIndex":128,"researcher":22,"roles":1339,"affiliations":1340,"properties":1346},"9e16c3a9-ca38-4dcb-bc23-ac3fc8931401",[159],[1341],{"id":22,"sortIndex":124,"affiliation":1342,"properties":22},{"id":1227,"createTime":1228,"updateTime":1229,"relativeEntities":1343,"slug":1231,"properties":1344,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1345},{"VI":1234},{"title":1347},{"VI":1348},"Asger Lund",{"id":1350,"sortIndex":259,"researcher":22,"roles":1351,"affiliations":1352,"properties":1365},"6c6ab20a-f74b-405b-a394-015b4f398fe4",[159],[1353,1358],{"id":22,"sortIndex":124,"affiliation":1354,"properties":22},{"id":1227,"createTime":1228,"updateTime":1229,"relativeEntities":1355,"slug":1231,"properties":1356,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1357},{"VI":1234},{"id":1359,"sortIndex":23,"affiliation":1360,"properties":1364},"a82ce156-8201-481f-a831-0ada24eec738",{"id":1260,"createTime":1261,"updateTime":1262,"relativeEntities":1361,"slug":1264,"properties":1362,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1363},{"VI":1267},{},{"title":1366},{"VI":1367},"Tina Vilsbøll",{"url":1190,"publisher":1369,"properties":1398},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1370,"slug":10,"properties":1371,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":1376,"manageAffiliations":1377,"indexDatabases":1378,"url":122,"thumbnailPath":22,"statistic":1393,"gsStatistic":22,"type":22,"analyzePriority":22},[],{"country":1372,"issn":1373,"introduce":1374,"title":1375},{"VOID":13},{"VOID":15},{"EN":17},{"EN":19},[],[],[1379,1386],{"id":101,"indexDatabase":1380,"url":114,"indexYears":115,"academicFieldIds":1385,"indexDatabaseRanking":121},{"id":103,"createTime":104,"updateTime":105,"relativeEntities":1381,"label":1382,"description":1383,"key":111,"publicationTags":1384,"standard":22},[],{"EN":108,"VI":108},{"EN":108,"VI":110},[113],[117,118,119,120],{"id":82,"indexDatabase":1387,"url":97,"indexYears":22,"academicFieldIds":1392,"indexDatabaseRanking":22},{"id":84,"createTime":85,"updateTime":86,"relativeEntities":1388,"label":1389,"description":1390,"key":93,"publicationTags":1391,"standard":22},[],{"EN":89,"VI":89},{"VI":91,"EN":92},[95,96],[99],{"impactFactor":124,"impactFactorByYear":1394,"i10Index":124,"i10IndexLast5Year":124,"totalPublication":126,"totalPublicationByYear":1395,"totalCitation":124,"totalCitationByYear":1396,"totalCitationPerPublication":124,"totalCitationPerPublicationByYear":1397,"hindexLast5Year":124,"hindex":124},{},{"2019":128,"2020":129,"2021":130,"2022":131,"2023":132,"2024":133},{},{},{"volume":1399,"pages":1400},{"VOID":1066},{"VOID":1401},"100299","2021-08-01",{"id":1404,"createTime":1405,"updateTime":1406,"relativeEntities":1407,"slug":1408,"properties":1409,"entityType":151,"verifyStatus":429,"verifyTime":1406,"verifyNote":430,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124,"primaryUrl":1416,"fullTextUrl":22,"authors":1417,"publicationType":377,"publisherRelationship":1470,"citationCount":22,"citationInfo":22,"publishDate":1504,"publishYear":414,"citationAnalyzeStatus":21,"lastCitationAnalyze":22,"indexDatabases":22,"openAccess":22,"references":22,"isForceReanalyzing":415},"f2e54071-943f-4a0c-8b50-4f358307d0db","2024-02-09T04:16:17.081+00:00","2024-12-18T23:40:46.380+00:00",[],"Management-of-liver-disease-and-portal-hypertension-in-common-variable-immunodeficiency-CVID-",{"references":1410,"title":1412,"doi":1414},{"VOID":1411},"Ameratunga, 2013, New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin, Clin Exp Immunol, 174, 203, 10.1111\u002Fcei.12178\nRoskin, 2015, IgH sequences in common variable immune deficiency reveal altered B cell development and selection, 7, 302ra135\nNotarangelo, 2009, International Union of Immunological Societies Expert Committee on Primary I. Primary immunodeficiencies: 2009 update, J Allergy Clin Immunol, 124, 1161, 10.1016\u002Fj.jaci.2009.10.013\nPecoraro, 2020, Heterogeneity of liver disease in common variable immunodeficiency disorders, Front Immunol, 11, 338, 10.3389\u002Ffimmu.2020.00338\nModell, 2018, Global report on primary immunodeficiencies: 2018 update from the Jeffrey Modell Centers Network on disease classification, regional trends, treatment modalities, and physician reported outcomes, Immunol Res, 66, 367, 10.1007\u002Fs12026-018-8996-5\nYazdani, 2020, Common variable immunodeficiency: epidemiology, pathogenesis, clinical manifestations, diagnosis, classification, and management, J Investig Allergol Clin Immunol, 30, 14, 10.18176\u002Fjiaci.0388\nHammarstrom, 2000, Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID), Clin Exp Immunol, 120, 225, 10.1046\u002Fj.1365-2249.2000.01131.x\nBoyle, 2007, Population prevalence of diagnosed primary immunodeficiency diseases in the United States, J Clin Immunol, 27, 497, 10.1007\u002Fs10875-007-9103-1\nBonilla, 2005, Practice parameter for the diagnosis and management of primary immunodeficiency, Ann Allergy Asthma Immunol, 94, S1, 10.1016\u002FS1081-1206(10)61142-8\nSalzer, 2012, Common variable immunodeficiency: an update, Arthritis Res Ther, 14, 223, 10.1186\u002Far4032\nZietkiewicz, 2020, Shorter diagnostic delay in polish adult patients with common variable immunodeficiency and symptom onset after 1999, Front Immunol, 11, 982, 10.3389\u002Ffimmu.2020.00982\nOksenhendler, 2008, Infections in 252 patients with common variable immunodeficiency, Clin Infect Dis, 46, 1547, 10.1086\u002F587669\nCunningham-Rundles, 1999, Common variable immunodeficiency: clinical and immunological features of 248 patients, Clin Immunol, 92, 34, 10.1006\u002Fclim.1999.4725\nResnick, 2012, Morbidity and mortality in common variable immune deficiency over 4 decades, Blood, 119, 1650, 10.1182\u002Fblood-2011-09-377945\nMarschall, 2015, The Swiss national registry for primary immunodeficiencies: report on the first 6 years’ activity from 2008 to 2014, Clin Exp Immunol, 182, 45, 10.1111\u002Fcei.12661\nYazdani, 2017, Infectious and noninfectious pulmonary complications in patients with primary immunodeficiency disorders, J Investig Allergol Clin Immunol, 27, 213, 10.18176\u002Fjiaci.0166\nSalavoura, 2008, Development of cancer in patients with primary immunodeficiencies, Anticancer Res, 28, 1263\nSarmiento, 2005, [Autoimmune disease in primary antibody deficiencies], Allergol Immunopathol (Madr), 33, 69, 10.1157\u002F13072916\nUzzan, 2016, Gastrointestinal disorders associated with common variable immune deficiency (CVID) and chronic granulomatous disease (CGD), Curr Gastroenterol Rep, 18, 17, 10.1007\u002Fs11894-016-0491-3\nSong, 2018, Common variable immunodeficiency and liver involvement, Clin Rev Allergy Immunol, 55, 340, 10.1007\u002Fs12016-017-8638-z\nGraziano, 2017, Delay in diagnosis affects the clinical outcome in a cohort of cvid patients with marked reduction of iga serum levels, Clin Immunol, 180, 1, 10.1016\u002Fj.clim.2017.03.011\nBonilla, 2016, International consensus document (ICON): common variable immunodeficiency disorders, J Allergy Clin Immunol Pract, 4, 38, 10.1016\u002Fj.jaip.2015.07.025\nHo, 2020, Non-infectious complications of common variable immunodeficiency: updated clinical spectrum, sequelae, and insights to pathogenesis, Front Immunol, 11, 149, 10.3389\u002Ffimmu.2020.00149\nWehr, 2015, Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency, J Allergy Clin Immunol, 135, 988, 10.1016\u002Fj.jaci.2014.11.029\nMilito, 2019, Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies, J Allergy Clin Immunol, 144, 584, 10.1016\u002Fj.jaci.2019.01.051\nCunningham-Rundles, 2008, Autoimmune manifestations in common variable immunodeficiency, J Clin Immunol, 28, S42, 10.1007\u002Fs10875-008-9182-7\nLima, 2022, Liver disease accompanied by enteropathy in common variable immunodeficiency: common pathophysiological mechanisms, Front Immunol, 13, 933463, 10.3389\u002Ffimmu.2022.933463\nFarmer, 2017, Common variable immunodeficiency non-infectious disease endotypes redefined using unbiased network clustering in large electronic datasets, Front Immunol, 8, 1740, 10.3389\u002Ffimmu.2017.01740\nMalamut, 2008, Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities, J Hepatol, 48, 74, 10.1016\u002Fj.jhep.2007.08.011\nWard, 2008, Abnormal liver function in common variable immunodeficiency disorders due to nodular regenerative hyperplasia, Clin Exp Immunol, 153, 331, 10.1111\u002Fj.1365-2249.2008.03711.x\nFuss, 2013, Nodular regenerative hyperplasia in common variable immunodeficiency, J Clin Immunol, 33, 748, 10.1007\u002Fs10875-013-9873-6\nGioia, 2018, Natural history of patients with non cirrhotic portal hypertension: comparison with patients with compensated cirrhosis, Dig Liver Dis, 50, 839, 10.1016\u002Fj.dld.2018.01.132\nSiramolpiwat, 2014, Idiopathic portal hypertension: natural history and long-term outcome, Hepatology, 59, 2276, 10.1002\u002Fhep.26904\nAzzu, 2019, Liver disease is common in patients with common variable immunodeficiency and predicts mortality in the presence of cirrhosis or portal hypertension, J Allergy Clin Immunol Pract, 7, 2484, 10.1016\u002Fj.jaip.2019.04.016\nDe Gottardi, 2019, Porto-sinusoidal vascular disease: proposal and description of a novel entity, Lancet Gastroenterol Hepatol, 4, 399, 10.1016\u002FS2468-1253(19)30047-0\nWanless, 1990, Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules, Hepatology, 11, 787, 10.1002\u002Fhep.1840110512\nSchouten, 2015, Idiopathic non-cirrhotic portal hypertension: a review, Orphanet J Rare Dis, 10, 67, 10.1186\u002Fs13023-015-0288-8\nValla, 2018, Vascular liver diseases on the clinical side: definitions and diagnosis, new concepts, Virchows Arch, 473, 3, 10.1007\u002Fs00428-018-2331-3\nReshamwala, 2006, Nodular regenerative hyperplasia: not all nodules are created equal, Hepatology, 44, 7, 10.1002\u002Fhep.21258\nJharap, 2015, Diagnosing nodular regenerative hyperplasia of the liver is thwarted by low interobserver agreement, PLoS One, 10, 10.1371\u002Fjournal.pone.0120299\nKleiner, 2015, Noncirrhotic portal hypertension: pathology and nomenclature, Clin Liver Dis (Hoboken), 5, 123, 10.1002\u002Fcld.459\nBakshi, 2020, Nodular regenerative hyperplasia - an under-recognized vascular disorder of liver, Pathol Res Pract, 216, 152833, 10.1016\u002Fj.prp.2020.152833\nCazals-Hatem, 2011, Obliterative portal venopathy: portal hypertension is not always present at diagnosis, J Hepatol, 54, 455, 10.1016\u002Fj.jhep.2010.07.038\nHillaire, 2002, Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients, Gut, 51, 275, 10.1136\u002Fgut.51.2.275\nNakanuma, 2001, Pathology and pathogenesis of idiopathic portal hypertension with an emphasis on the liver, Pathol Res Pract, 197, 65, 10.1078\u002F0344-0338-5710012\nZiol, 2004, Intrasinusoidal cytotoxic CD8+ T cells in nodular regenerative hyperplasia of the liver, Hum Pathol, 35, 1241, 10.1016\u002Fj.humpath.2004.06.016\nChapel, 2008, Common variable immunodeficiency disorders: division into distinct clinical phenotypes, Blood, 112, 277, 10.1182\u002Fblood-2007-11-124545\nGathmann, 2014, Clinical picture and treatment of 2212 patients with common variable immunodeficiency, J Allergy Clin Immunol, 134, 116, 10.1016\u002Fj.jaci.2013.12.1077\nBelkaid, 2014, Role of the microbiota in immunity and inflammation, Cell, 157, 121, 10.1016\u002Fj.cell.2014.03.011\nBrenchley, 2006, Microbial translocation is a cause of systemic immune activation in chronic HIV infection, Nat Med, 12, 1365, 10.1038\u002Fnm1511\nXavier, 2007, Unravelling the pathogenesis of inflammatory bowel disease, Nature, 448, 427, 10.1038\u002Fnature06005\nAhmad Kendong, 2021, Gut dysbiosis and intestinal barrier dysfunction: potential explanation for early-onset colorectal cancer, Front Cell Infect Microbiol, 11, 10.3389\u002Ffcimb.2021.744606\nYu, 2018, Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis, J Biomed Sci, 25, 79, 10.1186\u002Fs12929-018-0483-8\nBerg, 1979, Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model, Infect Immun, 23, 403, 10.1128\u002Fiai.23.2.403-411.1979\nWiest, 2003, Gastrointestinal disorders of the critically ill. Bacterial translocation in the gut, Best Pract Res Clin Gastroenterol, 17, 397, 10.1016\u002FS1521-6918(03)00024-6\nPinzone, 2012, Microbial translocation in chronic liver diseases, Int J Microbiol, 2012, 10.1155\u002F2012\u002F694629\nTripathi, 2018, The gut-liver axis and the intersection with the microbiome, Nat Rev Gastroenterol Hepatol, 15, 397, 10.1038\u002Fs41575-018-0011-z\nChopyk, 2020, Contribution of the intestinal microbiome and gut barrier to hepatic disorders, Gastroenterology, 159, 849, 10.1053\u002Fj.gastro.2020.04.077\nStehle, 2012, Lipopolysaccharide-binding protein, a surrogate marker of microbial translocation, is associated with physical function in healthy older adults, J Gerontol A Biol Sci Med Sci, 67, 1212, 10.1093\u002Fgerona\u002Fgls178\nAgarwal, 2019, Gastrointestinal manifestations and complications of primary immunodeficiency disorders, Immunol Allergy Clin North Am, 39, 81, 10.1016\u002Fj.iac.2018.08.006\nCrescenzi, 2019, Liver stiffness assessment by transient elastography suggests high prevalence of liver involvement in common variable immunodeficiency, Dig Liver Dis, 51, 1599, 10.1016\u002Fj.dld.2019.05.016\nJorgensen, 2016, Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation, Mucosal Immunol, 9, 1455, 10.1038\u002Fmi.2016.18\nvan Schewick, 2022, Bowel histology of CVID patients reveals distinct patterns of mucosal inflammation, J Clin Immunol, 42, 46, 10.1007\u002Fs10875-021-01104-5\nMalamut, 2010, The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease, Am J Gastroenterol, 105, 2262, 10.1038\u002Fajg.2010.214\nDaniels, 2007, Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): a clinicopathologic study and review, Am J Surg Pathol, 31, 1800, 10.1097\u002FPAS.0b013e3180cab60c\nCarter, 2013, CVID patients with autoimmunity have elevated T cell expression of granzyme B and HLA-DR and reduced levels of Treg cells, J Clin Pathol, 66, 146, 10.1136\u002Fjclinpath-2012-201046\nMyneedu, 2021, Autoimmune hepatitis in a patient with common variable immunodeficiency, ACG Case Rep J, 8, 10.14309\u002Fcrj.0000000000000547\nPollock, 2020, Autoimmune hepatitis in a patient with common variable immunodeficiency, ACG Case Rep J, 7, 10.14309\u002Fcrj.0000000000000467\nAustin, 2004, Nodular regenerative hyperplasia of the liver and coeliac disease: potential role of IgA anticardiolipin antibody, Gut, 53, 1032, 10.1136\u002Fgut.2003.036806\nEuropean Association for the Study of the, 2015, EASL clinical practice guidelines: autoimmune hepatitis, J Hepatol, 63, 971, 10.1016\u002Fj.jhep.2015.06.030\nGlobig, 2022, Evaluation of laboratory and sonographic parameters for detection of portal hypertension in patients with common variable immunodeficiency, J Clin Immunol, 42, 1626, 10.1007\u002Fs10875-022-01319-0\nde Franchis, 2022, Faculty. Corrigendum to ‘Baveno VII - renewing consensus in portal hypertension’ [J Hepatol (2022) 959-974], J Hepatol, 77, 271, 10.1016\u002Fj.jhep.2022.03.024\nFuruichi, 2013, Noninvasive diagnostic method for idiopathic portal hypertension based on measurements of liver and spleen stiffness by ARFI elastography, J Gastroenterol, 48, 1061, 10.1007\u002Fs00535-012-0703-z\nAhmad, 2019, Spleen stiffness measurements using point shear wave elastography detects noncirrhotic portal hypertension in human immunodeficiency virus, Medicine (Baltimore), 98, 10.1097\u002FMD.0000000000017961\nDe Gottardi, 2022, Porto-sinusoidal vascular disorder, J Hepatol, 77, 1124, 10.1016\u002Fj.jhep.2022.05.033\nGlatard, 2012, Obliterative portal venopathy: findings at CT imaging, Radiology, 263, 741, 10.1148\u002Fradiol.12111785\nAgarwal, 2009, Autoimmunity in common variable immunodeficiency, Curr Allergy Asthma Rep, 9, 347, 10.1007\u002Fs11882-009-0051-0\nAgarwal, 2013, Diagnosis and treatment of gastrointestinal disorders in patients with primary immunodeficiency, Clin Gastroenterol Hepatol, 11, 1050, 10.1016\u002Fj.cgh.2013.02.024\nMusumba, 2013, Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy, Aliment Pharmacol Ther, 38, 1025, 10.1111\u002Fapt.12490\nVernier-Massouille, 2007, Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine, Gut, 56, 1404, 10.1136\u002Fgut.2006.114363\nSeksik, 2011, Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine, Inflamm Bowel Dis, 17, 565, 10.1002\u002Fibd.21330\nde Boer, 2005, Nodular regenerative hyperplasia and thiopurines: the case for level-dependent toxicity, Liver Transplant, 11, 1300, 10.1002\u002Flt.20554\nTranah, 2021, Challenges in liver transplantation for common variable immunodeficiency-related liver disease: a case series and systematic review, J Liver Transplant, 4, 100038, 10.1016\u002Fj.liver.2021.100038\nTripathi, 2014, Beta-blockers in portal hypertension: new developments and controversies, Liver Int, 34, 655, 10.1111\u002Fliv.12360\nLi, 2016, Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis, BMJ Open, 6, 10.1136\u002Fbmjopen-2015-010902\nBanares, 1999, Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis, Hepatology, 30, 79, 10.1002\u002Fhep.510300124\nSarin, 2005, Evaluation of endoscopic variceal ligation (EVL) versus propanolol plus isosorbide mononitrate\u002Fnadolol (ISMN) in the prevention of variceal rebleeding: comparison of cirrhotic and noncirrhotic patients, Dig Dis Sci, 50, 1538, 10.1007\u002Fs10620-005-2877-1\nSarin, 2010, Equal efficacy of endoscopic variceal ligation and propranolol in preventing variceal bleeding in patients with noncirrhotic portal hypertension, Gastroenterology, 139, 1238, 10.1053\u002Fj.gastro.2010.06.017\nRodrigues, 2020, Beta-blockers in cirrhosis: evidence-based indications and limitations, JHEP Rep, 2\nBoike, 2022, North American practice-based recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension, Clin Gastroenterol Hepatol, 20, 1636, 10.1016\u002Fj.cgh.2021.07.018\nVizzutti, 2020, Transjugular intrahepatic portosystemic shunt (TIPS): current indications and strategies to improve the outcomes, Intern Emerg Med, 15, 37, 10.1007\u002Fs11739-019-02252-8\nGarcia-Pagan, 2020, Where does TIPS fit in the management of patients with cirrhosis?, JHEP Rep, 2\nGlobig, 2021, International multicenter experience of transjugular intrahepatic portosystemic shunt implantation in patients with common variable immunodeficiency, J Allergy Clin Immunol Pract, 9, 2931, 10.1016\u002Fj.jaip.2021.02.056\nZainaldain, 2020, Infectious complications reporting in common variable immunodeficiency: a systematic review and meta-analysis, Oman Med J, 35, 10.5001\u002Fomj.2020.64\nBissonnette, 2016, Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension, Hepatology, 64, 224, 10.1002\u002Fhep.28547\nBettinger, 2016, Procedural and shunt-related complications and mortality of the transjugular intrahepatic portosystemic shunt (TIPSS), Aliment Pharmacol Ther, 44, 1051, 10.1111\u002Fapt.13809\nRacanelli, 2006, The liver as an immunological organ, Hepatology, 43, S54, 10.1002\u002Fhep.21060\nNesseler, 2012, Clinical review: the liver in sepsis, Crit Care, 16, 235, 10.1186\u002Fcc11381\nAzzu, 2018, Liver transplantation in adults with liver disease due to common variable immunodeficiency leads to early recurrent disease and poor outcome, Liver Transpl, 24, 171, 10.1002\u002Flt.24979\nMagaz, 2023, Liver transplantation for porto-sinusoidal vascular liver disorder: long-term outcome, Transplantation, 107, 1330, 10.1097\u002FTP.0000000000004444\nBonatti, 2023, Good long-term outcome following liver transplant in a patient with common variable immunodeficiency syndrome despite multiple infections and recurrent nodular regenerative hyperplasia, Exp Clin Transpl, 21, 66, 10.6002\u002Fect.2022.0067\nApostolov, 2019, Successful liver transplantation in common variable immune deficiency with reversal of hepatopulmonary syndrome, BMJ Case Rep, 12, 10.1136\u002Fbcr-2018-226095\nHaboubi, 1988, Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: light microscopy and ultrastructural observations, Am J Gastroenterol, 83, 256\nGane, 1994, Nodular regenerative hyperplasia of the liver graft after liver transplantation, Hepatology, 20, 88, 10.1002\u002Fhep.1840200114\nGhabril, 2014, Drug-induced nodular regenerative hyperplasia, Semin Liver Dis, 34, 240, 10.1055\u002Fs-0034-1375963\nHadzic, 2000, Correction of the hyper-IgM syndrome after liver and bone marrow transplantation, N Engl J Med, 342, 320, 10.1056\u002FNEJM200002033420504\nGioia, 2020, Causes and management of non-cirrhotic portal hypertension, Curr Gastroenterol Rep, 22, 56, 10.1007\u002Fs11894-020-00792-0\nBihl, 2010, Anticoagulant therapy for nodular regenerative hyperplasia in a HIV-infected patient, BMC Gastroenterol, 10, 6, 10.1186\u002F1471-230X-10-6\nAbraldes, 2009, Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial, Gastroenterology, 136, 1651, 10.1053\u002Fj.gastro.2009.01.043\nPollo-Flores, 2015, Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial, Dig Liver Dis, 47, 957, 10.1016\u002Fj.dld.2015.07.156\nAbraldes, 2016, Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis, Gastroenterology, 150, 1160, 10.1053\u002Fj.gastro.2016.01.004\nAlbillos, 2020, The gut-liver axis in liver disease: pathophysiological basis for therapy, J Hepatol, 72, 558, 10.1016\u002Fj.jhep.2019.10.003\nVentura, 2014, Bifidobacteria and humans: our special friends, from ecological to genomics perspectives, J Sci Food Agric, 94, 163, 10.1002\u002Fjsfa.6356\nPoto, 2023, Is there a role for microbiome-based approach in common variable immunodeficiency?, Clin Exp Med, 1\nBlaser, 2016, Antibiotic use and its consequences for the normal microbiome, Science, 352, 544, 10.1126\u002Fscience.aad9358\nBajaj, 2013, Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy, PLoS One, 8, 10.1371\u002Fjournal.pone.0060042\nKalambokis, 2012, Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia, Liver Int, 32, 467, 10.1111\u002Fj.1478-3231.2011.02650.x\nJorgensen, 2019, Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency, Sci Rep, 9, 167, 10.1038\u002Fs41598-018-35367-7\nBelvoncikova, 2022, Gut dysbiosis and fecal microbiota transplantation in autoimmune diseases, Int J Mol Sci, 23\nCaira-Chuquineyra, 2022, Fecal microbiota transplantation for people living with human immunodeficiency virus: a scoping review, AIDS Res Hum Retroviruses, 38, 700, 10.1089\u002Faid.2022.0016\nMarcella, 2021, Systematic review: the global incidence of faecal microbiota transplantation-related adverse events from 2000 to 2020, Aliment Pharmacol Ther, 53, 33, 10.1111\u002Fapt.16148",{"EN":1413},"Management of liver disease and portal hypertension in common variable immunodeficiency (CVID)",{"VOID":1415},"10.1016\u002Fj.jhepr.2023.100882","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2589555923002136",[1418,1433,1455],{"id":1419,"sortIndex":23,"researcher":22,"roles":1420,"affiliations":1421,"properties":1430},"c83e33a9-1690-4a2a-ac18-25aa72ecec66",[159],[1422],{"id":22,"sortIndex":124,"affiliation":1423,"properties":22},{"id":1424,"createTime":1425,"updateTime":1425,"relativeEntities":1426,"slug":22,"properties":1427,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"6edcc040-37d8-4990-ab37-b017e321c2dc","2024-02-09T04:16:17.114+00:00",[],{"title":1428},{"VI":1429},"Liver Center, Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA",{"title":1431},{"VI":1432},"Raymond T. Chung",{"id":1434,"sortIndex":124,"researcher":22,"roles":1435,"affiliations":1436,"properties":1452},"2aa984a7-64e4-4458-bbd0-b5a7b259e957",[159],[1437,1442],{"id":22,"sortIndex":124,"affiliation":1438,"properties":22},{"id":1424,"createTime":1425,"updateTime":1425,"relativeEntities":1439,"slug":22,"properties":1440,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1441},{"VI":1429},{"id":1443,"sortIndex":152,"affiliation":1444,"properties":1451},"295151f3-3fc7-413b-909a-932c401f2da7",{"id":1445,"createTime":1446,"updateTime":1446,"relativeEntities":1447,"slug":22,"properties":1448,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"d59027a9-c09d-4f99-8089-346ff51adafb","2024-02-09T04:16:17.096+00:00",[],{"title":1449},{"VI":1450},"Faculty of Medicine, Eberhard-Karls University of Tübingen, Tübingen, Germany",{},{"title":1453},{"VI":1454},"Lukas S. Baumert",{"id":1456,"sortIndex":152,"researcher":22,"roles":1457,"affiliations":1458,"properties":1467},"8549a6a1-525f-4e56-a27a-770d6981bfd6",[159],[1459],{"id":22,"sortIndex":124,"affiliation":1460,"properties":22},{"id":1461,"createTime":1462,"updateTime":1462,"relativeEntities":1463,"slug":22,"properties":1464,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"d354e23d-2fd3-4367-a619-69c5ef8c5d50","2024-01-27T00:19:46.755+00:00",[],{"title":1465},{"VI":1466},"Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA",{"title":1468},{"VI":1469},"Angela Shih",{"url":1416,"publisher":1471,"properties":1500},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1472,"slug":10,"properties":1473,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":1478,"manageAffiliations":1479,"indexDatabases":1480,"url":122,"thumbnailPath":22,"statistic":1495,"gsStatistic":22,"type":22,"analyzePriority":22},[],{"country":1474,"issn":1475,"introduce":1476,"title":1477},{"VOID":13},{"VOID":15},{"EN":17},{"EN":19},[],[],[1481,1488],{"id":101,"indexDatabase":1482,"url":114,"indexYears":115,"academicFieldIds":1487,"indexDatabaseRanking":121},{"id":103,"createTime":104,"updateTime":105,"relativeEntities":1483,"label":1484,"description":1485,"key":111,"publicationTags":1486,"standard":22},[],{"EN":108,"VI":108},{"EN":108,"VI":110},[113],[117,118,119,120],{"id":82,"indexDatabase":1489,"url":97,"indexYears":22,"academicFieldIds":1494,"indexDatabaseRanking":22},{"id":84,"createTime":85,"updateTime":86,"relativeEntities":1490,"label":1491,"description":1492,"key":93,"publicationTags":1493,"standard":22},[],{"EN":89,"VI":89},{"VI":91,"EN":92},[95,96],[99],{"impactFactor":124,"impactFactorByYear":1496,"i10Index":124,"i10IndexLast5Year":124,"totalPublication":126,"totalPublicationByYear":1497,"totalCitation":124,"totalCitationByYear":1498,"totalCitationPerPublication":124,"totalCitationPerPublicationByYear":1499,"hindexLast5Year":124,"hindex":124},{},{"2019":128,"2020":129,"2021":130,"2022":131,"2023":132,"2024":133},{},{},{"volume":1501,"pages":1502},{"VOID":410},{"VOID":1503},"100882","2023-11-01",{"id":1506,"createTime":1507,"updateTime":1508,"relativeEntities":1509,"slug":1510,"properties":1511,"entityType":151,"verifyStatus":429,"verifyTime":1518,"verifyNote":430,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124,"primaryUrl":1519,"fullTextUrl":22,"authors":1520,"publicationType":377,"publisherRelationship":1589,"citationCount":22,"citationInfo":22,"publishDate":1623,"publishYear":414,"citationAnalyzeStatus":21,"lastCitationAnalyze":22,"indexDatabases":22,"openAccess":22,"references":22,"isForceReanalyzing":415},"78bfff54-7466-4e1e-9b74-363ff22b51dc","2024-01-12T15:27:44.858+00:00","2025-01-14T23:39:44.016+00:00",[],"Downregulation-of-hepatic-METTL3-contributes-to-APAP-induced-liver-injury-in-mice",{"references":1512,"title":1514,"doi":1516},{"VOID":1513},"Larson, 2005, Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study, Hepatology, 42, 1364, 10.1002\u002Fhep.20948\nWendon, 2017, EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure, J Hepatol, 66, 1047, 10.1016\u002Fj.jhep.2016.12.003\nBernal, 2010, Acute liver failure, Lancet, 376, 190, 10.1016\u002FS0140-6736(10)60274-7\nJaeschke, 2014, Acetaminophen-induced liver injury: from animal models to humans, J Clin Transl Hepatol, 2, 153\nLee, 1996, Role of CYP2E1 in the hepatotoxicity of acetaminophen, J Biol Chem, 271, 12063, 10.1074\u002Fjbc.271.20.12063\nHanawa, 2008, Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury, J Biol Chem, 283, 13565, 10.1074\u002Fjbc.M708916200\nMcGill, 2012, The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation, J Clin Invest, 122, 1574, 10.1172\u002FJCI59755\nHan, 2013, Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria, Trends Pharmacol Sc, 34, 243, 10.1016\u002Fj.tips.2013.01.009\nWin, 2018, New insights into the role and mechanism of c-Jun-N-terminal kinase signaling in the pathobiology of liver diseases, Hepatology, 67, 2013, 10.1002\u002Fhep.29689\nNakagawa, 2008, Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation, Gastroenterology, 135, 1311, 10.1053\u002Fj.gastro.2008.07.006\nShinohara, 2010, Silencing glycogen synthase kinase-3β inhibits acetaminophen hepatotoxicity and attenuates JNK activation and loss of glutamate cysteine ligase and myeloid cell leukemia sequence 1, J Biol Chem, 285, 8244, 10.1074\u002Fjbc.M109.054999\nSharma, 2012, Critical role for mixed-lineage kinase 3 in acetaminophen-induced hepatotoxicity, Mol Pharmacol, 82, 1001, 10.1124\u002Fmol.112.079863\nZhang, 2014, Role of receptor interacting protein (RIP)1 on apoptosis-inducing factor-mediated necroptosis during acetaminophen-evoked acute liver failure in mice, Toxicol Lett, 225, 445, 10.1016\u002Fj.toxlet.2014.01.005\nRamachandran, 2013, Receptor interacting protein kinase 3 is a critical early mediator of acetaminophen-induced hepatocyte necrosis in mice, Hepatology, 58, 2099, 10.1002\u002Fhep.26547\nZhang, 2017, The role of MAP2 kinases and p38 kinase in acute murine liver injury models, Cell Death Dis, 8, 10.1038\u002Fcddis.2017.295\nWancket, 2012, Mitogen-activated protein kinase phosphatase (Mkp)-1 protects mice against acetaminophen-induced hepatic injury, Toxicol Pathol, 40, 1095, 10.1177\u002F0192623312447551\nMobasher, 2013, Protein tyrosine phosphatase 1B modulates GSK3beta\u002FNrf2 and IGFIR signaling pathways in acetaminophen-induced hepatotoxicity, Cel Death Dis, 4, e626, 10.1038\u002Fcddis.2013.150\nYue, 2015, RNA N6-methyladenosine methylation in post-transcriptional gene expression regulation, Genes Dev, 29, 1343, 10.1101\u002Fgad.262766.115\nFustin, 2013, RNA-methylation-dependent RNA processing controls the speed of the circadian clock, Cell, 155, 793, 10.1016\u002Fj.cell.2013.10.026\nXiang, 2017, RNA m6A methylation regulates the ultraviolet-induced DNA damage response, Nature, 543, 573, 10.1038\u002Fnature21671\nMa, 2018, RNA m6A methylation participates in regulation of postnatal development of the mouse cerebellum, Genome Biol, 19, 68, 10.1186\u002Fs13059-018-1435-z\nLin, 2017, Mettl3-\u002FMettl14-mediated mRNA N6-methyladenosine modulates murine spermatogenesis, Cell Res, 27, 1216, 10.1038\u002Fcr.2017.117\nXu, 2017, Mettl3-mediated m6A regulates spermatogonial differentiation and meiosis initiation, Cel Res, 27, 1100, 10.1038\u002Fcr.2017.100\nChen, 2015, m6A RNA methylation is regulated by microRNAs and promotes reprogramming to pluripotency, Cell Stem Cell, 16, 289, 10.1016\u002Fj.stem.2015.01.016\nGeula, 2015, Stem cells. m6A mRNA methylation facilitates resolution of naive pluripotency toward differentiation, Science, 347, 1002, 10.1126\u002Fscience.1261417\nHe, 2018, The dual role of N6-methyladenosine modification of RNAs is involved in human cancers, J Cel Mol Med, 22, 4630, 10.1111\u002Fjcmm.13804\nWang, 2020, METTL3 is essential for postnatal development of brown adipose tissue and energy expenditure in mice, Nat Commun, 11, 1648, 10.1038\u002Fs41467-020-15488-2\nWang, 2022, WTAP regulates postnatal development of brown adipose tissue by stabilizing METTL3 in mice, Life Metab, 1, 270, 10.1093\u002Flifemeta\u002Floac028\nLi, 2021, The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression, Nat Commun, 12, 7213, 10.1038\u002Fs41467-021-27539-3\nLi, 2022, Deficiency of WTAP in hepatocytes induces lipoatrophy and non-alcoholic steatohepatitis (NASH), Nat Commun, 13, 4549, 10.1038\u002Fs41467-022-32163-w\nDe Jesus, 2019, m6A mRNA methylation regulates human β-cell biology in physiological states and in type 2 diabetes, Nat Metabo, 1, 765, 10.1038\u002Fs42255-019-0089-9\nLi, 2021, METTL3 is required for maintaining β-cell function, Metabolism, 116, 10.1016\u002Fj.metabol.2021.154702\nWang, 2020, m6A mRNA methylation controls functional maturation in neonatal murine β-cells, Diabetes, 69, 1708, 10.2337\u002Fdb19-0906\nLi, 2023, Downregulation of the m6A reader protein YTHDC1 leads to islet β-cell failure and diabetes, Metabolism, 138, 10.1016\u002Fj.metabol.2022.155339\nLi, 2023, Deficiency of WTAP in islet beta cells results in beta cell failure and diabetes in mice, Diabetologia, 66, 1084, 10.1007\u002Fs00125-023-05900-z\nRen, 2017, A small-molecule inhibitor of NF-κB-inducing kinase (NIK) protects liver from toxin-induced inflammation, oxidative stress, and injury, FASEB J, 31, 711, 10.1096\u002Ffj.201600840R\nLi, 2018, Islet α-cell inflammation induced by NF-κB inducing kinase (NIK) leads to hypoglycemia, pancreatitis, growth retardation, and postnatal death in mice, Theranostics, 8, 5960, 10.7150\u002Fthno.28960\nJia, 2020, Purβ promotes hepatic glucose production by increasing Adcy6 transcription, Mol Metab, 31, 85, 10.1016\u002Fj.molmet.2019.11.008\nHuang, 2019, Histone H3 trimethylation at lysine 36 guides m6A RNA modification co-transcriptionally, Nature, 567, 414, 10.1038\u002Fs41586-019-1016-7\nLiu, 2014, A METTL3–METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation, Nat Chem Biol, 10, 93, 10.1038\u002Fnchembio.1432\nBarbieri, 2017, Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control, Nature, 552, 126, 10.1038\u002Fnature24678",{"EN":1515},"Downregulation of hepatic METTL3 contributes to APAP-induced liver injury in mice",{"VOID":1517},"10.1016\u002Fj.jhepr.2023.100766","2025-01-14T23:39:44.015+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2589555923000976",[1521,1536,1548,1560,1572],{"id":1522,"sortIndex":124,"researcher":22,"roles":1523,"affiliations":1524,"properties":1533},"1a4a31dc-6abe-4d6c-a8bd-f66a6574e84e",[159],[1525],{"id":22,"sortIndex":124,"affiliation":1526,"properties":22},{"id":1527,"createTime":1528,"updateTime":1528,"relativeEntities":1529,"slug":22,"properties":1530,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"7b23833f-b222-4469-b292-780aba02ccfb","2023-12-12T20:52:44.297+00:00",[],{"title":1531},{"VI":1532},"HIT Center for Life Sciences, School of Life Science and Technology, Harbin Institute of Technology, Harbin 150001, China",{"title":1534},{"VI":1535},"Chunhong Liu",{"id":1537,"sortIndex":23,"researcher":22,"roles":1538,"affiliations":1539,"properties":1545},"76df724d-37e0-4b39-b372-3cda262ae0be",[159],[1540],{"id":22,"sortIndex":124,"affiliation":1541,"properties":22},{"id":1527,"createTime":1528,"updateTime":1528,"relativeEntities":1542,"slug":22,"properties":1543,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1544},{"VI":1532},{"title":1546},{"VI":1547},"Ming Gao",{"id":1549,"sortIndex":152,"researcher":22,"roles":1550,"affiliations":1551,"properties":1557},"1a5f7ae5-a425-405d-be95-fa4754cd44ca",[159],[1552],{"id":22,"sortIndex":124,"affiliation":1553,"properties":22},{"id":1527,"createTime":1528,"updateTime":1528,"relativeEntities":1554,"slug":22,"properties":1555,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1556},{"VI":1532},{"title":1558},{"VI":1559},"Xinzhi Li",{"id":1561,"sortIndex":129,"researcher":22,"roles":1562,"affiliations":1563,"properties":1569},"21d69f34-d9de-44ec-bbcb-a9e1d9da2166",[159],[1564],{"id":22,"sortIndex":124,"affiliation":1565,"properties":22},{"id":1527,"createTime":1528,"updateTime":1528,"relativeEntities":1566,"slug":22,"properties":1567,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1568},{"VI":1532},{"title":1570},{"VI":1571},"Zheng Chen",{"id":1573,"sortIndex":133,"researcher":22,"roles":1574,"affiliations":1575,"properties":1586},"08f0930b-c440-48e9-b3eb-87cd5cf9945e",[159],[1576],{"id":22,"sortIndex":124,"affiliation":1577,"properties":22},{"id":1578,"createTime":1579,"updateTime":1580,"relativeEntities":1581,"slug":1582,"properties":1583,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"0b0b9fe1-341a-4868-a080-bba27a2ad003","2023-11-26T13:55:29.286+00:00","2025-06-11T23:56:09.386+00:00",[],"Institute-of-Biophysics-Chinese-Academy-of-Sciences-Beijing-China",{"title":1584},{"VI":1585},"Institute of Biophysics, Chinese Academy of Sciences, Beijing, China",{"title":1587},{"VI":1588},"Yanbin Dong",{"url":1519,"publisher":1590,"properties":1619},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1591,"slug":10,"properties":1592,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":1597,"manageAffiliations":1598,"indexDatabases":1599,"url":122,"thumbnailPath":22,"statistic":1614,"gsStatistic":22,"type":22,"analyzePriority":22},[],{"country":1593,"issn":1594,"introduce":1595,"title":1596},{"VOID":13},{"VOID":15},{"EN":17},{"EN":19},[],[],[1600,1607],{"id":101,"indexDatabase":1601,"url":114,"indexYears":115,"academicFieldIds":1606,"indexDatabaseRanking":121},{"id":103,"createTime":104,"updateTime":105,"relativeEntities":1602,"label":1603,"description":1604,"key":111,"publicationTags":1605,"standard":22},[],{"EN":108,"VI":108},{"EN":108,"VI":110},[113],[117,118,119,120],{"id":82,"indexDatabase":1608,"url":97,"indexYears":22,"academicFieldIds":1613,"indexDatabaseRanking":22},{"id":84,"createTime":85,"updateTime":86,"relativeEntities":1609,"label":1610,"description":1611,"key":93,"publicationTags":1612,"standard":22},[],{"EN":89,"VI":89},{"VI":91,"EN":92},[95,96],[99],{"impactFactor":124,"impactFactorByYear":1615,"i10Index":124,"i10IndexLast5Year":124,"totalPublication":126,"totalPublicationByYear":1616,"totalCitation":124,"totalCitationByYear":1617,"totalCitationPerPublication":124,"totalCitationPerPublicationByYear":1618,"hindexLast5Year":124,"hindex":124},{},{"2019":128,"2020":129,"2021":130,"2022":131,"2023":132,"2024":133},{},{},{"volume":1620,"pages":1621},{"VOID":410},{"VOID":1622},"100766","2023-08-01",{"id":1625,"createTime":1626,"updateTime":1627,"relativeEntities":1628,"slug":1629,"properties":1630,"entityType":151,"verifyStatus":429,"verifyTime":1637,"verifyNote":430,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124,"primaryUrl":1638,"fullTextUrl":22,"authors":1639,"publicationType":377,"publisherRelationship":1897,"citationCount":22,"citationInfo":22,"publishDate":1504,"publishYear":414,"citationAnalyzeStatus":21,"lastCitationAnalyze":22,"indexDatabases":22,"openAccess":22,"references":22,"isForceReanalyzing":415},"be336612-818b-41bd-9b74-32dfb11d8d4b","2024-01-13T16:51:02.467+00:00","2025-01-14T23:39:43.969+00:00",[],"Single-cell-RNA-sequencing-analysis-reveals-that-N-acetylcysteine-partially-reverses-hepatic-immune-dysfunction-in-biliary-atresia",{"references":1631,"title":1633,"doi":1635},{"VOID":1632},"Nio, 2013, Multicenter randomized trial of postoperative corticosteroid therapy for biliary atresia, Pediatr Surg Int, 29, 1091, 10.1007\u002Fs00383-013-3377-6\nKim, 2019, Correlation of immune markers with outcomes in biliary atresia following intravenous immunoglobulin therapy, Hepatol Commun, 3, 685, 10.1002\u002Fhep4.1332\nBaumann, 2021, Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: phase 2 study, Clin Res Hepatol Gastroenterol, 45, 10.1016\u002Fj.clinre.2021.101751\nNguyen, 2022, Study protocol of Phase 2 open-label multicenter randomized controlled trial for granulocyte-colony stimulating factor (GCSF) in post-Kasai Type 3 biliary atresia, Pediatr Surg Int, 38, 1019, 10.1007\u002Fs00383-022-05115-0\nWang, 2020, Liver immune profiling reveals pathogenesis and therapeutics for biliary atresia, Cell, 183, 1867, 10.1016\u002Fj.cell.2020.10.048\nChiew, 2017, Massive paracetamol overdose: an observational study of the effect of activated charcoal and increased acetylcysteine dose (ATOM-2), Clin Toxicol (Phila), 55, 1055, 10.1080\u002F15563650.2017.1334915\nHu, 2015, Efficacy and safety of acetylcysteine in \"non-acetaminophen\" acute liver failure: a meta-analysis of prospective clinical trials, Clin Res Hepatol Gastroenterol, 39, 594, 10.1016\u002Fj.clinre.2015.01.003\nZhang, 2022, CD177+ cells produce neutrophil extracellular traps that promote biliary atresia, J Hepatol, 77, 1299, 10.1016\u002Fj.jhep.2022.06.015\nLuo, 2019, Gene expression signatures associated with survival times of pediatric patients with biliary atresia identify potential therapeutic agents, Gastroenterology, 157, 1138, 10.1053\u002Fj.gastro.2019.06.017\nSchulte-Schrepping, 2020, Severe COVID-19 is marked by a dysregulated myeloid cell compartment, Cell, 182, 1419, 10.1016\u002Fj.cell.2020.08.001\nEvrard, 2018, Developmental analysis of bone marrow neutrophils reveals populations specialized in expansion, trafficking, and effector functions, Immunity, 48, 364, 10.1016\u002Fj.immuni.2018.02.002\nAizarani, 2019, A human liver cell atlas reveals heterogeneity and epithelial progenitors, Nature, 572, 199, 10.1038\u002Fs41586-019-1373-2\nLong, 2022, Single-cell multiomics analysis reveals regulatory programs in clear cell renal cell carcinoma, Cell Discov, 8, 68, 10.1038\u002Fs41421-022-00415-0\nJo, 2019, Peroxisomal dysfunction in neurodegenerative diseases, Arch Pharm Res, 42, 393, 10.1007\u002Fs12272-019-01131-2\nAnsari, 2022, N-acetylglucosamine sensing and metabolic engineering for attenuating human and plant pathogens, Bioengineering (Basel), 9, 64, 10.3390\u002Fbioengineering9020064\nCao, 2023, Oxidative phosphorylation safeguards pluripotency via UDP-N-acetylglucosamine, Protein Cell, 14, 376\nBaudhuin, 2013, Exocytosis acts as a modulator of the ILT4-mediated inhibition of neutrophil functions, Proc Natl Acad Sci U S A, 110, 17957, 10.1073\u002Fpnas.1221535110\nLi, 2009, Ig-like transcript 4 inhibits lipid antigen presentation through direct CD1d interaction, J Immunol, 182, 1033, 10.4049\u002Fjimmunol.182.2.1033\nMartin, 2003, Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence, Immunity, 19, 583, 10.1016\u002FS1074-7613(03)00263-2\nFajgenbaum, 2020, Cytokine storm, N Engl J Med, 383, 2255, 10.1056\u002FNEJMra2026131\nDeng, 2018, Interaction between CD177 and platelet endothelial cell adhesion molecule-1 downregulates membrane-bound proteinase-3 (PR3) expression on neutrophils and attenuates neutrophil activation induced by PR3-ANCA, Arthritis Res Ther, 20, 213, 10.1186\u002Fs13075-018-1710-0\nSugimoto, 2016, Annexin A1 and the resolution of inflammation: modulation of neutrophil recruitment, apoptosis, and clearance, J Immunol Res, 2016\nSlota, 2015, Norepinephrine preferentially modulates memory CD8 T cell function inducing inflammatory cytokine production and reducing proliferation in response to activation, Brain Behav Immun, 46, 168, 10.1016\u002Fj.bbi.2015.01.015\nStrazzabosco, 2018, Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium, Biochim Biophys Acta Mol Basis Dis, 1864, 1374, 10.1016\u002Fj.bbadis.2017.07.023\nSzabo, 2015, Inflammasome activation and function in liver disease, Nat Rev Gastroenterol Hepatol, 12, 387, 10.1038\u002Fnrgastro.2015.94\nWang, 2020, ROS-producing immature neutrophils in giant cell arteritis are linked to vascular pathologies, JCI Insight, 5, 10.1172\u002Fjci.insight.139163\nRice, 2022, Hyperactive immature state and differential CXCR2 expression of neutrophils in severe COVID-19, Life Sci Alliance, 6\nAuffray, 2009, Blood monocytes: development, heterogeneity, and relationship with dendritic cells, Annu Rev Immunol, 27, 669, 10.1146\u002Fannurev.immunol.021908.132557\nGuo, 2020, Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm, Nat Commun, 11, 3924, 10.1038\u002Fs41467-020-17834-w\nLiu, 2021, Metabolic reprogramming in macrophage responses, Biomark Res, 9, 1, 10.1186\u002Fs40364-020-00251-y\nAl-Shukaili, 2009, Effect of N-acetyl-L-cysteine on cytokine production by human peripheral blood mononuclear cells, Sultan Qaboos Univ Med J, 9, 70\nLuo, 2021, Unique cholangiocyte-targeted IgM autoantibodies correlate with poor outcome in biliary atresia, Hepatology, 73, 1855, 10.1002\u002Fhep.31504\nTaylor, 2019, The contribution of B cells in autoimmune liver diseases, Semin Liver Dis, 39, 422, 10.1055\u002Fs-0039-1688751\nYe, 2022, Single-cell and spatial transcriptomics reveal the fibrosis-related immune landscape of biliary atresia, Clin Transl Med, 12, 10.1002\u002Fctm2.1070",{"EN":1634},"Single cell RNA-sequencing analysis reveals that N-acetylcysteine partially reverses hepatic immune dysfunction in biliary atresia",{"VOID":1636},"10.1016\u002Fj.jhepr.2023.100908","2025-01-14T23:39:43.968+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2589555923002392",[1640,1656,1668,1680,1692,1704,1716,1728,1740,1762,1774,1787,1799,1812,1824,1837,1849,1861,1873,1885],{"id":1641,"sortIndex":1642,"researcher":22,"roles":1643,"affiliations":1644,"properties":1653},"1771a9fb-605d-4e88-b55e-feb5d6c3c4b0",15,[159],[1645],{"id":22,"sortIndex":124,"affiliation":1646,"properties":22},{"id":1647,"createTime":1648,"updateTime":1648,"relativeEntities":1649,"slug":22,"properties":1650,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"4005675d-e789-4555-aa9a-5e0a55d463dc","2024-01-13T16:51:02.976+00:00",[],{"title":1651},{"VI":1652},"Guangdong Provincial Key Laboratory of Research in Structure Birth Defect Disease and Department of Pediatric Surgery, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangdong Provincial Clinical Research Center for Child Health, Guangzhou, 510623, China",{"title":1654},{"VI":1655},"Fei Liu",{"id":1657,"sortIndex":124,"researcher":22,"roles":1658,"affiliations":1659,"properties":1665},"98dab751-05b2-49e5-b979-38466d950dc2",[159],[1660],{"id":22,"sortIndex":124,"affiliation":1661,"properties":22},{"id":1647,"createTime":1648,"updateTime":1648,"relativeEntities":1662,"slug":22,"properties":1663,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1664},{"VI":1652},{"title":1666},{"VI":1667},"Rongchen Ye",{"id":1669,"sortIndex":246,"researcher":22,"roles":1670,"affiliations":1671,"properties":1677},"c64122d2-fb6c-4e6c-a036-af40d42a3638",[159],[1672],{"id":22,"sortIndex":124,"affiliation":1673,"properties":22},{"id":1647,"createTime":1648,"updateTime":1648,"relativeEntities":1674,"slug":22,"properties":1675,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1676},{"VI":1652},{"title":1678},{"VI":1679},"Wei Zhong",{"id":1681,"sortIndex":78,"researcher":22,"roles":1682,"affiliations":1683,"properties":1689},"027cf64b-89e6-4c7d-8f68-7e77c352b728",[159],[1684],{"id":22,"sortIndex":124,"affiliation":1685,"properties":22},{"id":1647,"createTime":1648,"updateTime":1648,"relativeEntities":1686,"slug":22,"properties":1687,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1688},{"VI":1652},{"title":1690},{"VI":1691},"Xiaoyu Zuo",{"id":1693,"sortIndex":259,"researcher":22,"roles":1694,"affiliations":1695,"properties":1701},"7adc9ce4-34ea-4cbc-9c2d-1f0fc9c97e2e",[159],[1696],{"id":22,"sortIndex":124,"affiliation":1697,"properties":22},{"id":1647,"createTime":1648,"updateTime":1648,"relativeEntities":1698,"slug":22,"properties":1699,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1700},{"VI":1652},{"title":1702},{"VI":1703},"Hongjiao Chen",{"id":1705,"sortIndex":152,"researcher":22,"roles":1706,"affiliations":1707,"properties":1713},"5f94ac3b-3e15-404a-9a1b-06f2973300bd",[159],[1708],{"id":22,"sortIndex":124,"affiliation":1709,"properties":22},{"id":1647,"createTime":1648,"updateTime":1648,"relativeEntities":1710,"slug":22,"properties":1711,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1712},{"VI":1652},{"title":1714},{"VI":1715},"Sige Ma",{"id":1717,"sortIndex":68,"researcher":22,"roles":1718,"affiliations":1719,"properties":1725},"14b35399-08a3-4bd7-8b73-62e4c07b327b",[159],[1720],{"id":22,"sortIndex":124,"affiliation":1721,"properties":22},{"id":1647,"createTime":1648,"updateTime":1648,"relativeEntities":1722,"slug":22,"properties":1723,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1724},{"VI":1652},{"title":1726},{"VI":1727},"Ming Fu",{"id":1729,"sortIndex":157,"researcher":22,"roles":1730,"affiliations":1731,"properties":1737},"b4aab0f7-09fd-4d09-b591-ad40b4b325cc",[159],[1732],{"id":22,"sortIndex":124,"affiliation":1733,"properties":22},{"id":1647,"createTime":1648,"updateTime":1648,"relativeEntities":1734,"slug":22,"properties":1735,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1736},{"VI":1652},{"title":1738},{"VI":1739},"Yanlu Tong",{"id":1741,"sortIndex":23,"researcher":22,"roles":1742,"affiliations":1743,"properties":1759},"2f4239f8-38b6-4b92-ac77-7f9c17c60085",[159],[1744,1752],{"id":22,"sortIndex":124,"affiliation":1745,"properties":22},{"id":1746,"createTime":1747,"updateTime":1747,"relativeEntities":1748,"slug":22,"properties":1749,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"a31cadf6-3bd2-4fb0-a17c-4e9eb6198da9","2024-01-04T10:21:36.900+00:00",[],{"title":1750},{"VI":1751},"Faculty of Medicine, Macau University of Science and Technology, Macau 999078, China",{"id":1753,"sortIndex":152,"affiliation":1754,"properties":1758},"5d540522-94b4-4362-ab20-6bc4066ca469",{"id":1647,"createTime":1648,"updateTime":1648,"relativeEntities":1755,"slug":22,"properties":1756,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1757},{"VI":1652},{},{"title":1760},{"VI":1761},"Yan Chen",{"id":1763,"sortIndex":133,"researcher":22,"roles":1764,"affiliations":1765,"properties":1771},"b1acfa57-5225-4223-97d4-299ca20b85e8",[159],[1766],{"id":22,"sortIndex":124,"affiliation":1767,"properties":22},{"id":1647,"createTime":1648,"updateTime":1648,"relativeEntities":1768,"slug":22,"properties":1769,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1770},{"VI":1652},{"title":1772},{"VI":1773},"Jiarou Shan",{"id":1775,"sortIndex":1776,"researcher":22,"roles":1777,"affiliations":1778,"properties":1784},"82508b2e-3816-4595-986f-377c0d0424c7",18,[159],[1779],{"id":22,"sortIndex":124,"affiliation":1780,"properties":22},{"id":1647,"createTime":1648,"updateTime":1648,"relativeEntities":1781,"slug":22,"properties":1782,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1783},{"VI":1652},{"title":1785},{"VI":1786},"Zhe Wang",{"id":1788,"sortIndex":275,"researcher":22,"roles":1789,"affiliations":1790,"properties":1796},"e27a19d6-ca8d-4973-a886-7becf65619a0",[159],[1791],{"id":22,"sortIndex":124,"affiliation":1792,"properties":22},{"id":1647,"createTime":1648,"updateTime":1648,"relativeEntities":1793,"slug":22,"properties":1794,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1795},{"VI":1652},{"title":1797},{"VI":1798},"Liang Su",{"id":1800,"sortIndex":1801,"researcher":22,"roles":1802,"affiliations":1803,"properties":1809},"ef5a0d04-c92c-471a-b7c2-ca1b4b9a8f16",16,[159],[1804],{"id":22,"sortIndex":124,"affiliation":1805,"properties":22},{"id":1647,"createTime":1648,"updateTime":1648,"relativeEntities":1806,"slug":22,"properties":1807,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1808},{"VI":1652},{"title":1810},{"VI":1811},"Chenwei Chai",{"id":1813,"sortIndex":129,"researcher":22,"roles":1814,"affiliations":1815,"properties":1821},"59e4de49-761e-4ba5-82ba-874d0af52541",[159],[1816],{"id":22,"sortIndex":124,"affiliation":1817,"properties":22},{"id":1647,"createTime":1648,"updateTime":1648,"relativeEntities":1818,"slug":22,"properties":1819,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1820},{"VI":1652},{"title":1822},{"VI":1823},"Ledong Tan",{"id":1825,"sortIndex":1826,"researcher":22,"roles":1827,"affiliations":1828,"properties":1834},"de84aa6a-fd17-4721-a22f-96bb2ff05a56",19,[159],[1829],{"id":22,"sortIndex":124,"affiliation":1830,"properties":22},{"id":1647,"createTime":1648,"updateTime":1648,"relativeEntities":1831,"slug":22,"properties":1832,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1833},{"VI":1652},{"title":1835},{"VI":1836},"Tao Liu",{"id":1838,"sortIndex":189,"researcher":22,"roles":1839,"affiliations":1840,"properties":1846},"954cf5bb-4e20-47cd-9f0d-edcc3471b45e",[159],[1841],{"id":22,"sortIndex":124,"affiliation":1842,"properties":22},{"id":1647,"createTime":1648,"updateTime":1648,"relativeEntities":1843,"slug":22,"properties":1844,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1845},{"VI":1652},{"title":1847},{"VI":1848},"Zhipeng Guo",{"id":1850,"sortIndex":329,"researcher":22,"roles":1851,"affiliations":1852,"properties":1858},"9ae27fca-1a81-4edf-a1a0-ca6792e7ea58",[159],[1853],{"id":22,"sortIndex":124,"affiliation":1854,"properties":22},{"id":1647,"createTime":1648,"updateTime":1648,"relativeEntities":1855,"slug":22,"properties":1856,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1857},{"VI":1652},{"title":1859},{"VI":1860},"Jiakang Yu",{"id":1862,"sortIndex":128,"researcher":22,"roles":1863,"affiliations":1864,"properties":1870},"1b6e4724-a869-4033-8253-5ccb3b62ce46",[159],[1865],{"id":22,"sortIndex":124,"affiliation":1866,"properties":22},{"id":1647,"createTime":1648,"updateTime":1648,"relativeEntities":1867,"slug":22,"properties":1868,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1869},{"VI":1652},{"title":1871},{"VI":1872},"Ziyang Zhao",{"id":1874,"sortIndex":130,"researcher":22,"roles":1875,"affiliations":1876,"properties":1882},"b0b5f5d6-5cd6-47da-9474-bacf0d0def99",[159],[1877],{"id":22,"sortIndex":124,"affiliation":1878,"properties":22},{"id":1647,"createTime":1648,"updateTime":1648,"relativeEntities":1879,"slug":22,"properties":1880,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1881},{"VI":1652},{"title":1883},{"VI":1884},"Xisi Guan",{"id":1886,"sortIndex":131,"researcher":22,"roles":1887,"affiliations":1888,"properties":1894},"2dabacb7-d666-4d75-8fa8-c15c993b3ff6",[159],[1889],{"id":22,"sortIndex":124,"affiliation":1890,"properties":22},{"id":1647,"createTime":1648,"updateTime":1648,"relativeEntities":1891,"slug":22,"properties":1892,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},[],{"title":1893},{"VI":1652},{"title":1895},{"VI":1896},"Jixiao Zeng",{"url":1638,"publisher":1898,"properties":1927},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1899,"slug":10,"properties":1900,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":1905,"manageAffiliations":1906,"indexDatabases":1907,"url":122,"thumbnailPath":22,"statistic":1922,"gsStatistic":22,"type":22,"analyzePriority":22},[],{"country":1901,"issn":1902,"introduce":1903,"title":1904},{"VOID":13},{"VOID":15},{"EN":17},{"EN":19},[],[],[1908,1915],{"id":101,"indexDatabase":1909,"url":114,"indexYears":115,"academicFieldIds":1914,"indexDatabaseRanking":121},{"id":103,"createTime":104,"updateTime":105,"relativeEntities":1910,"label":1911,"description":1912,"key":111,"publicationTags":1913,"standard":22},[],{"EN":108,"VI":108},{"EN":108,"VI":110},[113],[117,118,119,120],{"id":82,"indexDatabase":1916,"url":97,"indexYears":22,"academicFieldIds":1921,"indexDatabaseRanking":22},{"id":84,"createTime":85,"updateTime":86,"relativeEntities":1917,"label":1918,"description":1919,"key":93,"publicationTags":1920,"standard":22},[],{"EN":89,"VI":89},{"VI":91,"EN":92},[95,96],[99],{"impactFactor":124,"impactFactorByYear":1923,"i10Index":124,"i10IndexLast5Year":124,"totalPublication":126,"totalPublicationByYear":1924,"totalCitation":124,"totalCitationByYear":1925,"totalCitationPerPublication":124,"totalCitationPerPublicationByYear":1926,"hindexLast5Year":124,"hindex":124},{},{"2019":128,"2020":129,"2021":130,"2022":131,"2023":132,"2024":133},{},{},{"volume":1928,"pages":1929},{"VOID":410},{"VOID":1930},"100908",{"id":1932,"createTime":1933,"updateTime":1934,"relativeEntities":1935,"slug":1936,"properties":1937,"entityType":151,"verifyStatus":429,"verifyTime":1934,"verifyNote":430,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":23,"primaryUrl":1944,"fullTextUrl":22,"authors":1945,"publicationType":377,"publisherRelationship":2264,"citationCount":22,"citationInfo":22,"publishDate":1623,"publishYear":414,"citationAnalyzeStatus":21,"lastCitationAnalyze":22,"indexDatabases":22,"openAccess":22,"references":22,"isForceReanalyzing":415},"89295f98-f5bf-45e8-b405-c81d8fcb7f88","2023-12-06T12:29:28.236+00:00","2025-02-24T23:35:14.533+00:00",[],"Use-of-albumin-infusion-for-cirrhosis-related-complications-An-international-position-statement",{"references":1938,"title":1940,"doi":1942},{"VOID":1939},"Ginès, 2021, Liver cirrhosis, Lancet, 398, 1359, 10.1016\u002FS0140-6736(21)01374-X\nAsrani, 2019, Burden of liver diseases in the world, J Hepatol, 70, 151, 10.1016\u002Fj.jhep.2018.09.014\n2020, The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017, Lancet Gastroenterol Hepatol, 5, 245, 10.1016\u002FS2468-1253(19)30349-8\nGe, 2016, Treatment of patients with cirrhosis, N Engl J Med, 375, 767, 10.1056\u002FNEJMra1504367\nArroyo, 2014, Human serum albumin, systemic inflammation, and cirrhosis, J Hepatol, 61, 396, 10.1016\u002Fj.jhep.2014.04.012\n2018, EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis, J Hepatol, 69, 406, 10.1016\u002Fj.jhep.2018.03.024\nCaraceni, 2021, The search for disease-modifying agents in decompensated cirrhosis: from drug repurposing to drug discovery, J Hepatol, 75, S118, 10.1016\u002Fj.jhep.2021.01.024\nBernardi, 2018, Novel perspectives in the management of decompensated cirrhosis, Nat Rev Gastroenterol Hepatol, 15, 753, 10.1038\u002Fs41575-018-0045-2\nCaraceni, 2018, Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial, Lancet, 391, 2417, 10.1016\u002FS0140-6736(18)30840-7\nSolà, 2018, Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial, J Hepatol, 69, 1250, 10.1016\u002Fj.jhep.2018.08.006\nChina, 2021, A randomized trial of albumin infusions in hospitalized patients with cirrhosis, N Engl J Med, 384, 808, 10.1056\u002FNEJMoa2022166\nBai, 2019, Association of serum albumin level with incidence and mortality of overt hepatic encephalopathy in cirrhosis during hospitalization, Therap Adv Gastroenterol, 12, 10.1177\u002F1756284819881302\nHuang, 2011, Recurrence of spontaneous bacterial peritonitis in cirrhotic patients non-prophylactically treated with norfloxacin: serum albumin as an easy but reliable predictive factor, Liver Int, 31, 184, 10.1111\u002Fj.1478-3231.2010.02377.x\nBai, 2022, Use of human albumin infusion in cirrhotic patients: a systematic review and meta-analysis of randomized controlled trials, Hepatol Int, 16, 1468, 10.1007\u002Fs12072-022-10374-z\nBiggins, 2021, Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American association for the study of liver diseases, Hepatology, 74, 1014, 10.1002\u002Fhep.31884\nTarín Remohí, 2000, Costs related to inappropriate use of albumin in Spain, Ann Pharmacother, 34, 1198, 10.1345\u002Faph.19385\nTanzi, 2003, Evaluation of the appropriate use of albumin in adult and pediatric patients, Am J Health Syst Pharm, 60, 1330, 10.1093\u002Fajhp\u002F60.13.1330\nYazdani, 2017, Where does the Albumin go? Human Albumin Solution usage following the implementation of a demand management programme, Transfus Med, 27, 192, 10.1111\u002Ftme.12406\nGarioud, 2017, Albumin use in patients with cirrhosis in France: results of the “ALBU-LIVE” survey: a case for better EASL guidelines diffusion and\u002For revision, J Clin Gastroenterol, 51, 831, 10.1097\u002FMCG.0000000000000735\nRodrigues, 2021, Intravenous albumin in patients with cirrhosis: evaluation of practice patterns and secular trends of usage in ontario 2000 to 2017, J Can Assoc Gastroenterol, 4, 179, 10.1093\u002Fjcag\u002Fgwaa027\nBajaj, 2015, Variations in albumin use in patients with cirrhosis: an AASLD members survey, Hepatology, 62, 1923, 10.1002\u002Fhep.27789\nCaraceni, 2018, The use of human albumin in patients with cirrhosis: a European survey, Expert Rev Gastroenterol Hepatol, 12, 625, 10.1080\u002F17474124.2018.1460203\nAithal, 2021, Guidelines on the management of ascites in cirrhosis, Gut, 70, 9, 10.1136\u002Fgutjnl-2020-321790\nRunyon, 2009, Management of adult patients with ascites due to cirrhosis: an update, Hepatology, 49, 2087, 10.1002\u002Fhep.22853\nAngeli, 2015, Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites, Gut, 64, 531, 10.1136\u002Fgutjnl-2014-308874\n2016, AISF-SIMTI Position Paper: the appropriate use of albumin in patients with liver cirrhosis, Dig Liver Dis, 48, 4, 10.1016\u002Fj.dld.2015.11.008\nCaraceni, 2021, AISF-SIMTI position paper on the appropriate use of albumin in patients with liver cirrhosis: a 2020 update, Blood Transfus, 19, 9\nCastro-Narro, 2022, Position statement on the use of albumin in liver cirrhosis, Ann Hepatol, 100708, 10.1016\u002Fj.aohep.2022.100708\nJünger, 2013, Consensus building on access to controlled medicines: a four-stage Delphi consensus procedure, J Pain Symptom Manage, 46, 897, 10.1016\u002Fj.jpainsymman.2013.01.014\nHelmer, 1963, An experimental application of the DELPHI method to the use of experts, Manag Sci, 9, 458\nBrouwers, 2016, Agree Next Steps Consortium. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines, BMJ, 352, i1152, 10.1136\u002Fbmj.i1152\nEsteban, 2019, Attitudes of liver and palliative care clinicians toward specialist palliative care consultation for patients with end-stage liver disease, J Palliat Med, 22, 804, 10.1089\u002Fjpm.2018.0553\nBalshem, 2011, GRADE guidelines: 3. Rating the quality of evidence, J Clin Epidemiol, 64, 401, 10.1016\u002Fj.jclinepi.2010.07.015\nLevitt, 2016, Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements, Int J Gen Med, 9, 229, 10.2147\u002FIJGM.S102819\nQuinlan, 2005, Albumin: biochemical properties and therapeutic potential, Hepatology, 41, 1211, 10.1002\u002Fhep.20720\nKragh-Hansen, 2002, Practical aspects of the ligand-binding and enzymatic properties of human serum albumin, Biol Pharm Bull, 25, 695, 10.1248\u002Fbpb.25.695\nDröge, 2002, Aging-related changes in the thiol\u002Fdisulfide redox state: implications for the use of thiol antioxidants, Exp Gerontol, 37, 1333, 10.1016\u002FS0531-5565(02)00175-4\nMoman, 2021\nSleep, 2013, Albumin as a versatile platform for drug half-life extension, Biochim Biophys Acta, 1830, 5526, 10.1016\u002Fj.bbagen.2013.04.023\nNilsen, 2020, An intact C-terminal end of albumin is required for its long half-life in humans, Commun Biol, 3, 181, 10.1038\u002Fs42003-020-0903-7\nKerr, 1967, Use of 125-I- and 51-Cr-labeled albumin for the measurement of gastrointestinal and total albumin catabolism, J Clin Invest, 46, 2064, 10.1172\u002FJCI105694\nHartmann, 2013, Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice, Hepatology, 58, 108, 10.1002\u002Fhep.26321\nGarcia-Martinez, 2013, Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications, Hepatology, 58, 1836, 10.1002\u002Fhep.26338\nCarvalho, 2018, New insights about albumin and liver disease, Ann Hepatol, 17, 547, 10.5604\u002F01.3001.0012.0916\nBaldassarre, 2021, Determination of effective albumin in patients with decompensated cirrhosis: clinical and prognostic implications, Hepatology, 74, 2058, 10.1002\u002Fhep.31798\nDahlqvist, 2012, In-111 transferrin scintigraphy in cirrhosis with hypoalbuminemia: evidence for protein-losing enteropathy in a small group of selected cases, Scand J Gastroenterol, 47, 1247, 10.3109\u002F00365521.2012.696682\nDavcev, 1969, Protein-losing enteropathy in patients with liver cirrhosis, Digestion, 2, 17, 10.1159\u002F000196916\nJalan, 2013, Effective albumin concentration and cirrhosis mortality: from concept to reality, J Hepatol, 59, 918, 10.1016\u002Fj.jhep.2013.08.001\nRoche, 2008, The antioxidant properties of serum albumin, FEBS Lett, 582, 1783, 10.1016\u002Fj.febslet.2008.04.057\nEngelmann, 2021, Pathophysiology of decompensated cirrhosis: portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction, J Hepatol, 75, S49, 10.1016\u002Fj.jhep.2021.01.002\nManzoor, 2022\nSalerno, 2007, Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis, Gut, 56, 1310\nArroyo, 1996, Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis, International Ascites Club. Hepatology, 23, 164\nSimonetto, 2020, Hepatorenal syndrome: pathophysiology, diagnosis, and management, BMJ, 370, m2687, 10.1136\u002Fbmj.m2687\nAngeli, 2019, News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document, J Hepatol, 71, 811, 10.1016\u002Fj.jhep.2019.07.002\nMartín-Llahí, 2008, Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study, Gastroenterology, 134, 1352, 10.1053\u002Fj.gastro.2008.02.024\nBoyer, 2016, Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1, Gastroenterology, 150, 1579, 10.1053\u002Fj.gastro.2016.02.026\nWong, 2021, Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome, N Engl J Med, 384, 818, 10.1056\u002FNEJMoa2008290\nCavallin, 2015, Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial, Hepatology, 62, 567, 10.1002\u002Fhep.27709\nSanyal, 2008, A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome, Gastroenterology, 134, 1360, 10.1053\u002Fj.gastro.2008.02.014\nCavallin, 2016, Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study, Hepatology, 63, 983, 10.1002\u002Fhep.28396\nSaif, 2018, Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: a randomized controlled study, Indian J Gastroenterol, 37, 424, 10.1007\u002Fs12664-018-0876-3\nSharma, 2008, An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response, Am J Gastroenterol, 103, 1689, 10.1111\u002Fj.1572-0241.2008.01828.x\nPomier-Layrargues, 2003, Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study, Hepatology, 38, 238, 10.1053\u002Fjhep.2003.50276\nAlessandria, 2007, Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study, J Hepatol, 47, 499, 10.1016\u002Fj.jhep.2007.04.010\nGhosh, 2013, Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study, Liver Int, 33, 1187, 10.1111\u002Fliv.12179\nOrtega, 2002, Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study, Hepatology, 36, 941\nSalerno, 2015, Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis, BMC Gastroenterol, 15, 167, 10.1186\u002Fs12876-015-0389-9\nQuintero, 1985, Paracentesis versus diuretics in the treatment of cirrhotics with tense ascites, Lancet, 1, 611, 10.1016\u002FS0140-6736(85)92147-6\nGinés, 1987, Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study, Gastroenterology, 93, 234, 10.1016\u002F0016-5085(87)91007-9\nRuiz-del-Arbol, 1997, Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis, Gastroenterology, 113, 579, 10.1053\u002Fgast.1997.v113.pm9247479\nGinès, 1988, Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis, Gastroenterology, 94, 1493, 10.1016\u002F0016-5085(88)90691-9\nGinès, 1996, Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis, Gastroenterology, 111, 1002, 10.1016\u002FS0016-5085(96)70068-9\nSolà, 1994, Total paracentesis with dextran 40 vs diuretics in the treatment of ascites in cirrhosis: a randomized controlled study, J Hepatol, 20, 282, 10.1016\u002FS0168-8278(05)80070-4\nBernardi, 2012, Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials, Hepatology, 55, 1172, 10.1002\u002Fhep.24786\nSimonetti, 2019, Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis, Cochrane Database Syst Rev, 6, CD004039\nShrestha, 2021, Safety and efficacy of human serum albumin treatment in patients with cirrhotic ascites undergoing paracentesis: a systematic review and meta-analysis, Ann Hepatol, 26, 100547, 10.1016\u002Fj.aohep.2021.100547\nMoore, 2006, Guidelines on the management of ascites in cirrhosis, Gut, 55, vi1\nPeltekian, 1997, Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites, Am J Gastroenterol, 92, 394\nArora, 2020, Paracentesis-induced circulatory dysfunction with modest-volume paracentesis is partly ameliorated by albumin infusion in acute-on-chronic liver failure, Hepatology, 72, 1043, 10.1002\u002Fhep.31071\nFleming, 2010, The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study, Aliment Pharmacol Ther, 32, 1343, 10.1111\u002Fj.1365-2036.2010.04473.x\nBernardi, 2015, Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis, J Hepatol, 63, 1272, 10.1016\u002Fj.jhep.2015.07.004\nSchrier, 1988, Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis, Hepatology, 8, 1151, 10.1002\u002Fhep.1840080532\nWilkinson, 1962, The effect of repeated albumin infusions in patients with cirrhosis, Lancet, 2, 1125, 10.1016\u002FS0140-6736(62)90895-4\nGentilini, 1999, Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial, J Hepatol, 30, 639, 10.1016\u002FS0168-8278(99)80194-9\nRomanelli, 2006, Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial, World J Gastroenterol, 12, 1403, 10.3748\u002Fwjg.v12.i9.1403\nSandi, 2021, Long-term albumin administration in patients with cirrhosis and ascites: a meta-analysis of randomized controlled trials, J Gastroenterol Hepatol, 36, 609, 10.1111\u002Fjgh.15253\nDi Pascoli, 2019, Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites, Liver Int, 39, 98, 10.1111\u002Fliv.13968\nCaraceni, 2021, On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites, J Hepatol, 74, 340, 10.1016\u002Fj.jhep.2020.08.021\nFernández, 2012, Management of bacterial infections in cirrhosis, J Hepatol, 56, S1, 10.1016\u002FS0168-8278(12)60002-6\nFernández, 2012, Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study, Hepatology, 55, 1551, 10.1002\u002Fhep.25532\nFernández, 2002, Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis, Hepatology, 35, 140, 10.1053\u002Fjhep.2002.30082\nArvaniti, 2010, Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis, Gastroenterology, 139, 1246, 10.1053\u002Fj.gastro.2010.06.019\nJalan, 2014, Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013, J Hepatol, 60, 1310, 10.1016\u002Fj.jhep.2014.01.024\nPiano, 2016, The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: results of a randomized, controlled clinical trial, Hepatology, 63, 1299, 10.1002\u002Fhep.27941\nDever, 2015, Review article: spontaneous bacterial peritonitis--bacteriology, diagnosis, treatment, risk factors and prevention, Aliment Pharmacol Ther, 41, 1116, 10.1111\u002Fapt.13172\nSort, 1999, Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis, N Engl J Med, 341, 403, 10.1056\u002FNEJM199908053410603\nChen, 2009, Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis, Scand J Gastroenterol, 44, 619, 10.1080\u002F00365520902719273\nFernández, 2005, A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis, Hepatology, 42, 627, 10.1002\u002Fhep.20829\nTerra, 2005, Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score, Gastroenterology, 129, 1944, 10.1053\u002Fj.gastro.2005.09.024\nGuevara, 2012, Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study, J Hepatol, 57, 759, 10.1016\u002Fj.jhep.2012.06.013\nThévenot, 2015, Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial, J Hepatol, 62, 822, 10.1016\u002Fj.jhep.2014.11.017\nFernández, 2020, Efficacy of albumin treatment for patients with cirrhosis and infections unrelated to spontaneous bacterial peritonitis, Clin Gastroenterol Hepatol, 18, 963, 10.1016\u002Fj.cgh.2019.07.055\nFernández, 2019, Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis, Gastroenterology, 157, 149, 10.1053\u002Fj.gastro.2019.03.021\nWong, 2020, Efficacy and Safety of IV albumin for non-spontaneous bacterial peritonitis infection among patients with cirrhosis: a systematic review and meta-analysis, Dig Liver Dis, 52, 1137, 10.1016\u002Fj.dld.2020.05.047\nWijdicks, 2016, Hepatic encephalopathy, N Engl J Med, 375, 1660, 10.1056\u002FNEJMra1600561\n2022, EASL Clinical Practice Guidelines on the management of hepatic encephalopathy, J Hepatol, 77, 807, 10.1016\u002Fj.jhep.2022.06.001\n2014, European association for the study of the liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European association for the study of the liver and the American association for the study of liver diseases, J Hepatol, 61, 642, 10.1016\u002Fj.jhep.2014.05.042\nBrusilow, 2010, Astrocyte glutamine synthetase: importance in hyperammonemic syndromes and potential target for therapy, Neurotherapeutics, 7, 452, 10.1016\u002Fj.nurt.2010.05.015\nGonzález-Usano, 2013, Hyperammonemia alters the modulation by different neurosteroids of the glutamate-nitric oxide-cyclic GMP pathway through NMDA- GABAA - or sigma receptors in cerebellum in vivo, J Neurochem, 125, 133, 10.1111\u002Fjnc.12119\nGluud, 2016, Nonabsorbable disaccharides for hepatic encephalopathy: a systematic review and meta-analysis, Hepatology, 64, 908, 10.1002\u002Fhep.28598\nBass, 2010, Rifaximin treatment in hepatic encephalopathy, N Engl J Med, 362, 1071, 10.1056\u002FNEJMoa0907893\nKircheis, 1997, Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study, Hepatology, 25, 1351, 10.1002\u002Fhep.510250609\nBosoi, 2013, Oxidative stress: a systemic factor implicated in the pathogenesis of hepatic encephalopathy, Metab Brain Dis, 28, 175, 10.1007\u002Fs11011-012-9351-5\nJain, 2012, Serum endotoxin and inflammatory mediators in patients with cirrhosis and hepatic encephalopathy, Dig Liver Dis, 44, 1027, 10.1016\u002Fj.dld.2012.07.002\nSimón-Talero, 2013, Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study, J Hepatol, 59, 1184, 10.1016\u002Fj.jhep.2013.07.020\nSharma, 2017, Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy, J Gastroenterol Hepatol, 32, 1234, 10.1111\u002Fjgh.13666\nBai, 2019, Albumin infusion may decrease the incidence and severity of overt hepatic encephalopathy in liver cirrhosis, Aging (Albany NY), 11, 8502, 10.18632\u002Faging.102335\nFagan, 2023, A double-blind randomized placebo-controlled trial of albumin in patients with hepatic encephalopathy: HEAL study, J Hepatol, 78, 312, 10.1016\u002Fj.jhep.2022.09.009\nTeh, 2021, Efficacy and safety of albumin infusion for overt hepatic encephalopathy: a systematic review and meta-analysis, Dig Liver Dis, 53, 817, 10.1016\u002Fj.dld.2021.04.030\nIs, 2021, Albumin in the management of hepatic encephalopathy: a systematic review and meta-analysis, Ann Hepatol, 26\nWong, 2023, Albumin therapy for hepatic encephalopathy: current evidence and controversies, Metab Brain Dis, 38, 1759, 10.1007\u002Fs11011-022-01002-8\nAngeli, 2006, Hyponatremia in cirrhosis: results of a patient population survey, Hepatology, 44, 1535, 10.1002\u002Fhep.21412\nAttar, 2019, Approach to hyponatremia in cirrhosis, Clin Liver Dis (Hoboken), 13, 98, 10.1002\u002Fcld.790\nKim, 2008, Hyponatremia and mortality among patients on the liver-transplant waiting list, N Engl J Med, 359, 1018, 10.1056\u002FNEJMoa0801209\nBorroni, 2000, Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients, Dig Liver Dis, 32, 605, 10.1016\u002FS1590-8658(00)80844-0\nAlukal, 2020, Hyponatremia in cirrhosis: an update, Am J Gastroenterol, 115, 1775, 10.14309\u002Fajg.0000000000000786\nBajaj, 2018, The impact of albumin use on resolution of hyponatremia in hospitalized patients with cirrhosis, Am J Gastroenterol, 113, 1339, 10.1038\u002Fs41395-018-0119-3\nChina, 2021, Targeted albumin therapy does not improve short-term outcome in hyponatremic patients hospitalized with complications of cirrhosis: data from the ATTIRE trial, Am J Gastroenterol, 116, 2292, 10.14309\u002Fajg.0000000000001488\nZaccherini, 2023, Correction and prevention of hyponatremia in patients with cirrhosis and ascites - post hoc analysis of the ANSWER study database, Am J Gastroenterol, 118, 168, 10.14309\u002Fajg.0000000000001995\nBai, 2022, Use of human albumin administration for the prevention and treatment of hyponatremia in patients with liver cirrhosis: a systematic review and meta-analysis, J Clin Med, 11, 5928, 10.3390\u002Fjcm11195928\nRogal, 2022, AASLD Practice Guidance: palliative care and symptom-based management in decompensated cirrhosis, Hepatology, 76, 819, 10.1002\u002Fhep.32378\nAngeli, 1996, Cirrhosis and muscle cramps: evidence of a causal relationship, Hepatology, 23, 264, 10.1002\u002Fhep.510230211\nElfert, 2016, Randomized placebo-controlled study of baclofen in the treatment of muscle cramps in patients with liver cirrhosis, Eur J Gastroenterol Hepatol, 28, 1280, 10.1097\u002FMEG.0000000000000714\nLee, 1991, A randomized controlled trial of quinidine in the treatment of cirrhotic patients with muscle cramps, J Hepatol, 12, 236, 10.1016\u002F0168-8278(91)90944-7\nForeman, 2003, Cirrhosis as a risk factor for sepsis and death: analysis of the National Hospital Discharge Survey, Chest, 124, 1016, 10.1378\u002Fchest.124.3.1016\nGotts, 2016, Sepsis: pathophysiology and clinical management, BMJ, 353, i1585, 10.1136\u002Fbmj.i1585\nGustot, 2009, Severe sepsis in cirrhosis, Hepatology, 50, 2022, 10.1002\u002Fhep.23264\nPlessier, 2003, Coagulation disorders in patients with cirrhosis and severe sepsis, Liver Int, 23, 440, 10.1111\u002Fj.1478-3231.2003.00870.x\nSimonetto, 2019, Management of sepsis in patients with cirrhosis: current evidence and practical approach, Hepatology, 70, 418, 10.1002\u002Fhep.30412\nSauneuf, 2013, Increased survival of cirrhotic patients with septic shock, Crit Care, 17, R78, 10.1186\u002Fcc12687\nPhilips, 2021, Comparison of 5% human albumin and normal saline for fluid resuscitation in sepsis induced hypotension among patients with cirrhosis (FRISC study): a randomized controlled trial, Hepatol Int, 15, 983, 10.1007\u002Fs12072-021-10164-z\nMaiwall, 2022, A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial], J Hepatol, 77, 670, 10.1016\u002Fj.jhep.2022.03.043\nShasthry, 2017, Changes in cardiac output and incidence of volume overload in cirrhotics receiving 20% albumin infusion, Liver Int, 37, 1167, 10.1111\u002Fliv.13375\nUmgelter, 2008, Haemodynamic effects of plasma-expansion with hyperoncotic albumin in cirrhotic patients with renal failure: a prospective interventional study, BMC Gastroenterol, 8, 39, 10.1186\u002F1471-230X-8-39\nBai, 2021, Human albumin infusion strategy in liver cirrhosis: liberal or restrictive?, Ann Transl Med, 9, 1114, 10.21037\u002Fatm-21-2136\nAllegretti, 2022, Respiratory events with terlipressin and albumin in hepatorenal syndrome: a review and clinical guidance, Liver Int, 42, 2124, 10.1111\u002Fliv.15367\nFujita, 2007, Anaphylactoid shock in a patient following 5% human serum albumin infusion during off-pump coronary artery bypass grafting, J Anesth, 21, 396, 10.1007\u002Fs00540-007-0512-3\nMoreno Lozano, 2019, Human serum albumin induced anaphylaxis in a patient with good tolerance to human plasma, J Investig Allergol Clin Immunol, 29, 51, 10.18176\u002Fjiaci.0325\nRing, 1979, Anaphylactoid reactions to infusions of plasma protein and human serum albumin. Role of aggregated proteins and of stabilizers added during production, Clin Allergy, 9, 89, 10.1111\u002Fj.1365-2222.1979.tb01527.x\nStafford, 1988, Anaphylaxis to human serum albumin, Ann Allergy, 61, 85\nDengler, 1989, Chemical and immunochemical characterization of polymers of aggregates in preparations of human serum albumin, Infusionstherapie, 16, 160\nJensen, 1994, Identification and removal of polymer- and aggregate-forming proteins in human plasma albumin preparations, Vox Sang, 67, 125, 10.1111\u002Fj.1423-0410.1994.tb01646.x\nFaloon, 1949, An evaluation of human serum albumin in the treatment of cirrhosis of the liver, J Clin Invest, 28, 583, 10.1172\u002FJCI102108\nKunkel, 1948, The use of concentrated human serum albumin in the treatment of cirrhosis of the liver, J Clin Invest, 27, 305, 10.1172\u002FJCI101959\nWang, 2020, The impact of albumin infusion on the risk of rebleeding and in-hospital mortality in cirrhotic patients admitted for acute gastrointestinal bleeding: a retrospective study of a single institute, BMC Gastroenterol, 20, 198, 10.1186\u002Fs12876-020-01337-5",{"EN":1941},"Use of albumin infusion for cirrhosis-related complications: An international position statement",{"VOID":1943},"10.1016\u002Fj.jhepr.2023.100785","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS2589555923001167",[1946,1961,1976,1991,2006,2023,2040,2055,2070,2085,2100,2127,2144,2159,2174,2189,2204,2219,2234,2249],{"id":1947,"sortIndex":128,"researcher":22,"roles":1948,"affiliations":1949,"properties":1958},"325dabef-c4c2-4950-800d-9185ea719a6b",[159],[1950],{"id":22,"sortIndex":124,"affiliation":1951,"properties":22},{"id":1952,"createTime":1953,"updateTime":1953,"relativeEntities":1954,"slug":22,"properties":1955,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"8a854b6b-6002-48a9-b106-4f48a25a479f","2023-12-23T11:07:29.536+00:00",[],{"title":1956},{"VI":1957},"Division of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy",{"title":1959},{"VI":1960},"Massimo Primignani",{"id":1962,"sortIndex":152,"researcher":22,"roles":1963,"affiliations":1964,"properties":1973},"864c6fe8-2035-4d72-8f76-d2211284feb3",[159],[1965],{"id":22,"sortIndex":124,"affiliation":1966,"properties":22},{"id":1967,"createTime":1968,"updateTime":1968,"relativeEntities":1969,"slug":22,"properties":1970,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"f5776f25-76c6-435f-b66b-3cee494913f2","2023-12-06T12:29:28.283+00:00",[],{"title":1971},{"VI":1972},"Liver Research Unit, Medica Sur Clinic and Foundation, National Autonomous University of Mexico, Mexico City, Mexico",{"title":1974},{"VI":1975},"Nahum Méndez-Sánchez",{"id":1977,"sortIndex":78,"researcher":22,"roles":1978,"affiliations":1979,"properties":1988},"641754df-e21c-4d39-8510-b3fb56176855",[159],[1980],{"id":22,"sortIndex":124,"affiliation":1981,"properties":22},{"id":1982,"createTime":1983,"updateTime":1983,"relativeEntities":1984,"slug":22,"properties":1985,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"38eeb017-142c-4d50-be1e-fe6318d64205","2023-12-06T12:29:28.314+00:00",[],{"title":1986},{"VI":1987},"Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, Germany",{"title":1989},{"VI":1990},"Rolf Teschke",{"id":1992,"sortIndex":129,"researcher":22,"roles":1993,"affiliations":1994,"properties":2003},"0b2280f6-7931-41f4-bb8d-327ab7cf1a9d",[159],[1995],{"id":22,"sortIndex":124,"affiliation":1996,"properties":22},{"id":1997,"createTime":1998,"updateTime":1998,"relativeEntities":1999,"slug":22,"properties":2000,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"9471f1c6-4779-4f7c-8f3f-142f34514bd0","2023-12-11T10:08:25.965+00:00",[],{"title":2001},{"VI":2002},"Clinical and Translational Hepatology, The Liver Institute, Center of Excellence in GI Sciences, Rajagiri Hospital, Aluva, India",{"title":2004},{"VI":2005},"Cyriac Abby Philips",{"id":2007,"sortIndex":1826,"researcher":22,"roles":2008,"affiliations":2009,"properties":2020},"d0a78802-8372-4290-8b4a-d1f2afcc4bb6",[159],[2010],{"id":22,"sortIndex":124,"affiliation":2011,"properties":22},{"id":2012,"createTime":2013,"updateTime":2014,"relativeEntities":2015,"slug":2016,"properties":2017,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"30d4fa69-68d9-4196-a591-f9f58761ae64","2024-04-21T03:07:22.024+00:00","2024-09-20T15:47:08.120+00:00",[],"Department-of-Translational-and-Precision-Medicine-Sapienza-University-of-Rome-Rome-Italy",{"title":2018},{"EN":2019},"Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy",{"title":2021},{"VI":2022},"Lorenzo Ridola",{"id":2024,"sortIndex":259,"researcher":22,"roles":2025,"affiliations":2026,"properties":2037},"6f7f1ae4-7c29-46c9-8125-d62fd24593d8",[159],[2027],{"id":22,"sortIndex":124,"affiliation":2028,"properties":22},{"id":2029,"createTime":2030,"updateTime":2031,"relativeEntities":2032,"slug":2033,"properties":2034,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"00a8448b-b3e4-4e08-8bdf-55122d78bdea","2023-12-06T12:29:28.363+00:00","2025-06-11T14:09:10.583+00:00",[],"Department-of-Gastroenterology-and-Hepatology-Theodor-Bilharz-Research-Institute-Cairo-Egypt",{"title":2035},{"VI":2036},"Department of Gastroenterology and Hepatology, Theodor Bilharz Research Institute, Cairo, Egypt",{"title":2038},{"VI":2039},"Mostafa Ibrahim",{"id":2041,"sortIndex":133,"researcher":22,"roles":2042,"affiliations":2043,"properties":2052},"ab2c9ee6-b142-4e14-9108-9a1662ff8243",[159],[2044],{"id":22,"sortIndex":124,"affiliation":2045,"properties":22},{"id":2046,"createTime":2047,"updateTime":2047,"relativeEntities":2048,"slug":22,"properties":2049,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"f9462a08-24b1-4ffd-85f0-2c3549d919f7","2023-12-06T12:29:28.291+00:00",[],{"title":2050},{"VI":2051},"Medicina Interna 1, Azienda di Rilievo Nazionale ad Alta Specializzazione Civico-Di Cristina-Benfratelli, Palermo, Italy",{"title":2053},{"VI":2054},"Andrea Mancuso",{"id":2056,"sortIndex":68,"researcher":22,"roles":2057,"affiliations":2058,"properties":2067},"a452a6d0-580d-45fd-b3ea-af34331ccdf0",[159],[2059],{"id":22,"sortIndex":124,"affiliation":2060,"properties":22},{"id":2061,"createTime":2062,"updateTime":2062,"relativeEntities":2063,"slug":22,"properties":2064,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"3b9981ee-e7d1-47aa-96f2-ee7110ba6dcc","2023-12-13T08:47:39.621+00:00",[],{"title":2065},{"VI":2066},"Department of Gastroenterology and Hepatology, Changi General Hospital, Singapore",{"title":2068},{"VI":2069},"Yu Jun Wong",{"id":2071,"sortIndex":189,"researcher":22,"roles":2072,"affiliations":2073,"properties":2082},"1839f04a-30f8-47e2-b26d-e0b58cdaa948",[159],[2074],{"id":22,"sortIndex":124,"affiliation":2075,"properties":22},{"id":2076,"createTime":2077,"updateTime":2077,"relativeEntities":2078,"slug":22,"properties":2079,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"7bfab6fa-87aa-4280-864b-764d3003fdf5","2023-12-06T12:29:28.388+00:00",[],{"title":2080},{"VI":2081},"Serviço de Cuidados Intensivos, Unidade de Cuidados Intermédios Médico-Cirúrgica, Centro Hospitalar Universitário do Porto, Porto, Portugal",{"title":2083},{"VI":2084},"Filipe Gaio Nery",{"id":2086,"sortIndex":1776,"researcher":22,"roles":2087,"affiliations":2088,"properties":2097},"442081e8-f1c4-442e-8671-25f707b672b1",[159],[2089],{"id":22,"sortIndex":124,"affiliation":2090,"properties":22},{"id":2091,"createTime":2092,"updateTime":2092,"relativeEntities":2093,"slug":22,"properties":2094,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"a8f62ebe-002b-45fa-bdd9-d70890673863","2023-12-06T12:29:28.320+00:00",[],{"title":2095},{"VI":2096},"Department of Internal Medicine, Division of Hepatology, Sandra Atlas Bass Center for Liver Diseases & Transplantation, Donald and Barbara Zucker School of Medicine for Hofstra\u002FNorthwell Health, Manhasset, New York, USA",{"title":2098},{"VI":2099},"Sanjaya K. Satapathy",{"id":2101,"sortIndex":124,"researcher":22,"roles":2102,"affiliations":2103,"properties":2124},"0c8a0829-a9e1-4642-9d6e-778c5696a8cb",[159],[2104,2114],{"id":2105,"sortIndex":152,"affiliation":2106,"properties":2113},"db3d82cb-571b-4d12-94bf-81695d504980",{"id":2107,"createTime":2108,"updateTime":2108,"relativeEntities":2109,"slug":22,"properties":2110,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"67d7457b-d1af-413a-97a3-b922a0493ace","2024-01-22T11:27:56.793+00:00",[],{"title":2111},{"VI":2112},"Department of Life Sciences and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, China",{},{"id":22,"sortIndex":124,"affiliation":2115,"properties":22},{"id":2116,"createTime":2117,"updateTime":2118,"relativeEntities":2119,"slug":2120,"properties":2121,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"090746cb-4c13-45c7-99d2-620ceb0b00f9","2024-02-18T13:04:02.390+00:00","2025-06-11T21:59:44.007+00:00",[],"Department-of-Gastroenterology-General-Hospital-of-Northern-Theater-Command-Shenyang-China",{"title":2122},{"VI":2123},"Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, China",{"title":2125},{"VI":2126},"Zhaohui Bai",{"id":2128,"sortIndex":1642,"researcher":22,"roles":2129,"affiliations":2130,"properties":2141},"4ff6536a-5265-473b-8bfe-121f88fd452c",[159],[2131],{"id":22,"sortIndex":124,"affiliation":2132,"properties":22},{"id":2133,"createTime":2134,"updateTime":2135,"relativeEntities":2136,"slug":2137,"properties":2138,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"b7b663fa-8050-403f-bc39-5fe8a65ae745","2023-12-06T12:29:28.380+00:00","2024-09-01T12:15:14.184+00:00",[],"Centre-Hospitalier-Universitaire-de-Besan%C3%A7on-H%C3%B4pital-Jean-Minjoz-Service-d-H%C3%A9patologie-et-de-Soins-Intensifs-Digestifs-Besan%C3%A7on-France",{"title":2139},{"VI":2140},"Centre Hospitalier Universitaire de Besançon, Hôpital Jean Minjoz, Service d’Hépatologie et de Soins Intensifs Digestifs, Besançon, France",{"title":2142},{"VI":2143},"Thierry Thevenot",{"id":2145,"sortIndex":131,"researcher":22,"roles":2146,"affiliations":2147,"properties":2156},"cf14138b-215f-4d94-9e29-6f02d33104a2",[159],[2148],{"id":22,"sortIndex":124,"affiliation":2149,"properties":22},{"id":2150,"createTime":2151,"updateTime":2151,"relativeEntities":2152,"slug":22,"properties":2153,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"248639b6-b8f1-4e6f-8886-5f71f8cd04f4","2024-01-12T21:12:08.151+00:00",[],{"title":2154},{"VI":2155},"Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand",{"title":2157},{"VI":2158},"Kanokwan Pinyopornpanish",{"id":2160,"sortIndex":23,"researcher":22,"roles":2161,"affiliations":2162,"properties":2171},"21efa6d3-1438-4081-961d-0db469855ffb",[159],[2163],{"id":22,"sortIndex":124,"affiliation":2164,"properties":22},{"id":2165,"createTime":2166,"updateTime":2166,"relativeEntities":2167,"slug":22,"properties":2168,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"c82d2fd6-e8eb-4d69-8818-9abc6cb0d1bf","2023-12-06T12:29:28.247+00:00",[],{"title":2169},{"VI":2170},"Internal Medicine Department, Botucatu Medical School, São Paulo, Brazil",{"title":2172},{"VI":2173},"Fernando Gomes Romeiro",{"id":2175,"sortIndex":275,"researcher":22,"roles":2176,"affiliations":2177,"properties":2186},"97d20a9f-2322-4be9-87c8-25217fcf9af8",[159],[2178],{"id":22,"sortIndex":124,"affiliation":2179,"properties":22},{"id":2180,"createTime":2181,"updateTime":2181,"relativeEntities":2182,"slug":22,"properties":2183,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"7fe03184-ae55-4d5d-849e-b9a49812508b","2023-12-06T12:29:28.307+00:00",[],{"title":2184},{"VI":2185},"Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Berlin, Germany",{"title":2187},{"VI":2188},"Frank Tacke",{"id":2190,"sortIndex":246,"researcher":22,"roles":2191,"affiliations":2192,"properties":2201},"c0701313-640c-4d1e-866d-01d43d58310f",[159],[2193],{"id":22,"sortIndex":124,"affiliation":2194,"properties":22},{"id":2195,"createTime":2196,"updateTime":2196,"relativeEntities":2197,"slug":22,"properties":2198,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"eebdaad9-62cd-4595-89ca-8c57536a2b9c","2023-12-06T12:29:28.263+00:00",[],{"title":2199},{"VI":2200},"Sección Hepatología, Hospital Dr. Carlos B. Udaondo. Ciudad Autónoma de Buenos Aires, Argentina",{"title":2202},{"VI":2203},"Alberto E. Muñoz",{"id":2205,"sortIndex":157,"researcher":22,"roles":2206,"affiliations":2207,"properties":2216},"9a9be345-2917-48c5-8dd8-c8d9a2b898c2",[159],[2208],{"id":22,"sortIndex":124,"affiliation":2209,"properties":22},{"id":2210,"createTime":2211,"updateTime":2211,"relativeEntities":2212,"slug":22,"properties":2213,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"dae84828-c45c-4771-8a06-87602f8ca874","2023-12-06T12:29:28.339+00:00",[],{"title":2214},{"VI":2215},"Division of Gastroenterology, Department of Internal Medicine, Bezmialem Vakif University, Istanbul, Turkey",{"title":2217},{"VI":2218},"Metin Basaranoglu",{"id":2220,"sortIndex":329,"researcher":22,"roles":2221,"affiliations":2222,"properties":2231},"120adc59-04bd-460e-afd1-2b6f774faba0",[159],[2223],{"id":22,"sortIndex":124,"affiliation":2224,"properties":22},{"id":2225,"createTime":2226,"updateTime":2226,"relativeEntities":2227,"slug":22,"properties":2228,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"1ec58919-2647-4b68-8516-bf76b1328921","2023-12-06T12:29:28.374+00:00",[],{"title":2229},{"VI":2230},"Serviço de Gastrenterologia e Hepatologia, Hospital de Santa Maria-Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal",{"title":2232},{"VI":2233},"Carlos Noronha Ferreira",{"id":2235,"sortIndex":1801,"researcher":22,"roles":2236,"affiliations":2237,"properties":2246},"242871b4-e30c-48ae-84c0-74e6f24e4e1a",[159],[2238],{"id":22,"sortIndex":124,"affiliation":2239,"properties":22},{"id":2240,"createTime":2241,"updateTime":2241,"relativeEntities":2242,"slug":22,"properties":2243,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"bcfbb474-ea69-4a96-9bdb-545dbaf04d6e","2023-12-06T12:29:28.270+00:00",[],{"title":2244},{"VI":2245},"Kalinga Gastroenterology Foundation, Odisha, India",{"title":2247},{"VI":2248},"Shivaram Prasad Singh",{"id":2250,"sortIndex":130,"researcher":22,"roles":2251,"affiliations":2252,"properties":2261},"234e02d8-2134-42c7-a0d5-25925aaeac35",[159],[2253],{"id":22,"sortIndex":124,"affiliation":2254,"properties":22},{"id":2255,"createTime":2256,"updateTime":2256,"relativeEntities":2257,"slug":22,"properties":2258,"entityType":67,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":124},"8ebf2a28-20e3-45e7-8386-ab0529c43d7f","2023-12-06T12:29:28.277+00:00",[],{"title":2259},{"VI":2260},"Section of Gastroenterology, Boston Medical Center, Boston, MA, USA",{"title":2262},{"VI":2263},"Arpan Mohanty",{"url":1944,"publisher":2265,"properties":2294},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":2266,"slug":10,"properties":2267,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"syncStatus":21,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":2272,"manageAffiliations":2273,"indexDatabases":2274,"url":122,"thumbnailPath":22,"statistic":2289,"gsStatistic":22,"type":22,"analyzePriority":22},[],{"country":2268,"issn":2269,"introduce":2270,"title":2271},{"VOID":13},{"VOID":15},{"EN":17},{"EN":19},[],[],[2275,2282],{"id":101,"indexDatabase":2276,"url":114,"indexYears":115,"academicFieldIds":2281,"indexDatabaseRanking":121},{"id":103,"createTime":104,"updateTime":105,"relativeEntities":2277,"label":2278,"description":2279,"key":111,"publicationTags":2280,"standard":22},[],{"EN":108,"VI":108},{"EN":108,"VI":110},[113],[117,118,119,120],{"id":82,"indexDatabase":2283,"url":97,"indexYears":22,"academicFieldIds":2288,"indexDatabaseRanking":22},{"id":84,"createTime":85,"updateTime":86,"relativeEntities":2284,"label":2285,"description":2286,"key":93,"publicationTags":2287,"standard":22},[],{"EN":89,"VI":89},{"VI":91,"EN":92},[95,96],[99],{"impactFactor":124,"impactFactorByYear":2290,"i10Index":124,"i10IndexLast5Year":124,"totalPublication":126,"totalPublicationByYear":2291,"totalCitation":124,"totalCitationByYear":2292,"totalCitationPerPublication":124,"totalCitationPerPublicationByYear":2293,"hindexLast5Year":124,"hindex":124},{},{"2019":128,"2020":129,"2021":130,"2022":131,"2023":132,"2024":133},{},{},{"volume":2295,"pages":2296},{"VOID":410},{"VOID":2297},"100785"]